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Mouse embryonic stem cells (mESCs) and mouse epiblast stem cells (mEpiSCs) 
represent opposite ends of a pluripotency continuum, respectively referred to as naïve and 
primed pluripotent states. A third, recently discovered intermediate state has been 
described as the ‘formative state’.  Metabolism has been traditionally regarded as a by-
product of cell fate; however, recent evidence now supports metabolism as promoting 
stem cell fate.  Pyruvate kinase muscle isoforms 1 and 2 (PKM1 and PKM2) catalyze the 
final, rate limiting step of glycolysis generating adenosine triphosphate (ATP) and 
pyruvate; however, the precise role(s) of these isozymes in naïve, formative, and primed 
pluripotency is unclear.  Steric-blocking morpholino oligonucleotides were employed to 
modulate the levels of PKM1/2; this thesis characterized the cellular expression, 
localization patterns, and contributions of PKM1 and PKM2 in mESCs, chemically 
transitioned mouse epiblast-like cells (mEpiLCs) representing formative pluripotency, 
and mEpiSCs using immunoblotting, flow cytometry, and confocal microscopy.  My 
results indicate that PKM1 and PKM2 are not only localized to the cytoplasm, but also 
accumulate in distinct subnuclear regions of mESCs, mEpiLCs, and mEpiSCs as 
determined by a comprehensive and quantitative, confocal microscopy colocalization 
methodology.   
In Chapters 2 and 3, I employed orthogonal projections, and airyscan processing to 
investigate the localization patterns of PKM1/2.  I determined that the subnuclear 
localization of PKM1/2 shifts during the pluripotent development across mESCs, 
mEpiLCs, and mEpiSCs.  The appropriateness and power of the Pearson’s Correlation 





protein colocalization in pluripotent stem cells (PSCs) by immunofluorescence confocal 
microscopy was validated and expanded upon.  In Chapter 4, I describe a key research 
tool of this thesis using flow cytometry, this improved technique allows for the 
identification of formative pluripotency cells from naïve and primed populations using 
the cell surface markers SSEA1 and CD24.  Additionally, I utilized this advanced 
methodology in Chapter 5 to assess the influence of PKM1/2 modulation on pluripotency 
state.  Altering PKM1/2 levels affected the ability of naïve state cells to transition to the 
formative state, it also influenced the transition of formative cells to a primed-like state.  
In conclusion, the results suggest that nuclear PKM1/2 assists with distinct pluripotency 
state maintenance and lineage priming by non-canonical mechanisms.  These results 
advance our understanding of the overall mechanisms controlling naïve, formative, and 


















Prior to implantation, an embryo is referred to as a blastocyst.  The blastocyst contains a 
small pocket of cells called the inner cell mass.  These cells can become all cell types of 
an individual, a characteristic coined ‘pluripotency’.  Isolated inner cell mass cells can be 
grown in the lab to study how the embryo develops and how pluripotent stem cells 
function.  Stem cells require sources of energy to maintain themselves and growth with 
the process of metabolism.  Pluripotent stem cells progressively specialize over the 
timeline of the pluripotent continuum.  The first stage of the continuum is called the naïve 
state, where a cell is pluripotent, but is not fully ready to turn into a new cell.  First, a 
naïve cell must develop into a formative state cell, this state is an intermediate point 
needed to gain the ability to turn into any cell of the fetus, and the only state that a cell 
can turn into a germ cell.  Before making the decision to leave pluripotency, the cell 
enters the final stage, the primed state, where it is ‘primed’ for cell lineage choices.  This 
thesis examined two main proteins that are known to aid in cellular digestion of the 
building blocks needed to grow and generate energy, pyruvate kinase muscle isoforms 1 
and 2 (PKM1/2).  PKM1/2 affect the ability of pluripotent stem cells to stay as naïve cells 
or develop into becoming formative, or primed stem cells.  This thesis utilized several 
improved methods to examine the effects of altering the levels and localization of 
PKM1/2 on pluripotent and metabolic state of the naïve, formative, and primed stages. 
This knowledge helps us to understand how embryonic stem cells stay pluripotent and 
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“We can judge our progress by the courage of our questions and the depth of our 
answers, our willingness to embrace what is true rather than what feels good.” 
 
Dr. Carl Sagan 
 
Since starting this project in 2015, I have struggled with the concept of progression and 
finding contentment with the answers I was generating.  Failure was a big part of the first 
3 years of my PhD, few experiments worked, even fewer produced results worthy of 
further investigation.  During my first year in the lab, I witnessed PKM1 appearing to 
reside in the nucleus of my stem cells under a basic fluorescent microscope, something 
that had never been reported in any cell type at the time.  Naturally, I doubted this initial 
finding, but I thought it was interesting enough to present to my lab resulting in 
discussion.  This small qualitative finding was the seed to give me the courage to not only 
investigate whether it was in fact in the nucleus, but also create my own, more 
comprehensive, and improved methodology for nuclear cytoplasmic colocalization.  I 
embraced my ideas and forged a path to success. By finding courage in my questions and 
working to improve the field, I was able to begin answering my query.  Showing nuclear 
PKM1 felt like real progress, but it required asking deeper questions and answering those 
question in new and better ways.  Science is not static; science is highly dynamic and 
craves both improvement and change; this project resulted in enhancements to current 
methodologies that will benefit projects well outside of the scope of my study.  Overall, 
this project required a willingness to embrace the scientific method, and despite setbacks 
and troubleshooting, I was able to turn kernels of proof into more substantial evidence of 
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Chapter 1  
 
1.0.0.  Preface. 
1.0.1.  Mammalian blastocyst inner cell mass development. 
Following fertilization by the union of a sperm and egg, the first mammalian cell 
differentiation event yields two distinct cell lineages, the trophectoderm (TE) and the 
inner cell mass (ICM) (Marikawa and Alarcón 2009).  The TE and ICM are cellular 
precursors of the placenta and embryonic germ cell layers respectively.  The eutherian 
placenta provides a necessary means for maternal nourishment of the developing embryo 
and this unique feature is conserved in the eutherian evolution of the TE.  The cells of the 
ICM will go onto specialize into the cells of the adult organism, including the germ cells.  
These ICM cells are classified as pluripotent, they have the capability to self-renew 
indefinitely or specialize into any cell derivative of the three germ cell layers.    
1.0.2.  The first cell lineage determination.  
Approximately 16-20 hours post-fertilization, the first cleavage of the zygote occurs 
resulting in the formation of two blastomeres.  The subsequent cleavage events that 
follow, occur in 12- to 24-hour intervals.  Between the third and fourth cleavage events, 
individual blastomeres undergo a morphogenetic change called ‘compaction’, resulting in 
a dramatic increase in cell-to-cell contact.  This is fueled by the formation and action of 
E-Cadherin (Cadhern1; Cdh1) mediated adherens junction formation that transitions the 
eight-cell stage preimplantation embryo from a grape-like cluster into a fully mulberry-







E-Cadherin also plays a critical and indirect role in generating the contractile forces 
needed for tissue compaction by removing acto-myosin from ectopic cell-to-cell surfaces 
(Stephenson, Yamanaka, and Rossant 2010; Klompstra et al. 2015; S. Yamada and 
Nelson 2007).  This allows acto-myosin to accumulate and form a shell-like surface 
around the embryo, and generates the contraction necessary for compaction to occur 
(Maître et al. 2015).  The formation of the ICM begins following the fifth cleavage event, 
where secreted vacuoles from outer TE blastomeres begin to form, grow, and combine 
within the embryo to form the fluid-filled blastocyst cavity (Aziz and Alexandre 1991).  It 
is here that the TE and ICM combine to make up what is now referred to as the 
‘blastocyst’.  The TE epithelializes from the outer blastomeres with the ICM forming on 
the basal surface from aggregated cells on the opposite side of the blastocyst cavity, this 
orientation is referred to as the ‘embryonic and abembryonic poles’ respectively and 
forms the embryonic-abembryonic axis. 
1.1.0.  The pluripotent continuum. 
Within the developing murine embryo, naïve embryonic stem cells (mESCs) are derived 
from the inner cell mass (ICM) of an embryo at the pre-implantation blastocyst-stage, 
whereas primed epiblast stem cells (mEpiSCs) are more developmentally differentiated 
and can be derived from the late post-implantation epiblast (Nichols and Smith 2009).  
These two pluripotent states exist as the beginning and end of the pluripotent continuum.  
Both states have several distinguishing features aside from their developmental timeline.  
Morphologically, naïve cells are domed with a glistening appearance in culture, and their 
colonies are tolerant to single cell dissociation, whereas primed cells are characteristically 







cells contain two activated X chromosomes, the paternally inherited X chromosome is 
inactivated in extraembryonic lineages following cleavage and is correspondingly 
inactivated in primed cells (Heard 2004).  In terms of signalling, mESCs maintain the 
ability to indefinitely self-renew through activation of the transcription factor ‘signal 
transducer and activator of transcription 3’ (Stat3) by leukemia inhibitory factor (LIF) 
supplementation (Williams et al. 1988; A. G. Smith et al. 1988; H Niwa et al. 1998).  
When cultured with serum and LIF, mESCs can be maintained in vitro, however, they 
exist in a heterogenous composition that includes both naïve and cells exiting naïve state.  
In contrast, homogenous mESC cell culture is maintained through LIF supplementation 
with a small molecule blockage strategy referred to as 2i, a small molecular cocktail 
containing inhibitors of mitogen-activated protein kinase and glycogen synthase kinase 3 
(Wray et al. 2011; Burdon et al. 1999).  The combination of LIF/2i supplementation in the 
absence of sera promotes naïve cell homogeneity by suppressing differentiation without 
hindering cell division, the resulting state is referred to as the ‘ground-state’.  
Alternatively, mEpiSCs do not require LIF or 2i, instead they require activin and 
fibroblast growth factor (FGF, together FA supplemented media) addition to their 
medium to achieve a stable, proliferative primed state (Brons et al. 2007; Tesar et al. 
2007).  Either end of the pluripotent continuum is hallmarked with unique metabolic 
preferences, with naïve cells are metabolically bivalent, utilizing both glycolytic and 
oxidative phosphorylation (OXPHOS), whereas primed cells are preferentially glycolytic 









Figure 1.1.  Pluripotent stem cells of the pre- and post- implantation murine 
blastocyst and corresponding metabolic preferences. 
Phase contrast microscopy imaging of mESCs, mEpiLCs and mEpiSCs.  Explanting cells 
of the inner cell mass of between Embryonic day (E) 3.5 and E4.5, supplemented with 
LIF and 2i media promotes domed colonies of cells with glistening borders representing 
the naïve pluripotent state.  The formative state can be modelled by exchanging LIF/2i 
supplementation with FA media over 48 hours, these mEpiLCs are like the cells of the 
E5.5 to E6.0 post-implantation epiblast.  Explanting cells of the post-implantation epiblast 
between E6.0 and E7.5 cultured in FA results in flattened colonies of cells representing 
the primed pluripotent state.  The naïve and primed pluripotent states differ in metabolic 
preferences as naïve cells are bivalent utilizing glycolysis and OXPHOS and primed cells 








Between either end of the pluripotent continuum exists an interval of pluripotency 
hallmarked by the primordial germ cell and lineage differentiation competency.  This 
executive, intermediate phase is referred to as formative pluripotency, and corresponds 
with E5.5-6.0 in the mouse embryo (A. Smith 2017).  While naïve and primed pluripotent 
states are well characterized, the intermediate formative state and how stem cells exit 
pluripotency during differentiation is an area with much to still understand.  One area that 
has been particularly neglected is an investigation of formative state’s metabolic 
preferences.  In this thesis, mESCs were exposed to FA for 48, 72, and 96 hours to 
produce and model the formative state and exit of the naïve and formative states towards 
a primed-like state.  After 48 hours of FA treatment, mEpiLCs become reminiscent of 
E5.75 mouse ICM cells (Hayashi et al. 2011).  At 72 hours following FA media 
supplementation, mEpiLCs exhibit a apoptosis event, cementing them towards a primed-
like pluripotent fate path (Hayashi et al. 2011).  Through additional passages and 
continued FA media treatment, primed-like pluripotent state cells are achieved.  These 
conditions and timelines were employed to simulate a primed-like pluripotent state by 
exposing mESCs to FA over 96 hours with a single passage at 48 hours (Morgani, 
Nichols, and Hadjantonakis 2017).   
 
Recently, stable formative pluripotent lines have been derived from humans and mice 
(Kinoshita et al. 2020).  Stable formative lines can be generated though the addition of 
traditional FA media and supplementation of a tankyrase inhibitor, which works to inhibit 
Wnt/-Catenin signalling (Menon et al. 2019). This is a ground-breaking finding as the 







pluripotent development, which dictates that during development and achievement of 
competency for cell lineage specification, cells of the naïve pluripotent state will progress 
through formative into the primed pluripotent state before differentiating into a somatic 
cell (A. Smith 2017).  Additionally, formative state cells are the only stem cell capable of 
efficient differentiation into primordial germ-like cells (PGCLCs).  This demonstrates a 
competency for germ cell generation that is not inherent to naïve pluripotency (Hayashi et 
al. 2011).  If correct, the phased progression model of pluripotent development would 
benefit from an effective method in studying phased progression transitioning efficiency.  
The cell surface markers Stage specific embryonic antigen 1 (SSEA1) and CD24 have 
been used to distinguish between the naïve and primed pluripotent states via flow 
cytometry (Shakiba et al. 2015).  SSEA1 has elevated expression in naïve cells, whereas 
CD24 is elevated in primed pluripotency (Shakiba et al. 2015).  For these reasons I was 
inspired to pursue the investigation of cell surface marker expression in transitioning 
formative state pluripotency cells, relative to both naïve and primed state cells.  Currently, 
there are few effective methods for discriminating the formative state from naïve or 
primed pluripotency, and with the advent of a stable formative cell line (Kinoshita et al. 
2020), the study of exiting the naïve state and traversing through the phased progression 
model of cell specification is better enabled.  Delineation of naïve, formative, and primed 
states is important to the field of pluripotency as recent advances allow researchers to 
stably culture formative stem cells for the study of specification and development.  Until 
recently, primed pluripotency was the only stable culture of human PSCs, as the naïve 









1.1.1.  Non-canonical roles of metabolism.  
Increasing evidence promotes metabolism as having a critical role in the establishment, 
maintenance, and differentiation of pluripotent stem cells.  Elevated reactive oxygen 
species (ROS) associated with OXPHOS has been implicated not only with apoptosis, but 
also in cell differentiation acting as second messengers and influencing the epigenetic 
landscape (Sarsour et al. 2009; Maryanovich and Gross 2013).  When there is a demand 
for cells to proliferate, the proliferative state has a metabolic precursor response, whereby 
pyruvate shunting to the mitochondria is decreased.  In addition, there is an elevated 
glycolytic response resulting in an upregulation of anabolic gene expression and 
biosynthetic pathways.  This trend is profiled by a simultaneous increase in aerobic 
glycolysis, and decrease in OXPHOS; such phenotype is evident in both tumor and 
embryonic development (Vander Heiden, Cantley, and Thompson 2009).  When 
reprogramming from the primed-to-naïve pluripotent state through overactivation of LIF, 
the reverse metabolic shift is witnessed, a transition from aerobic glycolysis to increased 
OXPHOS and metabolic bivalency (Carbognin et al. 2016).  As OXPHOS is dependent 
on mitochondrial respiration, this shift also demonstrates mitochondrial reprogramming.  
Overactivation of LIF promotes the gene Stat3, which is critical in self-renewal, can bind 
to the mitochondrial genome and promotes the naïve phenotype and reversion of primed 
pluripotency (Carbognin et al. 2016).  Elevated Stat3 also promotes naïve associated 
genes, increases stem cell proliferation, and both OXPHOS and mitochondrial gene 
transcription (Carbognin et al. 2016).  My investigation sheds light on the role of 







cell conversion, this may advance the ability to effectively model disease, and eventually 
apply cell replacement therapies through enhanced cell differentiation.  
  
Traditionally, human induced pluripotent stem cells (hiPSCs) reflect metabolic trends of 
primed PSCs, exhibiting increased glycolytic flux and decreased OXPHOS.  Relative to 
their somatic cell origins, iPSCs are proliferative, requiring a greater amount of energy, 
yet have a substantial decrease in OXPHOS activity.  Indeed, hiPSCs exhibit aerobic 
glycolytic metabolism like primed cells, showing distinct similarities to cancer cell 
metabolism and structural differences within the mitochondria (Jasanoff 1992; Ishida et 
al. 2020).  Epigenetic changes are partially responsible for these metabolic trends.  One 
alternate route for this glycolytic flux is contribution towards the pentose phosphate 
pathway (PPP), which is implicated in having an a key role in energy flux in iPSCs 
(Prigione et al. 2015).  HIF-1𝛼 and HIF-2𝛽 are required during the initial stages of 
reprogramming and counter intuitively, HIF-2𝛽, if stabilized, can hinder reprogramming 
efficiency.  During early reprogramming of iPSCs from somatic cells, there is a sudden 
and unexpected burst of OXPHOS, this event is referred to as OXPHOS burst.  This 
sudden burst is required for reprogramming, despite the end iPSC metabolic fate being 
preferentially glycolytic.  Induction of the OXPHOS burst event upregulates estrogen-
related nuclear receptors and PGC-1/ (co-factors).  Recent evidence suggests that the 
OXPHOS burst is necessary to cause HIF-1𝛼 activation by increasing the activity of 
NRF2 promoting a switch in metabolism from being OXPHOS to glycolytic (Hawkins et 








1.1.2. Pyruvate kinase muscle isoforms. 
Mammals express four tissue specific pyruvate kinase (PK) isozymes: M1, M2, L, and R, 
each with unique properties and tissue expression to meet specific metabolic demands (K. 
Yamada and Noguchi 1999).  PK-Liver and Red Blood (LR) gene expresses L and R in a 
tissue-promotor specific manner.  L is present in the kidneys and liver tissue, whereas R 
in red blood cells (W. Yang and Lu 2015).  PKM1/2 is the enzyme responsible for 
catalyzing the final and rate limiting step of glycolysis, the enzyme plays a role in 
directing the fate of pyruvate towards lactate or acetyl CoA for glycolysis and OXPHOS 
(W. Yang and Lu 2015).  This step involves the catalysis of phosphate from 
phosphoenolpyruvate (PEP) to ADP producing the second ATP of glycolysis and 
pyruvate.  
 
PKM1/2 are alternatively spliced isoforms from the PKM gene (Figure 1.2) (Wong, De 
Melo, and Tang 2013).  Heterogeneous nuclear ribonucleoproteins A1/A2 and 
polypyrimidine-tract binding protein work to splice PKM1 through the exclusion of exon 
9 and inclusion of exon 10, whereas PKM2 is spliced to include exon 10 and exclude 
exon 9 (K. Yamada and Noguchi 1999).  PKM1 is expressed in most somatic tissues that 
have a high energy requirement.  The overexpression or replacement of PKM2 in place of 
PKM1 restricts tumorigenesis and cancer progression (Anastasiou et al. 2012; Chaneton 
and Gottlieb 2012).  However, PKM2 is the predominant pyruvate kinase isoform in 
cancer cells, but is also expressed in most somatic cells apart from liver, brain, and 
paradoxically muscle in adult tissues (W. Yang and Lu 2015; Christofk et al. 2008).  







heterotropic allosteric interactions with fructose 1,6-bisphosphate (FBP) and PEP 
respectively, allosteric interactions are not evident with M1 isozyme, which maintains an 
active homotetrameric conformation (Boles et al. 1997; Imamura and Tanaka 1982).  
When FBP levels decrease, PKM2 homotetramers dissociate into homodimers, these 
conformations are interconvertible (Wong, De Melo, and Tang 2013).  The PKM2 dimer 
is associated with aerobic glycolysis and anabolism, this isoform is also formed in the 
presence of Tyr phosphorylated peptides regardless of FBP levels. In turn, this causes 
phosphorylation on Y105 which prevents FBP binding, a key trait of Warburg 
metabolism (the Warburg Effect), where even in the presence of oxygen, cells are 
preferentially glycolytic (Gupta and Bamezai 2010).  The Warburg Effect is the metabolic 
preference for glycolysis, and it is typical of most cancers (O. Warburg. 1924).  Despite 
appearing to be a poor method of generating maximal ATP levels, most cancer cells do 
not reply on mitochondrial respiration, but rather employ aerobic glycolysis, despite 
apparent oxygen availability.  This metabolic preference was first characterized in 1924, 
yet we are only now starting to understand the mechanisms and rationale behind this 
counterintuitive process.  Mouse and human primed pluripotent cells are similar to 
specific cancer cells regarding their metabolic preferences as both are preferentially 
glycolytic despite oxygen being available (Zhou et al. 2012).  Given this similarity, the 
results of this thesis document PKM2 residing within the nucleus of these highly 
proliferative stem cells, this is a key trait of the Warburg Effect.  PKM2 is a target for 
many cancer treatments, and the results of my study demonstrate that PKM1 and PKM2 
isoforms have novel expression patterns between pluripotent states.  As human ESCs 







mechanisms of PKM2 interactions within PSCs is a critical area of focus (X. Liu et al. 


























Figure 1.2.  Alternative splicing schematic of pyruvate kinase muscle isoforms 1/2. 
Pyruvate kinase muscle isoforms 1 and 2 (PKM1/2) is alternatively spliced from the PKM 
gene.  Mature PKM1 mRNA excludes exon 10, and conversely, mature PKM2 mRNA 


























PKM2 interacts with: OCT4, a marker of pluripotency in ESCs, HIF-1𝛼 master regulator 
of metabolism, STAT3, and 𝛽-CATENIN (W. Yang and Lu 2015).  Interestingly, the 
interaction of OCT4 increases during a transition from the dimeric and phosphorylated 
conformation associated with the Warburg Effect (Morfouace et al. 2014).  It is currently 
assumed that the interaction of PKM2 and OCT4 has a role in mitosis and tumor 
nourishment, however, this mechanism has yet to be delineated (Hitoshi Niwa, Miyazaki, 
and Smith 2000).  Dimeric PKM2 also associates with HIF-1𝛼, this interaction promotes 
transcriptional coactivation of HIF-1𝛼 through positive feedback regulation, additionally, 
this promotes the Warburg Effect in at least two ways.  Firstly, when PKM2 is 
hydroxylated by and bound to prolyl hydroxylase 3, there is an interaction with HIF-1 𝛼 
that results in transactivation of the glycolytic enzymes lactate dehydrogenase A (LDHA) 
and pyruvate dehydrogenase kinase 1 (PDK1), transactivation of vascular endothelial 
growth factor can also occur.  PKM2 also transactivates HIF1𝛼 target genes such as 
GLUT1, LDHA and PDK1 (which inhibits OXPHOS via pyruvate shunting) by altering 
interactions at hypoxia response elements (HRE), and these alterations include improved 
recruitment of p300 and enhanced binding of HIF-1𝛼 (Luo et al. 2011).   HIF-1 works to 
regulate PKM expression for both isozymes (M1/M2), with only dimeric PKM2 
interacting directly with HIF-1𝛼 by enhancing HIF1𝛼 binding and enlisting p300 at 
HREs, this in turn transactivates key glycolytic enzymes required for the Warburg Effect.  
Additionally, HIF-1𝛼 transcriptionally regulates OCT4, further implicating PKM2 as an 
important gene in proliferation and aerobic glycolysis (Prigione et al. 2015).  Within the 
nucleus, dimeric PKM2 can operate as a protein kinase through phosphorylation of 







activating MEK5 and histone H3 (Thr11) (Gao et al. 2012).  PKM2 can translocate to the 
nucleus through epidermal growth factor induction by transactivation of 𝛽-CATENIN 
through the phosphorylation of tyrosine Y333 (Figure 1.3).  This interaction contributes 
to c-MYC and cyclin D transcription.  However, an interaction with Wnt and PKM2 is 
not evident (Weiwei Yang et al. 2011).  Interactions with c-MYC require more research, 
but interestingly a depletion of c-MYC in naïve cells will force mESC into a ‘diapause’ 
like state of quiescence (Scognamiglio et al. 2016).  PKM2 can also be methylated, for 
example, methylation by coactivator-associated arginine methyltransferase 1 (CARM1).  
Protein-protein interaction of PKM2 and CARM1 along with methylation of PKM2’s C-
domain also promotes the Warburg effect and activates a transition from oxidative 
phosphorylation to aerobic glycolysis (F. Liu et al. 2017).  Downregulating intragenic 
DNA methylation can influence pre-splicing of alternative splice events for PKM1/2.  
Importantly, CARM1 does not methylate PKM1, however, CARM1 and PKM1 proteins 
do interact, and CARM1 primarily methylates dimeric PKM2 over the tetrameric 
conformation.  Currently, epigenetic regulation of PKM2 in PSCs has not been 
thoroughly investigated (Singh et al. 2017).  Pyruvate destined for an OXPHOS is 
irreversibly decarboxylated into acetyl CoA within the mitochondria by pyruvate 
dehydrogenase complex (PDC) for processing within the tricarboxylic acid cycle.  PKM2, 
PDC-(E2 subunit), and histone acetyltransferase p300 form a complex with the CYP1A1 
enhancer of arylhydrocarbon receptor.  Through this complexing, nuclear PKM2 
promotes cell proliferation through enhanced detoxification of detrimental endogenous 
metabolites and aids in acetyl CoA production (Matsuda et al. 2016).  The mechanism of 
how transcriptional activation fully regulates these enzymes, and their function is still 







understudied, however, recent publications have determined PKM1 is involved in 
chemoresistance, and may have additional non-canonical roles (Fushida et al. 2018; Wei 
et al. 2017).  Indeed, PKM1 has been recently documented binding with Hepatocyte 
Nuclear Factor 4∝ (HNF4∝), before translocating to the nucleus of hepatoma cells(Wei et 
al. 2017). This may suggest a potential non-canonical role for the traditional cytoplasmic 
metabolic enzyme.  PKM1 has been found present in chemo-resistant cancerous cells and 
following knockdown increased cellular chemotherapy sensitivity (Taniguchi et al. 2016).  
There is a clinical need to study PKM1/2 modulation in metabolically active cells as 
PKM1/2 are heavily implicated in the transition of healthy cells to utilizing Warburg 
Effect over OXPHOS.  As such PKM2, and now PKM1 is the target of several cancer 
related approaches (Wei et al. 2017; W. Yang and Lu 2015).  As this transition is similar 
to the bivalent-to-glycolytic switch from naïve to primed pluripotency, there is a 
developmental importance in studying the influence of PKM1/2 modulation.  Current 
strategies have included knocking in alleles of PKM1/2 (Konno, Ishii, et al. 2015), using 
siRNA (Goldberg and Sharp 2012) and shRNA (Qin et al. 2017) strategies, lentiviral 
overexpression (Qin et al. 2017), pharmacological approaches (Giannoni et al. 2015; 
Hasenoehrl et al. 2017; Wei et al. 2017) and miRNAs (Konno, Koseki, et al. 2015; 
















Figure 1.3.  A proposed model of PKM1/2 isoforms in naïve and primed pluripotent 
stem cells. 
Intracellular PKM1/2 exist as active tetramers, the PKM2 tetrameric conformation is 
destabilized following phosphorylation promoting a dimeric conformation.  Dimeric 
PKM2 is translocated to nuclei and promotes the Warburg Effect.  As primed cells have 
been described as preferentially aerobic glycolytic in metabolic preference, nuclear 
PKM2 by dimeric PKM2 translocation is proposed.  As naïve cells are metabolically 
bivalent, a mix of OXPHOS and glycolytic promoting conformations is presumed.  Image 










My thesis is focused on providing an increased understanding of the mechanisms 
controlling early cell differentiation and enhanced cell reprogramming through 
modulation of metabolic processes.  This is an area of interest in stem cell biology as 
other groups have successfully and are continually attempting to achieve increased 
reprogramming efficiencies in iPSCs by promoting the characterized iPSC metabolism of 
elevated glycolysis and decreased OXPHOS.  A well-established example is the 
upregulation of HIF activity to promote glycolysis, which interestingly also increases 
PKM2 activity.  Likewise, pyruvate dehydrogenase kinase (PDHK) activity inhibits 
pyruvate dehydrogenase (PDH), stunting for OXPHOS to occur and even the addition of 
FBP treatment promotes a metabolic switch to glycolysis and increased reprogramming 
efficiency (Folmes et al. 2011; Zhu et al. 2010).  By promoting OXPHOS instead, cellular 
reprogramming efficiency of somatic cells can alternatively be decreased.  While cancer 
cells and primed pluripotent stem cells share a preference for aerobic glycolysis, there is 
still an apparent role for OXPHOS in PSCs, this is an area in need of greater research and 
PKM1/2 may have a vital role in this capacity.  Recent studies have no longer alluded to 
metabolism as influencing pluripotency, but have claimed that metabolism actively 
promotes pluripotency (Ryall et al. 2015).  When considering the metabolic preferences 
of naïve and primed pluripotent states, and the switch from aerobic to anaerobic 
metabolism, it is important to consider their in vivo counterparts, the cells of the pre- and 
post- implantation embryo.  These metabolic preferences are thought to be intrinsically 
programmed into these states due to the limited oxygen availability of their in vivo origins 
within the reproductive tract (Carbognin et al. 2016).  Further study into the metabolic 
preferences of the formative state, and the formative interval of embryo development is 







notion of intrinsic programming based on in vivo origins holds true, then it would be 
expected that the shift towards aerobic glycolysis is established during the formative 
interval and in the formative state.    
 
1.2.0.  Rationale. 
PKM1/2 have been independently implicated in naïve and primed cells, yet their role in 
the developmental transition between pluripotent states has yet to be fully elucidated 
(Konno, Ishii, et al. 2015; Qin et al. 2017).  Knocking in an allele of either the Pkm1 or 
Pkm2 gene indicates that Pkm2, but not Pkm1 has a role in maintaining the naïve state 
following a differentiation stimuli as determined by a transcriptional assay in mESCs 
(Konno, Ishii, et al. 2015).  Overexpression of either PKM1 or PKM2 increases 
pluripotent transcript abundance in naïve mESCs.  Additionally, it has been demonstrated 
that PKM2 can translocate to the nuclei of primed hESCs, when silenced, cells do not 
exhibit altered glucose metabolism suggesting a non-canonical role for PKM2 
(Christensen, Calder, and Houghton 2015).  PKM2, and recently PKM1 have been 
implicated to have other potential non-canonical roles, outside of metabolic enzymatic 
activities, such as promoting aerobic glycolytic activity and proliferation typical of 
cancerous cells (Hamabe et al. 2014; Wei et al. 2018; Palsson-McDermott et al. 2015; 
Stone et al. 2018; Weiwei Yang and Lu 2013; Growth 2018; Wei et al. 2017; Fushida et 
al. 2018).  With the advent of new flow cytometric approaches and improved 
characterization of the formative state, this thesis seeks to delineate expression, 
localization, and influence of PKM1/2 on the naïve, formative, and primed pluripotent 







1.3.0.  Governing Hypothesis. 
Pyruvate kinase muscle isoform 1 and 2 expression are differentially expressed in naïve, 
formative, and primed pluripotent states; and enhance the progression of pluripotent state 
development in murine embryonic stem cells. 
 
 
1.4.0.  Thesis Objectives. 
This research investigates the role of PKM1/2 in the maintenance and differentiation of 
naïve, formative, primed-like, and primed pluripotent states through the following 
objectives: 
1. Optimize quantitative confocal colocalization of fluorescently tagged antisera 
against PKM1 and PKM2 to subcellular regions of naïve, formative, and primed 
mESCs 
2. Characterize protein and transcript abundance along with subcellular localization 
of PKM1/2 isoforms in naïve, formative, and primed mPSCs. 
3. Optimise the application of flow cytometry using SSEA and CD24 cell surface 
markers to delineate naïve, formative and primed pluripotent states. 
4. Determine the influence of modulating PKM1/2 in naïve mESCs and primed 
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2.0.2.  Summary: 
 
This chapter details 3D morphological topography of mouse pluripotent stem cell colony 
architecture optimization and nuclear protein localization by co-immunofluorescence 
confocal microscopy analysis.  Colocalization assessment of nuclear and cytoplasmic cell 
regions is detailed to demonstrate nuclear localization in mouse epiblast stem cells 
(mEpiSCs) by confocal microscopy and orthogonal colocalization assessment.  Protein 
colocalization within mouse embryonic stem cells (mESCs), mouse epiblast-like cells 
(mEpiLCs), and mEpiSCs, or any pluripotent stem cell with a high nuclear-to-
cytoplasmic ratio, can be efficiently completed using these optimized protocols. 
 
2.1.0.  Introduction: 
Immunofluorescence microscopy allows for the visualization of fluorescence light energy 
emitted from a fluorophore representing the cellular localization of a specific protein of 
interest.  Activation of a fluorophore can be direct or indirect, depending on whether it is 
conjugated to a primary or secondary antibody respectively (Joshi and Yu 2017).  
Observable differences in immunofluorescence localization is readily distinguished 
within a cell using this technique, however, quantification of target protein levels is 
challenging.  Colocalization is an effective quantitative method of comparison between 
two images within a specific region of interest (ROI), and their level of correlated spatial 
overlap in pixels used to determine quantity (Adler and Parmryd 2012).  The following 
methods have been developed to quantitatively compare the levels of nuclear and 
cytoplasmic colocalization for a gene of interest within a specific ROI using 








Pluripotency markers such as octamer-binding transcription factor 4 (OCT4), sex 
determining region Y – box 2 (SOX2), and NANOG are nuclear localized transcription 
factors that are expressed within pluripotent stem cells (PSCs).  They represent ideal 
candidate nuclear markers that can be contrasted with overall nuclear DNA staining using 
Hoechst DNA or an equivalent binding dye as a nuclear reference.  Since PSCs, such as 
mouse epiblast stem cells (mEpiSCs), are typically grown on a feeder cell layer of mouse 
embryonic fibroblasts (MEFs) for support, OCT4, SOX2, and NANOG become useful 
stem cell colocalization proteins, as they are not expressed in the MEFs.  Choosing the 
optimal control protein is key, as PSCs have high nuclear to cytoplasmic size ratios, 
increasing the difficulty in distinguishing between nuclear and cytoplasmic protein 
localizations (Oh et al. 2005; Pagliara et al. 2014).   
 
The protein of interest in this protocol is pyruvate kinase muscle isoform 2 (PKM2), a 
metabolic protein that can translocate from the cytoplasm to the nucleus in cancer cells 
(Yang and Lu 2013).  The metrics described compare spatial overlap and correlation 
between two fluorescent channels include the algorithms for calculating Manders’s 
Overlap Coefficient (MOC) and Pearson Correlation Coefficient (PCC), these metrics are 
published for induced PSCs and neuronal differentiation (Seibler et al. 2011).  The MOC 
is a measure of the spatial overlap of pixels between two images within a ROI (Manders, 
Verbeek, and Aten 1993). However, the MOC is quite sensitive to photobleaching, 
therefore ensuring proper confocal imaging with appropriate laser intensities is paramount 
(Dunn, Kamocka, and McDonald 2011),(Zinchuk, Zinchuk, and Okada 2007).  By 







problems associated with the signal-to-noise sensitivity affected by photobleaching.  
Therefore, the MOC is a valuable tool in determining if the pixels associated with the two 
validated proteins exist in the same spatially-relevant ROI (Aaron, Taylor, and Chew 
2019).  Conversely, the PCC is a measure of covariance between pixels.  It is more 
accommodating in terms of what images can be compared, and represents the other main 
measurable parameter of colocalization, correlation of pixel distribution between images 
(Dunn, Kamocka, and McDonald 2011).  The PCC of pluripotent stem cell colonies may 
be decreased compared to individual cells as the PCC measures pixel correlation, 
therefore, examining the subcellular structures of individual cells will be emphasized 
more than areas representing extra, non-relevant pixels found in generalized regions of 
cell colonies (Dunn, Kamocka, and McDonald 2011).  Due to the large nuclear-
cytoplasmic size ratio of pluripotent stem cells, this limitation of PCC, should not be an 
issue, and in my experience, there is little to no change between individual cells and total 
colony PCC or MOC.  Proper optimization and consistency in cell fixation and processing 
is critical for consistency and successful colocalization in all studies of this type.  It is 
essential that all samples, specimens, treatments, and replicates are consistently exposed 
to well thought out, empirically determined protocols that are consistently applied 
throughout the entire process and across all experimental replicates.  Additionally, the 
following protocol is also effective for quantifying protein colocalization within naïve 
mouse embryonic stem cells (mESCs) and formative mouse epiblast-like cells 
(mEpiLCs), but should work well for any colocalization study, especially for pluripotent 








The mechanisms controlling PKM1 and PKM2 nuclear translocation are largely 
unknown, however, PKM1 may complex with hepatocyte nuclear factor 4∝ (HNF4∝), 
and this can be enhanced with the addition of the drug Oroxylin A (OA) and the oncogene 
JMJD5 is implicated in the nuclear translocation of PKM2 (Wei et al. 2017; Wang et al. 
2014).  Nuclear translocation of PKM2 as a characteristic of the Warburg effect is well 
supported by fluorescent imaging and nuclear-to-cytoplasmic fractionation (Yang et al. 
2011, 2012; Yang and Lu 2013; Prakasam et al. 2017; Giannoni et al. 2015).  Typical 
confocal image analysis employing visual interpretation of overlaid fluorescent images is 
a purely qualitative means of spatial localization, however, accurate quantitative 
measurement of spatial localization can effectively occur within the context of a well-
controlled comparison of two fluorophores to determine the degree of colocalization (Wu 
et al. 2012).  Quantitative colocalization analysis (QCA) is most commonly divided into 
two metrics representing the relationship between two fluorophores, these measures are 
the degree of, i) overlap and ii) correlation (Dunn, Kamocka, and McDonald 2011).  The 
degree of spatial location by overlapping images was first quantified by Otsu in 1979, 
where pixels of two images were overlapped after applying a threshold (Otsu 1979).  
Manders’s Overlap Coefficient (MOC) better distinguishes pixels ignored from the 
threshold from higher intensity pixels but at the cost of being influenced by 
autofluorescence and an insensitively to differences between the signal-to-noise ratios of 
the two fluorophores (Manders, Verbeek, and Aten 1993; Aaron, Taylor, and Chew 
2019).  While the MOC is a measure of co-occurrence of two fluorophores, within the 
spatially shared regions of a cell, two markers may interact or share a similar trend in 
intensity localization and may be functionally related or interact.  Thus, the colocalization 







(Aaron, Taylor, and Chew 2019).  The Pearson Correlation Coefficient (PCC) compares 
the variation of signal intensity between the intersection of two images, taking into 
account the total population of pixels (Aaron, Taylor, and Chew 2019).  As such, this 
calculation can determine the direction of linear association between the fluorophores 
(Aaron, Taylor, and Chew 2019; Pearson and Henrici 1896).  The MOC and the PCC are 
commonly used calculations to quantify fluorescent protein spatial overlap and 
correlation (Adler and Parmryd 2012).  Despite the accuracy and power of QCA, this 
technique has been not been utilized to its full extent, especially so, in its application to 
measuring protein colocalization in pluripotent stem cells (Dunn, Kamocka, and 
McDonald 2011).  This may be due to an on-going debate within the field of QCA over 
the correct use and interpretation of overlap and correlation metrics (Adler and Parmryd 
2010; Aaron, Taylor, and Chew 2019).  Thus, a second primary objective of my study 
was to contrast both PCC versus MOC in the analysis of PKM1/2 colocalization with 
nuclear and cytoplasmic protein markers during naïve, formative, and primed 
pluripotency cell cultures (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013). 
 
The measurement of colocalization is a complicated and hotly debated area of biology 
(Adler and Parmryd 2010; Aaron, Taylor, and Chew 2019).  The term colocalization is 
largely used to measure two main components with different applications, namely 
correlation or co-occurrence of two fluorophores to each other based on pixel distribution 
(Aaron, Taylor, and Chew 2019).  Co-occurrence in immunofluorescence is the 
presentation of fluorescent pixels existing in the same spatial distribution, it is an 
indicator of overlap between markers, whereas correlation is a measurement of the 







(Manders, Verbeek, and Aten 1993).  There are several coefficients used to quantify 
colocalization such as M1, M2, k1, k2 (Manders’s coefficients), MOC, PCC, Spearman’s 
rank correlation, and the intensity correlation quotient (Manders, Verbeek, and Aten 
1993; Agnati et al. 2005; Adler and Parmryd 2012).  The controversy lies specifically in 
the usefulness and relevance of the MOC, and the alleged superiority of the PCC.  In 
2010, Alder and Parmryd first published work that diminished the usefulness of MOC in 
colocalization studies, outlining the metric as a hybrid measurement of correlations and 
co-occurrences, and arguing that the MOC was not a suitable metric for either 
colocalization by correlation or co-occurrence (Adler and Parmryd 2010).  This was 
determined by an additive offset of pixels which did not affect the PCC but increased the 
MOC to a higher level of co-occurrence.  As such, the MOC has been criticized as not 
being the best metric of co-occurrence due to the influence of correlation (Adler and 
Parmryd 2010).  However, this view has since been contested using biological samples 
demonstrating that both the MOC and PCC are valid measures of colocalization that add 
different qualities to determining interactions between two fluorochromes and their target 
proteins (Aaron, Taylor, and Chew 2019).  Immunofluorescence is commonly considered 
as primarily a qualitative technique and the literature into colocalization often uses 
generalized descriptors, such as ‘moderate’ or ‘strong’ association within PCC ranges.  
To bring greater consistency to the field, and offer greater validity to the quantitative 
nature of colocalization, a method of colocalization range descriptors has been developed 
by Zinchuk et al. (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013), and it is this 
approach that was implemented in this thesis to assign a quantitative designate to the 
colocalization of PKM1 and PKM2 within mESCs.  Zinchuk et al. labelled PCC values 







weak: -0.26 - 0.09, moderate: 0.1 – 0.48, strong: 0.49 – 0.84, and very strong: 0.85 – 1.0 
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  MOC values fall into set ranges of: 
Overlap: very weak: 0 – 0.49, weak: 0.50 – 0.70, moderate: 0.71 – 0.88, strong: 0.89 – 
0.97, and very strong: 0.98 – 1.0 (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  My 
results support claims that the MOC is a valuable metric of colocalization.  By comparing 
MOC and PCC values relative to a positive and negative biological reference, a stronger 
baseline set than that produced by using only the improved descriptors.  Nuclear (OCT4) 
and cytoplasmic (GAPDH) proteins were uniquely employed as control markers to 
correlate their nuclear localization with a well characterized DNA intercalating nuclear 
stain- Hoechst, which established a robust positive and negative reference to nuclear 
colocalization, allowing for the direct comparison of MOC and PCC values to one 
another.  Comparing these well-defined positive references to the qualifying range 
standards set by Zinchuk et al. has produced data that supports comparing colocalization 
by correlation as being superior to spatial overlap in my system (Zinchuk, Wu, and 
Grossenbacher-Zinchuk 2013).  However, there is still valuable knowledge to gain from 
the MOC, but the PCC data shows a greater distinction between internal reference 
controls.  
 
2.2.0.  Materials: 
1. Washing Solution: Dulbecco’s Phosphate Buffered Saline (no magnesium, no 
calcium) (DPBS(-/-))(GibcoTM 14190144). 








3. Sterilizing Ethanol: 70 % lab-grade ethanol diluted in MilliQ water. 
4. Antibody Dilution Solution: 10 % serum from host-species of secondary antibody 
diluted in DPBS(-/-)-T (0.1 % Tween-20). 
Primary Antibodies: 
• OCT4: Oct-3/4 Antibody (C-10) (Santa Cruz sc-5279) – 1:50 dilution. 
• GAPDH: GAPDH (6C5) (Santa Cruz sc-32233) – 1:50 dilution. 
• PKM2: PKM2-specific Polyclonal antibody (ProteinTech 15822-1-AP) – 1:50 
dilution. 
Secondary Antibodies: 
• Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa 
Fluor Plus 555 (Invitrogen A32732) – 10 g/mL dilution. 
• Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 
488 (Invitrogen A11001) – 1 g/mL dilution. 
5. mESC and mEpiLC substratum: 0.1 % porcine gelatin (Sigma-Aldrich G2500) in 
MilliQ water and autoclave sterilized. 
6. mEpiSC substratum: 10 g/mL/cm2 sterile fibronectin (Roche 11051407001) 
MilliQ water.  
7. 1.25mm glass coverslips. 
8. Kimberly-Clark Professional™ Kimtech Science™ Kimwipes™ Delicate Task 
Wipers, 1-Ply (Kimberly-Clark Professional™ 34155). 
9. Parafilm™ M Wrapping Film (Fisher Scientific S37441). 
10. Humidified container (i.e., Pyrex dish filled with a small amount of water and 







11. Light-tight box. 
12. 6-Well cell culture plates (Thermo Scientific NuncTM Cell-Culture treated 
Multidishes 140675). 
13. Tweezers (the finer tipped, the better). 
14. Nuclear stain such as NucBlue™ Live Ready Probes™ Reagent (Invitrogen 
R37605). 
15. Mounting medium such as ProLong™ Gold Antifade Mountant (ThermoFisher 
Scientific P10144). 
 
2.3.0.  Methods: 
The quantification of immunofluorescence colocalization protocol requires detailed 
planning of the experimental design prior to starting.  The theory behind the set-up of this 
methodology is similar to a multi-stain flow cytometry experiment, where controls of 
each cell type including unstained, single florescent stains, and multi-fluorescent stains 
(including both antibody stains and live/dead viability stains) are required in biological 
triplicate.  To complete an accurate colocalization experiment or perform an optimal 
immunofluorescence study, it is advised that an antibody titration (concentration dilution 
series) be completed for each new cell type or antiserum used.  A control sample of each 
cell type with a single Hoechst stain or another DNA binding equivalent should be 
included.  If an isotype control for each marker is not available, minimally include a 
secondary only control.  A dual fluorescent stain of Hoechst to the nuclear or 
pluripotency marker of choice will provide a valuable nuclear reference as well.  It is 







colonies within each passage and imaging set are representative of the true post-imaging 
calculations.  All biological replications within a statistical set should be run within a 
single sitting of an experimental run by confocal microscopy, including the identical laser 
settings and general threshold parameters.  Deviating from these will result in inconsistent 
measures.  A benefit to completing this modality that cannot be accomplished with flow 
cytometry is that you can revisit the imaging process of coverslips at any point in time 
using confocal microscopy if controls are re-analyzed and new thresholds are set. 
2.3.1.  Coverslip Preparation. 
Wash 1.25 mm thick coverslips with 70 % ethanol diluted in MilliQ water.  Dry the 
coverslip with a Kimwipe and UV within a covered 6-well culture dish in a biosafety 
cabinet for 1 hour to sterilize and dry (see Note 1).  Coat coverslips with 200 L of sterile 
0.1 % gelatin or substratum of choice.  Incubate overnight in an incubator (37 C at 5 % 
CO2).  Alternatively, for mEpiSCs weaned off MEFs, coat coverslips with 200 L of 10 
g/mL/cm2 fibronectin for 45 minutes at room temperature (see Note 2).  Aspirate 
residual substratum.  Plate cells on the outline of the substratum.  Eject cell suspension in 
place of the substratum (see Note 2).  Allow for cells to attach for 1 hour before gently 
filling the well with the corresponding cell media for overnight incubation (see Note 3). 
2.3.2.  Staining Preparation. 
Wash cells once with Dulbecco’s Phosphate-Buffered Saline without calcium/magnesium 
(DPBS(-/-)) (see Note 4).  Incubate coverslips in chilled 4 % paraformaldehyde (Sigma -
Aldrich) diluted in DPBS(-/-) for 10 minutes.  Wash once with chilled DPBS(-/-) for 10 







(see Note 6).  Wash once for 10 minutes with chilled DPBS(-/-).  Block the samples by 
incubating the colony adhered coverslips in 10 % serum (from host-species of secondary 
antibody) diluted in chilled DPBS(-/-)-T (0.1 % Tween-20) for 30 minutes.  No additional 
washing step is required. 
2.3.3.  Simultaneous Primary Antibody Staining. 
Dilute primary antibodies in 10 % serum (from host-species of secondary antibody) 
diluted in chilled DPBS(-/-)-T.  On a piece of parafilm, pipette 100 L per coverslip 
spaced out 5 cm apart (see Note 7).  Using a pair of sterile tweezers, lift each coverslip 
from the corner and gently dry the coverslip by touching the edge of the glass with a 
folded Kimwipe (see Note 8).  Once dry, place the coverslip cell-side-down on the diluted 
antibody.  The solution should fully cover the surface of the glass in contact with the 
parafilm if done correctly.  Incubate coverslips with primary antibodies in blocking serum 
overnight at 4℃.  To avoid dehydration of the coverslip, allow the incubation to take 
place in a humidified container.  All samples should incubate for the same length of time 
to be comparable by colocalization.  Remove the coverslip from the humified container 
by lifting the upside-down coverslip from the parafilm slowly.  Place the coverslip in a 6-
well plate cell side-up submerged in chilled DPBS(-/-).  Wash coverslip(s) once for 10 
minutes each in chilled DPBS(-/-).  Dilute secondary antibodies in 10% serum (from host-
species of secondary antibody) diluted in chilled DPBS(-/-)-T.  On a piece of parafilm, 
pipette 100 L per coverslip spaced out 5 cm apart.  The surface tension will hold the 
diluted antibody in place.  Incubate coverslips with secondary antibodies in blocking 
serum for 1 hour at room temperature.  Humidified incubation is not necessary for this 







sensitive, it is recommended that handling and future steps are completed under dim-
lighting.  Wash coverslip(s) with chilled DPBS(-/-), add 4 drops/mL of NucBlue™ Live 
Ready Probes™ Reagent (Hoechst 33342) for 5 minutes.  Not all samples will get a 
Hoechst staining step, always pay attention to your experimental design. Wash once with 
chilled DPBS(-/-) for 10 minutes. 
2.3.4.  Mounting and Slide Preparation. 
Mount onto 70 % ethanol cleaned, dry, and labelled microscope slides using a 
commercially available mounting media such as ProLong™ Gold Antifade Mountant.  
Place the coverslip cell side-down on an edge held up by the cover using tweezers and 
gently drop the lifted edge over the mounting media to avoid bubbles.  Seal with nail 
polish unless using an adhesive resin-based mounting media (see Note 9).  Store in a 
light-tight box until you are ready to image on a fluorescent microscope. 
2.3.5. Immunofluorescence Colocalization Optimization and Analysis. 
To accurately image, quantify, and compare mESCs, mEpiLCs and mEpiSCs, one must 
establish and apply a single, consistent set of laser parameters for each marker.  My 
analysis was completed on a ZEISS LSM800 confocal microscope with an Airyscan 
detector and ZEISS Zen system imaging software.  Zen Lite, while a free option, does not 
have the ability to do colocalization analysis in suite.  The basic steps of this protocol 
should be effective for all confocal immunofluorescence microscopic systems, however, 
if ZEISS Zen system software is unavailable, ImageJ/FIJI are free softwares that offer 
similar colocalization capabilities and other valuable plugins such as particle analysis and 
























































Figure 2.1.  Nuclear and cytoplasmic colocalization optimization of mEpiSCs. 
a) 3D representation of a mEpiSC colony generated from a Z-stack before being 
processed into an orthogonal projection.  X, Y and Z dimensions can be measured, as 
mEpiSC colonies have a flattened morphology, this approach is useful when comparing 
the morphologically domed/glistening, naïve mESCs.  b) Nuclear, cytoplasmic and 
protein of interest thresholds of the markers OCT4, GAPDH, and PKM2 respectively in 
mEpiSCs.  Channel thresholds are set to just above the solid green phase of the 
scatterplots in single stained controls with both lasers running at their optimized 
intensities.  c) Dual stained mEpiLC for GAPDH (green) and PKM2 (orange).  
Scatterplot of the dual stained specimens detailing nuclear to protein of interest areas of 
colocalization.  Pixel correlation and overlap are measured above the thresholds.  Scale 





















Identify the appropriate stage settings and focus onto colonies at 40x and 63x objectives 
using a Hoechst or equivalent single stained samples (see Notes 10 and 11).  Optimize 
the corresponding laser to each protein marker of interest to the brightest specimen.  All 
the select laser parameters should not result in autofluorescence of any cell type in that 
laser configuration.  If your microscope does not contain a Z-stack module (see Note 12).  
Complete a Z-stack series at 40x magnification set to just beyond the top and bottom of a 
centered colony.  For mESCs, mEpiSCs and mEpiSC, 40x should allow for an entire 
medium size colony to be in view.  These images can be used to examine and visually 
compare the 3D topography of each pluripotent state colony (Figure 2.1.a) (see Note 13).  
Process z-stacks into orthogonal projections (see Note 14).  Select the brightest samples 
of each single stained marker to set the base threshold.  Select the colocalization or 
scatterplot option, in Zeiss software this is a tab labelled ‘Colocalization’.  This should 
appear as a quadrant with a crosshair containing two, adjustable thresholds (Figure 2.1.b).  
Set the x-axes to one of the channels examined and the y-axes to the other channel.  
Threshold should be adjusted to keep the signal below the solid green fluorescence 
(Figure 2.1.b) (see Note 15).  Once the threshold is set, use these settings on each of the 
dual stained images (Figure 2.1.c), the quadrant labelled ‘3’ represents pixels beyond both 
control thresholds.  A corresponding table with completed calculations is available on the 
Zeiss Zen system under the table option.  Depending on your software, you may need to 










Use the following formulae and compare biological replicates as mean ±SEM (Dunn, 
Kamocka, and McDonald 2011): 
 
𝑀𝑂𝐶 =  
∑ (𝑅𝑖 × 𝐺𝑖)𝑖
√∑ 𝑅𝑖
2
𝑖 × ∑ 𝐺𝑖
2
𝑖
 𝑃𝐶𝐶 =  
∑ (𝑅𝑖 − ?̅?)𝑖 × (𝐺𝑖 − ?̅?)
√∑ (𝑅𝑖 − ?̅?)2 × ∑ (𝐺𝑖 − ?̅?)2𝑖𝑖
 
 
Where ‘R’ and ‘G’ represent the fluorophore intensities of the first and second laser 
channels respectively.  As a check compare Hoechst-stained controls (nuclear reference) 
to nuclear protein markers such as OCT4, SOX2, or NANOG to verify the accuracy of 
overlap and correlation to nuclear staining. 
2.3.5.  Qualifying Descriptors: 
PCC and MOC ranges can be qualified into useful and publishable descriptors (Zinchuk, 
Wu, and Grossenbacher-Zinchuk 2013).   
PCC: [very weak: -1 – -0.27], [weak: -0.26 - 0.09], [moderate: 0.1 – 0.48], [strong: 0.49 
– 0.84], [very strong: 0.85 – 1.0]   
MOC: [very weak: 0 – 0.49], [weak: 0.50 – 0.70], [moderate: 0.71 – 0.88], [strong: 0.89 
– 0.97], [very strong: 0.98 – 1.0] 
 
2.4.0.  Notes: 
 
Note 1: To avoid coverslips from sticking to the dish, prop coverslips onto a wall of the dish. 







Note 3. If seeding MEFs prior to mEpiSCs, repeat this step 24-hours post-MEF seeding with 
mEpiSCs. 
Note 4. Typical protocols state to wash cells up to 3 times, however, mEpiSCs do not stick to 
their substratum very well, especially when coated onto feeders.  The generation of mEpiLCs 
results in a mass-apoptosis event 48 hours into generation, it is highly recommended that they be 
treated with the utmost care during washing steps.  All washing steps need to be completed 
gently and all liquid ejection needs to be directed off the adhered cells.  Avoid agitation of the 
plate during washing steps to improve adherence. 
Note 5. Take care that the DPBS(-/-) is in liquid form without slush that may increase 
mechanical stress upon ejection.   
Note 6. This concentration and duration allow for small, medium, and large colonies 
maintaining either the domed or flattened morphologies of mESCs or mEpiSCs to be 
permeabilization throughout the structure and underlying MEF layer.  Exceeding this 
concentration or duration will lead to decreased adherence and morphological integrity leading 
to poor 3D topographical imaging. 
Note 7. The surface tension will hold the diluted antibody in place.   
Note 8. Residual liquid will be pulled off of the coverslip without physically contacting the 
adhered cells or subjecting them to unnecessary aspiration.  Lifting the coverslips is performed 
easier in liquid, reducing the surface tension effect of the glass on the plate.   
Note 9. Clear, viscous nail polish works best if no resin-based mounting media is available. 
Note 10. If your microscope has the option to save stage settings, save this parameter for each 







Note 11. If you are unsure of which protein marker will fluoresce, the brightest out of the cell 
types or treatments you are examining, briefly image each and select the brightest and least 
bright of each protein marker.   
Note 12. If your microscope does not contain a Z-stack module.  Single slice images can still be 
compared using this protocol, proceed to Step.6.  Individual cells can be outlined in both modes, 
this is especially important for examining only mEpiSCs if grown on feeders (Figure 2.1. B)) or if 
comparing individual cells to the total colony. 
Note 13. If time and memory space is not an issue, use the smallest slice size possible at 
the greatest resolution for optimal imaging. 
Note 14. These images retain data from the individual slices and are easier to compute 
for post-image analysis.    
Note 15. Some microscopes have a Costes algorithm included, if this option is opted for, 
double check that the crosshair is accurately placed. 
 
2.5.0.  Discussion: 
Traditionally, colocalization is employed to investigate close interaction between two 
proteins of interest through fluorescent imaging.  However, this view is myopic and 
understates the power that a well-controlled and optimized colocalization study can 
demonstrate.  Colocalization is not simply a method to propose interaction, but rather a 
form of quantitative analysis that demonstrates correlation between proteins indicative of 
biomolecular interaction and localization overlap within a defined cellular region.  
Colocalization is actually a physics-based approach to determining trends in pixel 







this approach, when a greater quantity pixel of one set of data occupies the same space, 
they will overlap to a higher degree than another set that is offset.  Additionally, when 
compared based on a scatterplot of pixel orientation, trends in pixel distribution can 
determine if there is a correlation to their placement (Dunn, Kamocka, and McDonald 
2011).  Taken together, two fluorophores that occupy the same cellular space can be 
measured in terms of overlap and two fluorophores that show similar pixel distribution 
may also correlate in pixel intensity.  These two metrics can be measured by the 
Manders’s overlap coefficient (MOC) and Pearson’s correlation coefficient (PCC) 
respectively and represent the two components of colocalization (Dunn, Kamocka, and 
McDonald 2011). 
 
These methods will accurately and comprehensively determine differences in nuclear and 
cytoplasmic expression and changes by fluorescence imaging.  Due to the high nuclear-
to-cytoplasmic size ratio, traditional methods of nuclear translocation validation, such as 
nuclear extraction and subsequent immunoblotting, present a challenge in separating the 
cytoplasmic and nuclear fractions within stem cells (Oh et al. 2005).  Nuclear-to-
cytoplasmic ratios are valuable for validating pluripotency state, due to the defined 
nuclear localization of OCT4, SOX2, and NANOG, imaging studies are of particular 
relevance to establishing mPSC pluripotency (Perestrelo et al. 2017).   
 
The accuracy of this methodology relies on the addition of the nuclear reference, namely 
Hoechst relative to OCT4.  Comparing two nuclear references ensures that the 
localization differences between the proteins of interest (in example; PKM2) and the 







utilized this methodology however my unpublished works show that this is an invaluable 
tool of validation (Dierolf, Watson, and Betts 2020).  Additionally, I apply an entire 
additional dimension relative to a typical colocalization by analysing orthogonal 
projections of three-dimensional stacks of colonies as opposed to a two-dimensional 
comparison, this is beneficial as cells are not 2-dimensional and their expressed proteins 
do not simply conform to a single layer of expression and localization (Dunn, Kamocka, 
and McDonald 2011).  The main challenge of applying this methodology is the difficulty 
associated with transitioning and plating pluripotent states.  When transitioning from 
naïve-to-primed-like states your samples will also shift from expressing E- to N- 
cadherins and undergo a period of mass apoptosis 48 hours into transitioning (Theunissen 
et al. 2016; Hayashi et al. 2011).  Taken together, cell adhesion and viability are 
extraordinarily difficult to optimize and control for during this pivotal stage of the 
protocol (Hayashi et al. 2011).  This is one of the few, if not only colocalization methods 
designed specifically for cells grown in colonies and with cells having high nuclear-to-
cytoplasmic size ratios, as such, other colocalization methodologies likely will not 
provide for accurate colocalization of proteins in these cell types.  Additionally, I further 
improved this methodology by implementing qualified descriptor sets for MOC and PCC 
ranges to serve as accurate descriptors and metrics of spatial overlap and correlation 
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  
 
The field of colocalization microscopy is mired in controversy, and perhaps rightly so, as 
the variety and reproducibility of techniques leaves much to be desired and the lack of 
proper guidelines is evident (Adler and Parmryd 2010; Aaron, Taylor, and Chew 2019; 







a way to measure spatial overlap or as a metric of colocalization at all (Aaron, Taylor, and 
Chew 2019; Adler and Parmryd 2010).  These varying points of view stem from 
differences in opinion on biologic relevance and physics-based approaches on validation 
(Adler and Parmryd 2010, 2012; Zinchuk, Zinchuk, and Okada 2007).  This doubt in the 
MOC is valid in a poorly optimized study as the MOC is sensitive to the intensity of 
undesired signals of interest due to high saturation or poor imaging techniques (Aaron, 
Taylor, and Chew 2019).  When poorly imaged or oversaturated MOC is elevated, 
however, I circumvent such an artefact in three ways; 1) by setting a threshold on a 
titrated sample in the cell type of the highest expression for each parameter, 2) by 
outlining areas/regions of interest to avoid any potential non-specific binding sites, and 
finally 3) using a the nuclear reference to the nuclear comparison marker allows for any 
potential elevated MOC value to be precisely localized.  In a poorly executed study, an 
elevated MOC would show little difference between controls and the additional nuclear 
reference.  These results promote the MOC is a valuable metric of spatial overlap for stem 
cell related colocalization studies.  In the context of the traditional misconception of 
colocalization, the MOC is will not demonstrate any level of molecular interaction 
between two proteins of interest.   
 
The ways in which the degree of interaction between two or more molecules is 
determined by the metric of correlation or the degree of colocalization.  With regards to 
correlation, the algorithm recommended in this study and that which is used in most 
publications is PCC.  PCC is not as controversial as MOC, however, it can be improved 
upon by calculating the Spearman coefficient, a metric of correlation that identifies non-







which is only sensitive to direct, linear relationships (Aaron, Taylor, and Chew 2019).  
The Spearman coefficient measures intensity in ranks instead of raw intensity like the 
PCC, allowing for an averaging of intensities that will reveal correlated, non-linear 
relationships to be portrayed and analyzed as linear scatterplots.  Unlike the MOC, the 
PCC is sensitive to a high signal to noise ratio, similar to the recommendations for a 
quality MOC measurement, a well-controlled and calibrated study needs to take place for 
an accurate PCC value, otherwise, increases the signal-to-noise ratio will decrease any 
measured correlation (Dunn, Kamocka, and McDonald 2011).  To accurately compare 
PCC values amongst groups it is important that colony size and cell culture parameters 
are as similar as possible to allow for the highest signal-to-noise ratio possible.  Together 
the metrics of MOC and PCC are the basic, core components of colocalization and work 
together to inform the relationship of two fluorophores co-occurrence and correlation 
with each other. This metholodology comprehensively assesses all these parameters and 
has applied both PCC and MOC to functions to measure differences accurately and 
precisely in nuclear and cytoplasmic protein localization patterns in pluripotent stem 
cells. 
 
2.6.0.  Acknowledgements: 
mESC and mEpiSC pluripotent stem cell lines were graciously gifted from Dr. Janet 
Rossant. This research was funded by a Canadian Institutes of Health Research operating 
grant to A.J.W. and D.H.B. and Natural Sciences and Engineering Research Council of 
Canada grant to D.H.B. The funding sources played no role in design, data collection, 







2.7.0.  References: 
Aaron, Jesse S, Aaron B Taylor, and Teng-Leong Chew. 2019. “The Pearson’s 
Correlation Coefficient Is Not a Universally Superior Colocalization Metric. 
Response to ‘Quantifying Colocalization: The MOC Is a Hybrid Coefficient – an 
Uninformative Mix of Co-Occurrence and Correlation.’” Journal of Cell Science 
132 (1): jcs227074. https://doi.org/10.1242/jcs.227074. 
Adler, Jeremy, and Ingela Parmryd. 2010. “Quantifying Colocalization by Correlation: 
The Pearson Correlation Coefficient Is Superior to the Mander’s Overlap 
Coefficient.” Cytometry Part A 77A (8): 733–42. 
https://doi.org/10.1002/cyto.a.20896. 
———. 2012. “Colocalization Analysis in Fluorescence Microscopy.” Methods in 
Molecular Biology 931: 97–109. https://doi.org/10.1007/978-1-62703-56-4_5. 
Agnati, Luigi F, Kjell Fuxe, Maria Torvinen, Susanna Genedani, Rafael Franco, Stan 
Watson, Gastone G Nussdorfer, Giuseppina Leo, and Diego Guidolin. 2005. “New 
Methods to Evaluate Colocalization of Fluorophores in Immunocytochemical 
Preparations as Exemplified by a Study on A2A and D2 Receptors in Chinese 
Hamster Ovary Cells.” Journal of Histochemistry & Cytochemistry 53 (8): 941–53. 
https://doi.org/10.1369/jhc.4A6355.2005. 
Comeau, Jonathan W D, Santiago Costantino, and Paul W Wiseman. 2006. “A Guide to 
Accurate Fluorescence Microscopy Colocalization Measurements.” Biophysical 
Journal 91 (12): 4611–22. https://doi.org/10.1529/biophysj.106.089441. 
Dierolf, Joshua G, Andrew J Watson, and Dean H Betts. 2020. “Differential Localization 
Patterns of Pyruvate Kinase Isoforms in Murine Naïve, Formative and Primed 
Pluripotent States.” BioRxiv, January, 2020.04.12.036251. 
https://doi.org/10.1101/2020.04.12.036251. 
Dunn, Kenneth W., Malgorzata M. Kamocka, and John H. McDonald. 2011. “A Practical 
Guide to Evaluating Colocalization in Biological Microscopy.” American Journal of 
Physiology-Cell Physiology 300 (4): C723–42. 
https://doi.org/10.1152/ajpcell.00462.2010. 
Giannoni, Elisa, Maria Letizia Taddei, Andrea Morandi, Giuseppina Comito, Maura 
Calvani, Francesca Bianchini, Barbara Richichi, et al. 2015. “Targeting Stromal-
Induced Pyruvate Kinase M2 Nuclear Translocation Impairs Oxphos and Prostate 
Cancer Metastatic Spread.” Oncotarget 6 (27): 24061–74. 
https://doi.org/10.18632/oncotarget.4448. 
Hayashi, Katsuhiko, Hiroshi Ohta, Kazuki Kurimoto, Shinya Aramaki, and Mitinori 
Saitou. 2011. “Reconstitution of the Mouse Germ Cell Specification Pathway in 
Culture by Pluripotent Stem Cells.” Cell 146 (4): 519–32. 
https://doi.org/10.1016/j.cell.2011.06.052. 
Joshi, Sonali, and Dihua Yu. 2017. “Chapter 8 - Immunofluorescence.” In , edited by 
Morteza Jalali, Francesca Y L Saldanha, and Mehdi B T - Basic Science Methods for 
Clinical Researchers Jalali, 135–50. Boston: Academic Press. 
https://doi.org/https://doi.org/10.1016/B978-0-12-803077-6.00008-4. 
Manders, EMM, FJ Verbeek, and JA Aten. 1993. “Measurement of Co-Localization of 
Objects in Dual-Colour Confocal Images.” Journal of Microscopy 169 (3): 375–82. 
https://doi.org/10.1111/j.1365-2818.1993.tb03313.x. 







Bin Park, Chul Jong Yoon, Dong-Wook Kim, Seok Hyun Kim, and Shin Yong 
Moon. 2005. “Derivation and Characterization of New Human Embryonic Stem Cell 
Lines: SNUhES1, SNUhES2, and SNUhES3.” STEM CELLS 23 (2): 211–19. 
https://doi.org/https://doi.org/10.1634/stemcells.2004-0122. 
Otsu, Nobuyuki. 1979. “A Threshold Selection Method from Gray-Level Histograms.” 
IEEE Transactions on Systems, Man and Cybernetics 20 (1): 62–66. 
https://doi.org/0018-9472/79/0100-0062$00.75. 
Pagliara, Stefano, Kristian Franze, Crystal R McClain, George W Wylde, Cynthia L 
Fisher, Robin J M Franklin, Alexandre J Kabla, Ulrich F Keyser, and Kevin J 
Chalut. 2014. “Auxetic Nuclei in Embryonic Stem Cells Exiting Pluripotency.” 
Nature Materials 13 (6): 638–44. https://doi.org/10.1038/nmat3943. 
Pearson, Karl, and Olaus Magnus Friedrich Erdmann Henrici. 1896. “VII. Mathematical 
Contributions to the Theory of Evolution.—III. Regression, Heredity, and 
Panmixia.” Philosophical Transactions of the Royal Society of London. Series A, 
Containing Papers of a Mathematical or Physical Character 187 (January): 253–
318. https://doi.org/10.1098/rsta.1896.0007. 
Perestrelo, Tânia, Weitong Chen, Marcelo Correia, Christopher Le, Sandro Pereira, Ana S 
Rodrigues, Maria I Sousa, João Ramalho-Santos, and Denis Wirtz. 2017. “Pluri-IQ: 
Quantification of Embryonic Stem Cell Pluripotency through An&#xa0;Image-
Based Analysis Software.” Stem Cell Reports 9 (2): 697–709. 
https://doi.org/10.1016/j.stemcr.2017.06.006. 
Prakasam, Gopinath, Rajnish Kumar Singh, Mohammad Askandar Iqbal, Sunil Kumar 
Saini, Ashu Bhan Tiku, and Rameshwar N K Bamezai. 2017. “Pyruvate Kinase M 
Knockdown–Induced Signaling via AMP-Activated Protein Kinase Promotes 
Mitochondrial Biogenesis, Autophagy, and Cancer Cell Survival.” Journal of 
Biological Chemistry  292 (37): 15561–76. 
https://doi.org/10.1074/jbc.M117.791343. 
Seibler, Philip, John Graziotto, Hyun Jeong, Filip Simunovic, Christine Klein, and 
Dimitri Krainc. 2011. “Mitochondrial Parkin Recruitment Is Impaired in Neurons 
Derived from Mutant PINK1 Induced Pluripotent Stem Cells.” The Journal of 
Neuroscience 31 (16): 5970 LP – 5976. https://doi.org/10.1523/JNEUROSCI.4441-
10.2011. 
Theunissen, Thorold W, Marc Friedli, Yupeng He, Evarist Planet, Ryan C O’Neil, 
Styliani Markoulaki, Julien Pontis, et al. 2016. “Molecular Criteria for Defining the 
Naive Human Pluripotent State.” Cell Stem Cell 19 (4): 502–15. 
https://doi.org/10.1016/j.stem.2016.06.011. 
Wang, H.-J., Y.-J. Hsieh, W.-C. Cheng, C.-P. Lin, Y.-S. Lin, S.-F. Yang, C.-C. Chen, et 
al. 2014. “JMJD5 Regulates PKM2 Nuclear Translocation and Reprograms HIF-1 -
Mediated Glucose Metabolism.” Proceedings of the National Academy of Sciences 
111 (1): 279–84. https://doi.org/10.1073/pnas.1311249111. 
Wei, Libin, Yuanyuan Dai, Yuxin Zhou, Zihao He, Jingyue Yao, Li Zhao, Qinglong Guo, 
and Lin Yang. 2017. “Oroxylin A Activates PKM1/HNF4 Alpha to Induce 
Hepatoma Differentiation and Block Cancer Progression.” Cell Death & Disease 8 
(7): e2944. https://doi.org/10.1038/cddis.2017.335. 
Wu, Yong, Vadim Zinchuk, Olga Grossenbacher-Zinchuk, and Enrico Stefani. 2012. 
“Critical Evaluation of Quantitative Colocalization Analysis in Confocal 







4 (1): 27–37. https://doi.org/10.1007/s12539-012-0117-x. 
Yang, Weiwei, and Zhimin Lu. 2013. “Nuclear PKM2 Regulates the Warburg Effect.” 
Cell Cycle 12 (19): 3154–58. https://doi.org/10.4161/cc.26182. 
Yang, Weiwei, Yan Xia, Haitao Ji, Yanhua Zheng, Ji Liang, Wenhua Huang, Xiang Gao, 
Kenneth Aldape, and Zhimin Lu. 2011. “Nuclear PKM2 Regulates β-Catenin 
Transactivation upon EGFR Activation.” Nature 480 (7375): 118–22. 
https://doi.org/10.1038/nature10598. 
Yang, Weiwei, Yanhua Zheng, Yan Xia, Haitao Ji, Xiaomin Chen, Fang Guo, Costas A. 
Lyssiotis, Kenneth Aldape, Lewis C. Cantley, and Zhimin Lu. 2012. “ERK1/2-
Dependent Phosphorylation and Nuclear Translocation of PKM2 Promotes the 
Warburg Effect.” Nature Cell Biology 14 (12): 1295–1304. 
https://doi.org/10.1038/ncb2629. 
Zinchuk, Vadim, Yong Wu, and Olga Grossenbacher-Zinchuk. 2013. “Bridging the Gap 
between Qualitative and Quantitative Colocalization Results in Fluorescence 
Microscopy Studies.” Scientific Reports 3 (1): 1365. 
https://doi.org/10.1038/srep01365. 
Zinchuk, Vadim, Olga Zinchuk, and Teruhiko Okada. 2007. “Quantitative Colocalization 
Analysis of Multicolor Confocal Immunofluorescence Microscopy Images: Pushing 
Pixels to Explore Biological Phenomena.” ACTA HISTOCHEMICA ET 






























Chapter 3  
 
A version of this Chapter has been accepted for publication in Experimental Cell 
Research. 
 
3.0.0.  Chapter Title:  Differential localization patterns of pyruvate kinase isoforms 
in murine naïve, formative, and primed pluripotent states 
 
3.0.1.  CRediT Author Statement: 
Joshua Dierolf: Conceptualization, Methodology, Validation, Formal Analysis, 
Investigation, Writing – Original Draft, Writing – Review & Editing, Visualization  
Dean Betts: Resources, Writing – Review & Editing, Funding Acquisition, Supervision 

















3.1.0.  Abstract: 
Mouse embryonic stem cells (mESCs) and mouse epiblast stem cells (mEpiSCs) 
represent opposite ends of a pluripotency continuum, referred to as naïve and primed 
pluripotent states, respectively.  These divergent pluripotent states differ in several ways 
including growth factor requirements, transcription factor expression, DNA methylation 
patterns, and metabolic profiles.  Naïve cells employ both glycolysis and oxidative 
phosphorylation (OXPHOS), whereas primed cells preferentially utilize aerobic 
glycolysis, a trait shared with cancer cells referred to as the ‘Warburg Effect’.  Until 
recently, metabolism has been regarded as a by-product of cell fate, however, evidence 
now supports metabolism as being a promoter of stem cell state and fate decisions.  
Pyruvate kinase muscle isoforms (PKM1 and PKM2) are important for generating and 
maintaining pluripotent stem cells (PSCs) and mediating the Warburg Effect.  Both 
isoforms catalyze the last step of glycolysis generating adenosine triphosphate and 
pyruvate, however, the precise role(s) of PKM1/2 in naïve and primed pluripotency is not 
well understood.  The primary objective of this study was to characterize the cellular 
expression and localization patterns of PKM1 and PKM2 in mESCs, chemically 
transitioned epiblast-like cells (mEpiLCs) representing formative pluripotency, and 
mEpiSCs using immunoblotting and confocal microscopy.  The results indicate that 
PKM1 and PKM2 are not only localized to the cytoplasm, but also accumulate in 
differential subnuclear regions of mESC, mEpiLCs, and mEpiSCs as determined by a 
quantitative, confocal microscopy colocalization employing orthogonal projections, and 
airyscan processing.  Importantly, the results demonstrate subnuclear localization of 
PKM1/2 shifts during the transition from mESCs, mEpiLCs, and mEpiSCs.  Finally, the 







Pearson’s correlation coefficient and Manders’s overlap coefficient for assessing nuclear 
and cytoplasmic protein colocalization in PSCs by immunofluorescence confocal 
microscopy.  I propose that nuclear PKM1/2 may assist with distinct pluripotency state 
maintenance and lineage priming by non-canonical mechanisms.  These results advance 
the understanding of the overall mechanisms controlling naïve, formative, and primed 
pluripotency.  
 
3.2.0.  Introduction: 
Pluripotent stem cells (PSCs) have the capacity for indefinite self-renewal and the 
potential to differentiate into the cell types of all three germ layers including the germ line 
(Nichols and Smith 2009).  The potency of PSCs, such as embryonic stem cells (ESCs), 
exists within a continuum with opposite ends described as naïve and primed states 
(Nichols and Smith 2009).  In mice, naïve mESCs are derived from the inner cell mass 
(ICM) of an early, embryonic day (E)3.5 to E4.5, blastocyst-stage embryo, whereas 
primed mouse epiblast stem cells (mEpiSCs) are derived later from the epiblast of E5.0-
8.0 post-implantation embryos (Morgani, Nichols, and Hadjantonakis 2017; Evans and 
Kaufman 1981; Brons et al. 2007; Tesar et al. 2007; Martin 1981).  However, when 
cultured in vitro, mEpiSCs more closely resemble the epiblast of E7.25-E8.0 embryos 
(Joo et al. 2014; Tesar et al. 2007; Morgani, Nichols, and Hadjantonakis 2017; Kojima et 
al. 2014).  Human ESCs (hESCs) have traditionally been stabilized at the primed 
pluripotent state, however, a naïve hESC line has been recently derived (Ge Guo et al. 
2016).  Between both ends of the pluripotent continuum exists a recently described 







2017).  Formative pluripotency is an executive phase and may represent the gene 
expression patterns and attributes of mouse epiblast cells within E5.5-6.25 embryo 
(Morgani, Nichols, and Hadjantonakis 2017).  Like naïve and primed PSCs, formative 
PSCs also express NANOG, OCT4, and SOX2 (Chambers et al. 2003; Kalkan and Smith 
2014; Hayashi et al. 2011).  However, unlike naïve and primed PSCs, the formative 
mouse epiblast-like cells (mEpiLCs) can efficiently differentiate into primordial germ 
cell-like cells when presented with the appropriate growth factors such as bone 
morphogenic protein 4 (Morgani, Nichols, and Hadjantonakis 2017; Ohinata et al. 2009).  
Each pluripotent state has several distinguishing features such as unique morphology, 
growth factor dependencies, gene expression profiles, epigenetic status, and metabolic 
preferences (Morgani, Nichols, and Hadjantonakis 2017; Nichols and Smith 2009).  
Morphologically, naïve PSCs are more rounded in appearance and grow as colonies with 
glistening edges compared to flattened primed PSC colonies (Nichols and Smith 2009).  
This hemispherical morphology of naïve cells is largely due to greater Cdh1 expression, 
which can be replicated in mEpiSCs following overexpression of Cdh1 (Ohtsuka, 
Nishikawa-Torikai, and Niwa 2012).  Culture of mESCs requires leukemia inhibitor 
factor (LIF) which promotes ‘ground state’ naïve pluripotency and resists differentiation 
through activation of the transcription factor STAT3 (Ohtsuka, Nakai-Futatsugi, and 
Niwa 2015).  Stabilizing naïve pluripotency requires LIF and the addition of two small 
molecule inhibitors (LIF/2i) of MEK1/2 (PD00032) and glycogen synthase kinase-3 
(CHIR99021) (Ying et al. 2008; Silva and Smith 2008).  Formative cells can be 
chemically transitioned from mESCs-to-mouse epiblast-like cells (mEpiLCs) over 48 
hours as a transient and heterogenous population (Kinoshita and Smith 2018; Hayashi et 







chemically transitioned mEpiLCs are cultured with ACTIVIN-A and FGF-2.  While naïve 
and primed cells express the core pluripotency associated genes Oct4, Sox2, Nanog, both 
states differ in transcriptional programs with Rex1, Esrrb, Dppa3, Klf2/4/5, Tcfcp2l1, and 
Pecam delineating the naïve state, and Zic2, T (Brachyury), and Cer1, to list a few, 
distinguishing the primed pluripotent state (Morgani, Nichols, and Hadjantonakis 2017).  
The formative pluripotent state is reported to highly express Lef1, Pou1fc, and Dnmt3 
(Kalkan et al. 2019).  Naïve and primed pluripotent states also differ in terms of their 
epigenetic landscape, including X-activation and chromatin methylation status 
(Takahashi, Kobayashi, and Hiratani 2018).  Female primed PSCs display random X 
chromosome inactivation, whereas naïve PSCs display activation of both X chromosomes 
(Heard 2004).  Relative to primed cells, naïve PSCs contain larger regions of active 
chromatin as indicated by higher levels of H2k4me3 and histone acetylation (G. Guo et 
al. 2009; Gafni et al. 2013).  Importantly, naïve and primed PSCs also differ in terms of 
their metabolic preferences (W. Zhou et al. 2012).  Naïve cells are characterised as being 
metabolically bivalent, utilizing both glycolytic and oxidative phosphorylation 
(OXPHOS) processes, whereas primed cells are preferentially glycolytic (W. Zhou et al. 
2012).  Even when cultured in oxygen rich conditions, primed PSCs utilize aerobic 
glycolysis and display low OXPHOS gene expression, which, is characteristic of the 
Warburg Effect that is active in many cancer cells (Prigione et al. 2010).   
 
Despite the original observations of Dr. Otto Warburg that cells exhibiting the Warburg 
Effect consume elevated glucose and direct increased levels of pyruvate towards lactate 
formation, most cancers do not gain ATP by glycolysis primarily (Weinhouse et al. 







ATP, but rather increase precursors necessary for enhancing anabolic processes 
(DeBerardinis and Chandel 2016).  Indeed, glucose oxidation by OXPHOS still produces 
the bulk of ATP in most cancer cells with anaplerotic flux of metabolic intermediates 
produced by glutaminolysis and lactic acid fermentation into the TCA cycle including α-
ketoglutarate and even lactate respectively (Feron 2009).  The sourcing of metabolites for 
ATP production appears to be dependent on the surrounding microenvironments and 
cancer subtype (Hensley et al. 2016).  For example, non-small cell lung cancer (NSCLC) 
cells illustrate metabolic heterogeneity and preferential aerobic and non-aerobic 
metabolism processes (Hensley et al. 2016).  Within cells exhibiting the Warburg Effect, 
an increase in lactate production would be expected within NSCLC cells, elevated lactate 
is used a carbon source in the TCA cycle and other increased expression of pyruvate 
carboxylase promote higher levels of anaplerotic processes feeding into the TCA cycle 
compared to normal lung tissue (Hensley et al. 2016).  Misconceptions in distinguishing 
the concepts of anabolic processes for cellular proliferation and energy generation 
relating to the Warburg Effect need to be tackled not only in cancer research, but also in 
stem cell research going forward (DeBerardinis and Chandel 2016).   
The Warburg Effect is orchestrated by an upregulation of key transcription factors 
including: Oct4, c-Myc, Hif-1∝, and Nf𝜅b along with the glycolytic genes: Hk2, Pgm, 
Pdk, and pyruvate kinase muscle isoform 2 (Pkm2) (Levine and Puzio-Kuter 2010). 
When upregulated, these aerobic glycolytic associated genes promote anabolism and ATP 
generation to boost glycolytic flux (Feron 2009; Guppy, Greiner, and Brand 1993).  It is 
hypothesized that the high glycolytic flux of mESC maintains their high proliferative 







pluripotency and as a regulator of gene expression controlling cell proliferation and 
differentiation (Kondoh et al. 2007; Zhang et al. 2018).  While metabolism has 
traditionally been viewed as a by-product of cell fate decisions, the manipulation of 
metabolic genes and their products in stem cells can promote or resist cellular 
differentiation and reprogramming (Hawkins et al. 2016; Rodrigues et al. 2015; W. Zhou 
et al. 2012).  Thus, the developmental progression of naïve-to-primed transitioning occurs 
in synchrony with metabolic programming to influence cell fate and pluripotent state as 
both a driver and a passenger (Dahan et al. 2019).  
Recently, pyruvate kinase muscle isoforms 1 and 2 (PKM1/2) have been implicated in 
regulating pluripotency, proliferation, and in the generation of pluripotent stem cells 
during reprogramming (Qin et al. 2017).  PKM1 and PKM2 are the metabolic enzymes 
responsible for catalyzing the final, rate limiting step of glycolysis by directing pyruvate 
towards either a lactate or acetyl-CoA fate (Noguchi et al. 1987; Christofk et al. 2008).  
Mammals express four tissue specific pyruvate kinase isozymes; M1, M2, L, and R, each 
with unique properties and tissue expression patterns to meet specific metabolic demands 
(Yamada and Noguchi 1999).  PKM1/2 are alternatively spliced isoforms from the PKM 
gene and both PKL and PKR are encoded by the PKLR gene (Noguchi et al. 1987).  The 
M1 and M2 isoforms are spliced by three different heterogenous nuclear 
ribonucleoproteins; hnRNPI/hnRNP1/hnRNP2 that involve the inclusion of exon 9 or 10, 
respectively (David et al. 2010).  PKM1/2 activity is regulated by homotropic and 
heterotropic allosteric interactions with fructose 1,6-bisphosphate (FBP) and 
phosphoenolpyruvate respectively (Boles et al. 1997; Imamura and Tanaka 1982).  PKM1 







cancer cell types exhibit elevated PKM2 with certain types of tumours such as 
glioblastomas displaying a complete isoform switch from PKM1 to PKM2 (Desai et al. 
2013).  The elevated PKM2 found in cancer cells is predominantly the inactive PKM2 
homodimer form, which is due to pulsatile phosphofructokinase (Shi, You, and Luo 
2019).  The active homotetramer is typically bound to its cofactor FBP, however, when 
the PKM2 homodimer is phosphorylated (Y105) by the oncogenic linked fibroblast 
growth factor receptor type 1, the homotetrameric configuration is disrupted (Hitosugi et 
al. 2009; Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley 2008).  
This interrupts glucose oxidation and increases glycolysis and lactate production in 
aerobic glycolytic preferential cancer cells, even in the presence of abundant oxygen 
levels.  In contrast, PKM1 operates as a constitutively active homotetramer without a 
described allosteric binding site (Jurica et al. 1998).  
 
PKM2 has additional non-canonical roles including its function as a protein kinase, 
cytosolic receptor, transcriptional co-activator, and is also implicated in cytokinesis and 
chromosome segregation (W. Yang and Lu 2015; Jiang, Wang, et al. 2014; Jiang, Li, et 
al. 2014).  PKM2 can form a complex with OCT4 resulting in decreased OCT4 
transcriptional activity and stemness with increased apoptosis and differentiation (Lee et 
al. 2008; Morfouace et al. 2014).  Studies also indicate that the interaction of PKM2 and 
OCT4 affects mitosis and tumor energy production (Niwa, Miyazaki, and Smith 2000).  
PKM2 is implicated in pluripotency through its interaction and transcriptional regulation 
of OCT4 in hESCs (Christensen, Calder, and Houghton 2015).  Knockdown of PKM2 in 
hESCs exhibited no change in lactate production or glucose uptake, however, OCT4 







observed in the nuclei of the hESCs cultured under both normoxic (20%), and hypoxic 
(5%) oxygen conditions, but a significant reduction in PKM2 expression was observed 
under normoxia (Christensen, Calder, and Houghton 2015).  Overexpression of either 
PKM1 or PKM2 results in increased transcript abundance of the pluripotency associated 
genes; Eras, Rex1, and Nanog in mESCs (Qin et al. 2017).  Upon knockdown of total 
PKM, pluripotency associated gene transcript abundance also decreases, but self-renewal 
and morphology appear unperturbed (Qin et al. 2017).  During reprogramming of somatic 
cells into iPSCs, both PKM1 and PKM2 are upregulated within the first 8 days (Qin et al. 
2017).  Additionally, the knockdown of total PKM during this period hinders 
reprogramming and overexpression of PKM2 significantly increases the generation of 
iPSC colonies (Qin et al. 2017).  PKM1 was originally thought to only be expressed in the 
cells of non-proliferative tumors, however, PKM1 has recently been localized in the 
nuclei of hepatoma (HepG2 and SMMC-7721 cell lines) cells following Oroxylin A (OA) 
treatment and this localization was concluded to promote cellular differentiation to 
hepatocytes-like cells (Wei et al. 2017; Israelsen et al. 2013).   
 
Quantitative colocalization analysis (QCA) is most commonly divided into two metrics, 
these measures are the degree of overlap and correlation (Dunn, Kamocka, and McDonald 
2011).  Both MOC and the PCC are commonly used to quantify fluorescent protein 
spatial overlap and correlation (Adler and Parmryd 2012).  Despite the accuracy and 
power of QCA, this technique has been not been utilized to its full extent, especially so, 
in its application to measuring protein colocalization in pluripotent stem cells (Dunn, 







analysis of PKM1/2 colocalization with nuclear and cytoplasmic protein markers during 
naïve, formative, and primed pluripotency within mouse ES cell cultures  
 
This study, for the first time, comprehensively characterized the subcellular localization 
and expression patterns of PKM1 and PKM2 isoforms during transition from naïve, 
through the formative and onto the primed murine embryonic pluripotent states.  I 
accomplished this by optimizing a confocal microscopy colocalization approach 
comparing correlation and co-occurrence of PKM1 and PKM2 localization to nuclear 
localized OCT4 and cytoplasmic localized GAPDH.  Degrees of colocalization were then 
applied to our measured values of overlap and correlation using qualified ranges 
indicating a spectrum of ‘very weak’ to ‘very strong’ variables of colocalization 
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  Using these approaches, the data 
suggests an elevated nuclear presence of PKM1 and PKM2 in naïve mESCs, formative 
state mEpiLCs and primed mEpiSCs as assessed by spatial overlap of PKM1 and PKM2 
localization to OCT4 localization.  The results also demonstrate a moderate association of 
PKM1 and PKM2 to OCT4 localization in naïve mESCs and a strong association between 
PKM1 and OCT4 in formative mEpiLCs.  Together, the findings suggest a novel, non-
canonical role for PKM1 in pluripotent stem cells. 
 
3.3.0.  Materials and methods: 
3.3.1.  Antibody specificity: 
Rabbit polyclonal antibodies specific for PKM1 and PKM2 (Proteintech 15821-1-AP, 







abundance in this study.  These PKM1 and PKM2 antibodies recognize the corresponding 
immunogens of LVRASSHSTDLMEAMAMGSV and LRRLAPITSDPTEATAVGAV, 
respectively, and have been knockdown-verified confirming their isoform specificity 
(Nakatsu et al. 2015; Horiuchi et al. 2017; Christofk et al. 2008; Ma et al. 2019; Jianan 
Chen et al. 2018). 
3.3.2.  Feeder cell derivation and culture conditions: 
Mouse embryonic fibroblasts (MEFs) (CF1 cell line, ThermoFisher) derived from E12.5 
mouse embryos were plated and expanded on 0.1% porcine gelatin (Sigma G2500) coated 
dishes and irradiated (8000 rads).  Irradiated MEFs were cultured in media containing the 
following: DMEM (ThermoFisher11960044), 8.9% Qualified FBS (ThermoFisher 
12483020, lot# 1936657), 1.1% MEM NEAA (100x) (ThermoFisher 11140050), 1.1% 
GlutaMAX (ThermoFisher 35050061).  Irradiated MEFs were plated on 0.1% gelatin 
dishes and cultured for a minimum of 1 hour prior to mEpiSC plating for 
immunofluorescence and 24 hours for all other molecular analyses. 
3.3.3.  Stem cell culture conditions: 
Feeder-free, naïve, mouse embryonic stem cells (mESCs, R1 strain – 129X1 x 129S1; 
provided courtesy of Dr. Janet Rossant, Hospital for Sick Children, Toronto, Canada), 
feeder-free, primed-like mouse epiblast-like cells (mEpiLCs, chemically converted R1 
mESCs) and primed mouse epiblast stem cells (mEpiSCs, strain – 129S2; also provided 
by Dr. Janet Rossant) were cultured in the following base media; a 1:1 mixture of 
KnockOut DMEM/F12 (ThermoFisher 12660012) and Neurobasal Media (ThermoFisher 







(ThermoFisher 35050061), 1.0% N2 Supplement (100x) (ThermoFisher 17502048), 2.0% 
B27 Supplement (50x) (ThermoFisher 17504044).  Base media for the culture of mESCs 
were supplemented with 1000 units/mL ESGRO Recombinant mouse LIF protein (EMD 
Millipore ESG1107), and 2i small molecule inhibitors: 1 µM PD0325901 (Reagents 
Direct 39-C68) and 3 µM CHIR99021 (Reagents Direct 27-H76).  Base media for the 
culture of mEpiLCs and mEpiSCs were supplemented with 20ng/mL Activin A from 
mouse (Sigma-Aldrich SRP6057) and 12ng/mL Fgf-2 from mouse (Sigma-Aldrich 
SRP3038).  mESCs were passaged using Accutase (STEMCELL Technologies 07920) 
and centrifuged at 244 x g for 5 minutes.  Primed mouse epiblast stem cells were cultured 
in the base medium and supplements as mEpiLCs were along with a substratum of 
irradiated mouse embryonic fibroblasts (MEFs).  One hour prior to passaging, growth 
medium was replaced.  Passaging was completed using Gentle Cell Dissociation Buffer 
(Gibco 13151-014) for 5 minutes at room temperature.  Lifted cells were then centrifuged 
at 244 x g for 3 minutes and plated at a density of 1:12 onto fibronectin coated dishes 
with MEFs.  RNA and protein abundance studies were completed by excluding MEFS for 
feeder-free conditions and passaging mEpiSCs with StemProTM AccutaseTM (Thermo 
Fisher A1110501) to ensure only MEF free lysates were used.  Additionally, during the 
preliminary work for this study it was clear that the MEF feeder cells supporting the 
mEpiSCs, express the PKM isoforms in abundance.  mEpiSCs were weaned off irradiated 
MEFs by gentle enzymatic passaging onto fibronectin over two passages, this resulted in 
a clean and healthy population of feeder-free mEpiSCs ready for protein abundance 








3.3.4.  Real-Time Quantitative qRT-PCR: 
RNA isolation was completed using a RNeasy RNA isolation kit (Qiagen 74104) and 
Trizol (Ambion 15596018) hybrid protocol followed by DNAse treatment (Invitrogen 
AM1906).  cDNA synthesis was completed in accordance with iScript (BioRad 170-
8891) protocols.  Total RNA was extracted from adherent cells using TRIzol Reagent 
(Invitrogen) and a RNeasy mini kit (Qiagen).  DNAses were then removed using DNAse 
Free Kit (AM1906).  cDNA synthesis using iScript.  Primers were tested in temperature 
gradients before cDNA dilution series to determine primer efficiencies.  Relative 
transcript abundance was compared using mean±SEM with a two-way ANOVA with 
Tukey’s multiple comparison test with three biological replicates.  Relative transcript 
abundance was calculated using the Pfaffl method of quantification, normalized to 
mESCs and relative to TATA-binding protein (Tbp) transcript abundance.  Forward and 
reverse primer designs and annealing temperatures are available in Table 3.1. 
 















57.0 - 63.0 F- TACTGAAGAAAGGGAGAATCATGG 
R- GAGACTGTTGGTGTTCTGAATAGG 
Pecam Naïve  89.999919 63.0 
F- CAAGGCCAAACAGAAACCCG 
R- GCCTTCCGTTCTCTTGGTGA 
Dppa3 Naïve 90.327424 63.0 
F- AAAGTCGACCCAATGAAGGA 
R- CGGGGTTTAGGGTTAGCTTT 
Rex1 Naïve 96.622863 63.0 
F- AGAAGAAAGCAGGATCGCCT 
R- TATGACTCACTTCCAGGGGG 









Klf2 Naïve 106.23229 63.0 
F- TCGAGGCTAGATGCCTTGTGA 
R- AAACGAAGCAGGCGGCAGA 
Klf4 Naïve 102.51493 63.0 
F- TGGTGCTTGGTGAGTTGTGG 
R- GCTCCCCCGTTTGGTACCTT 
Klf5 Naïve 102.58943 63.0 
F- TACGGGCGAGAAGCCCTACA 
R- GGCACACCATGCACTGGAAC 





57.0 F- AGAAGAAGAAGAGGAAGAGAGAGAAGC 
R- AGATGTAGGCAGCTGTCATTCTGG 
 
Dnmt3 Formative 99.041999 63.0 
F- GGCAAGGACGACGTTTTGTG 
R- GTTGGACACGTCCGTGTAGTGAG 
Pou1fc Formative 98.95197 59.4 
F- TTTCTCAAGTGTCCCAAGCC 
R- ACCACCTCCTTCTCCAGTTG 
Zic2 Primed 89.96254 63.0 
F- GGTGACCCACGTCTCTGTG  
R- CGGATGTGGTTGACCAGTTT 
Cer1 Primed 99.767999 60.0 
F- ACCTATGTGTGGATGGCTGC 
R- AGATCCGGCTTGTCTTCTGC 




3.3.5.  Western blotting: 
Mouse ESCs and mEpiLCs were washed with cold DPBS (calcium chloride/magnesium 
chloride/) (PBS(+/+)) (Gibco 14040-133) and all cell types were lysed with PierceTM 
RIPA Buffer (ThermoScientific 89900) supplemented with 1X Phosphatase Inhibitor 
Cocktail Set 2 (Calbiochem 5246251) and 1X Protease Inhibitor Cocktail Set 1 
(Calbiochem 539131).  mEpiSCs passaged off MEF-coated plates onto fibronectin 
(Roche 11051407001) coated plates for a single passage using StemProTM AccutaseTM to 
avoid MEF contamination. mEpiSCs were centrifuged at 244 x g and lysed.  Lysates were 
sonicated for five, 30 joule pulses over 30 seconds and were rotated at 4 °C for 30 







supernatant removed into a fresh, chilled tube.  Protein quantification was completed 
using a PierceTM BCA Protein Assay kit (Thermo Fisher Scientific 23225). Protein 
loading mixes were prepared at 10-25 µg samples in MilliQ H2O, LDS, and Reducing 
Agent at 70°C for 10 minutes. Loading mixes were loaded in NuPAGETM 4-12% Bis-Tris 
Gels (Invitrogen NuPAGE NP0336), the electroporation solution consisting of 1x MOPS 
(BOLT Invitrogen B000102) and 500 µL of sample reducing agent containing 
dithiothreitol (Thermofisher NP0009) added. Electrophoresis was completed at 200 V for 
50 minutes. Proteins were transferred to a PVDF membrane at 100V for 2 hours in ice-
cold conditions.  The protein transferred PVDF membrane (EMD Immobilon 
IPVH00010) was blocked in 5% bovine serum albumin (BSA) (ALB001) for 
phosphorylated antibodies or 5% skimmed milk (Carnation) in 1x TBST for 1 hour at 
room temperature with end-to-end agitation.  Primary antibodies were introduced to the 
membrane overnight at 4 °C with rotation.  Membranes were washed 3 times for 10 
minutes in TBST and HRP conjugated secondary antibodies were introduced for 1 hour at 
room temperature with rotation.  Membranes were then washed three times for 10 
minutes each and imaged with Luminata Classico Western HRP Substrate (EMD 
WBLUC0500) or Immobilon Forte Western HRP Substrate (EMD WBLUF0500) on a 
ChemiDoc.  Membranes were stripped using antibody stripping buffer (FroggaBio 
ST010) until previous antibody binding was no longer evident. Bands of interest were 
compared to 𝛽-ACTIN and/or Ponceaus S for total lane protein densitometry.  Western 
blotting densitometry results were compared using mean ± SEM, One-way ANOVA, 
Tukey’s multiple comparison test with three biological replicates.  Primary and secondary 










































































































5% Skim milk 
in TBST 
∝-TUBULIN 1ug/mL 
















3.3.6.  Immunofluorescence and confocal microscopy: 
Cells were plated onto 1.25mm thick coverslips coated with gelatin.  When ready, cells 
were fixed with 2% paraformaldehyde (PFA) (EMS 15714) in PBS(+/+) for 10 minutes 
and washed for 5 minutes with chilled PBS(+/+).  Following fixation, cells were 
permeabilized with 0.1% Triton X-100 (TX1568-1) in PBS(+/+) for 10 minutes and 
washed for 5 minutes with room temperature PBS(+/+).  Cells were then blocked in 10% 
animal serum of the host-species of the secondary antibody, diluted in 0.1% PBS(+/+)-







the host-species of secondary antibody, diluted with 0.1% PBST overnight.  Following 
primary incubation, cells were washed once for 5 minutes in PSB(+/+) before incubation 
in secondary antibody, diluted in 10% animal serum of the host-species of secondary 
antibody in 0.1% PBST for 1 hour.  See supplementary Table 3.3. for primary and 
secondary antibody dilutions. Hoechst staining was completed where necessary 
(secondary only controls in the case of colocalization) for 5 minutes in PBS(+/+) 
followed two washes in PBS(+/+) for 5 minutes per wash.  Cells were then mounted onto 
coverslips with Prolong Gold (P36934).  Each experiment and their individual cell types 
included a secondary only control that was analysed with the same laser intensities as the 
treatment samples.  Individual treatments were completed in three biological replicates.  
Primary and secondary antibodies and their concentrations are listed in Table 3.3.  
 
Table 3.3  Immunofluorescence antibody and stain list: 
 















































4ug/mL N/A N/A 
Hoechst (NucBlue) 3 drops/mL N/A N/A 
 
3.3.7.  Colocalization: co-occurrence and correlation by immunofluorescence: 
Orthogonal projections of colony optimal slice generated image stacks were taken at 40x 
and 63x immersed in oil by a Zeiss LSM800 confocal microscope.  Thresholds were set 
by optimized single stain samples (channel 488 - OCT4, GAPDH and channel 555 - 
PKM1, PKM2) exposed to all tested lasers and exposures.  These exposures and laser 
intensities were tested against secondary antibody only controls.  Double stains 
(PKM1/OCT4, PKM1/GAPDH, PKM2/OCT4 and PKM2/GAPDH) were taken in stacks 
containing full colonies and processed into orthogonal projections. The projections were 
then set to the predetermined co-localization thresholds (Costes thresholds were set when 
applicable) as set from the single stain controls.  Each treatment was analysed in at least 
biological triplicate and each biological replicate was examined for several technical 
replicates of different colonies within their respective samples.  Double stained treatments 
were compared for co-occurrence and correlation using Manders’s Overlap Coefficient 
(MOC) and Pearson’s Correlation Coefficient (PCC) respectively.  MOC and PCC 







within regions of interest respectively.  Areas of interest and negation of background 
information was completed using the outline tool to circle colonies and cells of interest 
while removing staining on MEFs and potential sources of non-specific binding.  
Additionally, individual cells were compared to whole colonies using airyscan processing 
under 63x magnification by confocal microscopy.  This process increased the signal-to-
noise ratio thus increasing signal resolution.  Due to the intensity of light during an 
airyscan process, photobleaching prevented stacks of colonies at 63x when examining the 
individual cells.  PCC values were categorised within set ranges to a classification, that 
included: correlation: very weak: -1 – -0.27, weak: -0.26 - 0.09, moderate: 0.1 – 0.48, 
strong: 0.49 – 0.84, and very strong: 0.85 – 1.0 (Zinchuk, Wu, and Grossenbacher-
Zinchuk 2013).  MOC values fall into set ranges of: overlap: very weak: 0 – 0.49, weak: 
0.50 – 0.70, moderate: 0.71 – 0.88, strong: 0.89 – 0.97, very strong: 0.98 – 1.0 (Zinchuk, 
Wu, and Grossenbacher-Zinchuk 2013).  Statistical analysis included application of a two 
tailed Mann-Whitney test of mean ±SEM MOC and PCC scores run in at least three 
biological and technical replicates. All tested samples were stained and treated in the 
same manner and processed in the same session.  Between microscopy sessions, single 
stain laser thresholds were retaken to account for any potential photobleaching.  Statistics 
of PCC and MOC treatments relative to the positive reference represent a two-way 
ANOVA with Sidak’s multiple comparisons test of mean±SEM PCC and MOC scores 








3.3.8.  Nuclear and cytoplasmic fractionation. 
Rapid isolation of nuclei from cells was completed using the REAP protocol (Nabbi and 
Riabowol 2015).  mESCs were grown to 90% confluency on 10 cm dishes.  Prior to 
collection, culture medium was aspirated, and the cells were washed with ice-cold PBS(-
/-) with 1X Protease Inhibitor Cocktail Set 1 (Calbiochem 539131).  The PBS was 
aspirated, and the dish was placed on ice where 1 mL of PBS was added, and the cells 
were scraped and centrifuged for 10 seconds at 10,000 rpm.  The supernatant was 
aspirated and resuspended in 900 µL of ice-cold 0.1% Tergitol-NP-40 (Sigma NP-40S) in 
PBS(-/-) before being triturated 5 times.  At this point a 300 µL total lysate sample was 
removed and stabilized in Laemmli buffer and vortexed.  This sample was sonicated at 20 
kHz for 2 pulses each 8 seconds long and the sample was then boiled for 1 minute and 
frozen prior to western blotting.  The remaining NP-40 suspended sample was then 
centrifuged at 10,000 rpm for 10 seconds and 300 µL was removed as the cytoplasmic 
fraction.  This fraction was stabilized in Laemmli buffer, vortexed and boiled for 1 minute 
before being frozen prior to western blotting. The remaining NP-40 suspended sample 
was aspirated and resuspended in 1 mL 0.1% NP-40 in PBS(-/-) with 1X Protease 
Inhibitor Cocktail Set 1 before centrifuged at 10,000 rpm.  The supernatant was 
discarded, and the pellet resuspended in water and Laemmli buffer before sonication at 20 
kHz for 2 pulses at 8 seconds per pulse.  This nuclear fraction was boiled for 1 minute 
and frozen for future western blotting as described above.  Antibody staining for control 
markers LAMIN A and ∝-TUBULIN and the markers of interest PKM1, pPKM2, and 
PKM2 were compared relative to total lane protein content by Ponceau staining (0.1% 







applying a one-way ANOVA with Tukey’s multiple comparison test or unpaired, two 
tailed t-test respectively with 3 biological replicates. 
 
3.4.0.  Results: 
3.4.1.  Characterization of naïve mESCs transitioning towards a primed pluripotent 
state. 
By 72 hours following the removal of mouse LIF and 2i supplementation with the 
addition of Fgf-2/Activin A (FA media), mESCs approximating a primed-like pluripotent 
state underwent an apoptotic event with the resulting colonies transitioning to a flattened 
morphology (Supplementary Figure 3.01.).  The mESCs by 72 hours had transitioned to 
mEpiLCs (primed-like state) and the mESCs, mEpiLCs, and mEpiSCs showed 
homogenous colony expression of the pluripotency associated genes NANOG, OCT4, 
and SOX2 (Figure 3.01.A).  Secondary antibody only controls confirmed the specificity 

















Supplementary Figure 3.01.  mEpiLC generation and mPSC cell morphology.   
 
(A) Schematic depicting the generation of mEpiLCs from mESCs and the associated 
pluripotent states. (B)  Phase contrast microscopy of mESCs, mEpiLCs (24, 48, 72, 96, 
and 120 hours) and mEpiSCs grown on MEFs.  Images take using 10x Magnification and 










Supplementary Figure 3.02.  Secondary antibody only immunofluorescence controls 
for pluripotency markers.  
Immunofluorescence of mESC, mEpiLC, and mEpiSC stained for Hoechst, phalloidin 
and the secondary antibodies (Table 3.3.) used throughout this study, assessed by 
confocal microscopy.  Images taken using 40x magnification and scale bars represent 20 











Assessment of stage specific transcript abundance of naïve, formative, and primed 
markers verified the pluripotent state of mESCs, mEpiLCs, and mEpiSCs, respectively 
(Figure 3.01.).  The naïve pluripotent associated genes: Rex1, Esrrb, Pecam, Tcfcp2l1, 
Klf2, Klf4, Dppa3, and Klf5 all underwent a significant (p<0.05) reduction in transcript 
abundance in mEpiLCs and mEpiSCs relative to mESCs (Figure 3.01.B).  The transcript 
abundance of formative pluripotent associated genes; Lef1, Dnmt3, and Pou1fc were 
significantly (p<0.05) increased in mEpiLCs compared to mESCs with Dnmt3 and 
Pou1fc mRNAs also significantly (p<0.05) elevated in mEpiLCs over that observed in 
mEpiSCs (Figure 3.01.B).  The transcript abundance of primed pluripotent state 
associated markers Zic2, T(Brachyury), and Cer1 were significantly (p<0.05) increased in 












Figure 3.01.  mESC, mEpiLC, and mEpiSC populations transcript abundance for 
pluripotency genes.   
(A) Immunofluorescence of mESC, mEpiLC, and mEpiSC stained with Hoechst (blue), 
phalloidin (red) and the core pluripotency associated markers (green): NANOG, OCT4, 
SOX2 assessed by confocal microscopy.  Images taken using 40x magnification and scale 
bars represent 20 𝜇𝑚. (B) Histogram of transcript abundance of naïve, formative, and 
primed pluripotent associated genes relative to Tbp and normalized to mESCs. Error bars 
represent standard error of the mean (SEM), n=3, *p<0.05.  Statistics for the transcript 
abundance study represent a two-way ANOVA with Tukey’s multiple comparisons of 









3.4.2.  PKM1/2 protein abundance and localization fluctuate in naïve mESCs, 
primed-like mEpiLCs, and primed mEpiSCs. 
There was a significant (p<0.05) increase in PKM1 and PKM2 protein abundance relative 
to 𝛽-ACTIN in formative primed-like mEpiLCs cultured in Fgf-2/Activin A (FA 
medium) compared to naïve mESCs or primed mEpiSCs (Figure 3.02.A).  The ratio of 
phosphorylated (Tyr105), homodimeric conformation of PKM2 to total PKM2 protein 
abundance relative to 𝛽-ACTIN significantly (p<0.05) decreased when naïve mESCs 
were transitioned to formative, primed-like mEpiLCs.  However, no significant (p>0.05) 
difference in the ratio of PKM1 to PKM2 protein abundance relative to 𝛽-ACTIN was 
observed in any pluripotency cell state cultures investigated.  PKM1 and PKM2 protein 
fluorescence were detected in the cytoplasm and nuclei of mESCs, mEpiLCs, and 
mEpiSCs as demonstrated by morphological comparison with Hoechst and rhodamine 
phalloidin stains representing nuclear and cytoskeletal compartments respectively (Figure 
3.02.B).  Secondary antibody only controls confirmed the specificity of the PKM1/2 





















Figure 3.02.  Distinct PKM1 and PKM2 protein profiles in mESCs, mEpiLCs, and 
mEpiSCs.   
A) Histogram comparing protein abundance of PKM1, PKM2, and pPKM2 relative to 𝛽-
ACTIN in mESCs, mEpiLCs, and mEpiSCs in total protein lysates. Error bars represent 
SEM, n=3, *p<0.05.  B) Immunofluorescence of mESC, mEpiLC, and mEpiSC stained 
for Hoechst (blue), phalloidin (red) and the metabolic markers: PKM1 and PKM2 (green) 
assessed by confocal microscopy.  Images taken using 40x magnification and scale bars 
represent 20 𝜇𝑚.  Error bars represent SEM, n=3, *p<0.05. Statistics represent a one-way 
ANOVA with Tukey’s multiple comparisons of mean±SEM MOC and PCC scores run in 




























3.4.3.  Qualitative PKM1/2 nuclear translocation in naïve mESCs, formative 
mEpiLCs, and primed mEpiSCs 
Following the first indication of nuclear PKM1/2 in naïve mESCs, a series of pre-
colocalization imaging studies were completed as a precursor for Chapters 2 and 3.  
Nuclear PKM1/2 was not always clearly visible in colonies or individual cells, this led us 
to taking a 3-dimension (3D) approach to imaging.  Using a confocal microscope, 
individual slices of fluorescent images were stacked to generate a 3D structure of entire 
colonies of mESCs and mEpiSCs for PKM1 and PKM2 (Figure 3.03.). Visually 
examining the 3D architecture of mESCs stained for PKM1 provide our first truly 
promising evidence of nuclear PKM1 translocation as cells closer to the upper layers of 










Figure 3.03.  3D rendered immunofluorescence imaging of mESC and mEpiSC 
PKM1 and PKM2 indicate potential nuclear localization patterns. 
Colonies of mESCs and mEpiSCs stained for PKM1 and PKM2 demonstrate a 3D 
rendering of localization patterns within cells.  Nuclear localization of PKM1 in mESCs 
is visually demonstrated in cells of the upper layers of the colony.  Scale bars are depicted 
on all 3 axes and imaging was completed at 40x objective; scale bars depict 









To further promote the notion of nuclear translocation of PKM1/2 in mESCs and 
mEpiSCs, I utilized the pharmacological agent Leptomycin B.  Leptomycin B is an 
antibiotic and the first agent found that works to block nuclear export in cells (Wolff, 
Sanglier, and Wang 1997).  As Leptomycin B doesn’t impede nuclear import, it served as 
a useful tool in the study of nuclear PKM1/2 translocation.  Leptomycin was first 
assessed in a time course (Supplementary Figure 3.03, Figures 3.04., and 3.05.).  As small 
colonies visually appeared to show the most consistent nuclear PKM1, I examined the 
influence of adding the nuclear export blocking agent Leptomycin B in mESCs over 3, 6, 
9, and 12 hours comparing no Leptomycin to 2 ng/mL treatments by fluorescence 
imaging.  Based on these images, there is a qualitative increase in nuclear PKM2 at 12 





















Figure 3.04.  Nuclear translocation of PKM2 following Leptomycin B treatment. 
 
Elevated PKM2 nuclear translocation in naïve mESCs were treated with Leptomycin B to 
block nuclear export over 12 hours.  Cells were stained for the nuclear localized 
pluripotency marker SOX2, DAPI, PKM2, and Phalloidin.  Scale bars represent 10 m.  









































Figure 3.05.  Nuclear translocation of PKM1 following Leptomycin B treatment time 
course. 
Progression of nuclear translocation of PKM1 in mESCs with the addition of Leptomycin 
B to hinder nuclear export over 12 hours.  Cells were stained for the nuclear localized 
pluripotency marker SOX2, DAPI, PKM1, and Phalloidin.  Scale bars represent 10 m.  


































Supplementary Figure 3.03.  No Primary controls for small colony nuclear 
localization imaging. 
No primary controls of mESCs grown in small colonies stained with DAPI and 






















The concentration of Leptomycin B was then increased to better demonstrate nuclear 
localization in larger colonies.  Examining mESCs at 5 and 10 hours following the 
addition of 20 µg/mL of Leptomycin B showed clearer nuclear translocation of PKM1 at 
10 hours relative to no leptomycin B treatment (Figure 3.06.).  The addition of nuclear 
and cytoplasmic markers further allowed for a comparison of nuclear translocation.  
SOX2, Hoechst, and Phalloidin made comparing nuclear PKM1 substantially more 
evident and further promoted the idea of adding nuclear references to (see Chapter 2 
colocalization methodology).  It was clear that blocking nuclear export in these cells was 













Supplementary Figure 3.04.  Secondary antibody only immunofluorescence controls 
for PKM1 and PKM2 and colocalization study.   
Immunofluorescence microscopy of mESC, mEpiLC and mEpiSC stained for Hoechst, 
phalloidin and the secondary antibodies (Table 3.3.) used throughout this study, assessed 
by confocal microscopy.  Images taken using 40x magnification and scale bars represent 














Supplementary Figure 3.05.  mESC PKM1, PKM2, OCT4, and GAPDH 
colocalization settings.   
Immunofluorescence microscopy of mESCs demonstrating single fluorescence images for 
PKM1, PKM2, OCT4, and GAPDH along with their respective thresholds.  Images taken 
using 40x magnification and scale bars represent 20 𝜇𝑚.  Confocal laser channels 












Figure 3.06.  Time course fluorescence imaging of mESCs treated with Leptomycin 
B prevent nuclear export of PKM1. 
The addition of the nuclear export blocking agent Leptomycin B to mESCs at 20 µg/mL 
over 5 and 10 hours demonstrates that PKM1 translocated to the nuclei.  Scale bars 














Finally, I examined both naïve mESCs and primed mEpiSCs for PKM1 and PKM2 
protein localization by fluorescence imaging with the addition of 20 µg/ml Leptomycin B 
(Figure 3.07.).  This imaging provided evidence that not only naïve mESCs experience 
nuclear translocation, but primed mEpiSCs, exhibiting the aerobic glycolytic metabolic 
preference also have a degree of nuclear PKM1 and PKM2 nuclear translocation.  I 
originally hypothesized that primed mEpiSCs would have nuclear PKM2 as this 
localization pattern is indicative of dimeric pPKM2 and the Warburg Effect (Weiwei 
Yang et al. 2012; W. Zhou et al. 2012).  Nuclear translocation of PKM1 and PKM2 in 
either end of the pluripotent continuum naturally led us to investigate what happens in 




















Figure 3.07.  Initial results indicating potential nuclear localization of PKM1 in 
mESCs.  
Naïve and primed mPSCs appear to show nuclear localization of the metabolic proteins 
PKM1 and PKM2.  This was an early finding following the addition of Leptomycin B for 
a nuclear export blockade to demonstrate nuclear translocation of PKM1.  Cultured 
mESCs and mEpiSCs treated with 20 g/mL of Leptomycin B for 5 hours, stained for 




















3.4.4.  Subnuclear localization of PKM1 and PKM2 with OCT4 within naïve 
mESCs. 
To authenticate the subcellular immunofluorescence results (Figure 3.02.B), a 
colocalization study investigating spatial co-occurrence or overlap and correlation of 
PKM1 and PKM2 with the nuclear localized marker OCT4 and the cytoplasmic localized 
marker GAPDH using confocal microscopy was conducted.  Colocalization of 
immunofluorescent spatial overlap and correlation was compared using Manders’s 
overlap coefficient (MOC) and Pearson’s correlation coefficient (PCC), respectively on 
orthogonal projections with background pixels removed from quantification (Dunn, 
Kamocka, and McDonald 2011).  Using these methods, total mESC colony colocalization 
of PKM1 and PKM2 with OCT4 and GAPDH showed a high instance of spatial overlap 
to both marker proteins with a significantly (p<0.05) greater overlap to nuclear OCT4 
(Figure 3.08.A, B).  However, PKM1 displayed significantly (p<0.05) higher correlation 
to OCT4 localization compared to GAPDH (Figure. 3.08. B).  Using the standards set by 
Zinchuk et al., PKM1 and PKM2 exhibited a ‘moderate’ correlation and a ‘strong’ 
overlap to both OCT4 and GAPDH localization (PCC range: moderate = 0.1-0.48, MOC 
range: strong = 0.89-0.97) (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  By 
increasing the signal-to-noise ratio through airyscan processing, the colocalization 
resolution was improved and the analysis was applied to individual mESCs.  Individual 
cell analysis aligned closely with the colony analysis by indicating a strong correlation for 
spatial co-occurrence for PKM1 and PKM2 in mESCs (Supplementary Figure 3.06.A, B).  









Figure 3.08.  PKM1 and PKM2 are translocated to the nuclei of mESCs and both 
PKM1 and PKM2 are associated with OCT4 and GAPDH localization. 
(A) Immunofluorescence of mESCs stained for OCT4 (green), GAPDH (green), and 
PKM2 (orange) for a confocal, colocalization analysis.  Images taken using 40x 
magnification and scale bars represent 20 𝜇𝑚.  Histogram comparing PKM2 to OCT4 
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s 
Correlation Coefficient (PCC).  Error bars represent SEM, n=3, *p<0.05.  (B) 
Immunofluorescence of mESCs stained for OCT4 (green), GAPDH (green), and PKM1 
(orange) for a confocal, colocalization analysis.  Images taken using 40x magnification 
and scale bars represent 20 𝜇𝑚.  Histogram comparing PKM1 to OCT4 and GAPDH 
spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s Correlation 
Coefficient (PCC).  Error bars represent SEM, n=3, *p<0.05. Statistics represent a two 
tailed Mann-Whitney test of mean±SEM MOC and PCC scores run in n=4 biological 




















Supplementary Figure 3.06.  PKM1/2 colocalization within individual cells of mESC 
colonies.   
Immunofluorescence microscopy of mESC colonies, colocalization analysis compared 
MOC and PCC of the total colony to that of a single cell.  (A) PKM2 staining versus 
OCT4 and GAPDH in mESCs comparing orthogonal projections of whole colonies to 
individual cells by airyscan processing.  (B) PKM1 staining versus OCT4 and GAPDH in 
mESCs comparing orthogonal projections of whole colonies to individual cells by 
airyscan processing.  Images taken using 40x magnification with scale bars represent 20 
𝜇𝑚 and 63x magnification with scale bars representing 5 𝜇𝑚.  Square boxes indicate 
areas of interest from the 40x for 63x magnification.  White outlines around cells 

















3.4.5.  Subnuclear localization of PKM1 and PKM2 with Oct4 in mEpiLCs.  
Immunofluorescence colocalization was quantified in mEpiLCs cultured in transitioning 
FA medium at 48 hours via confocal microscopy of orthogonal projections and airyscan 
processing.  These cells represent the formative pluripotent state.  I applied total colony 
and single cell colocalization analysis as described above, and observed co-occurrence of 
PKM1 and PKM2 compared to OCT4 and GAPDH with a significantly (p<0.05) greater 
PKM1 spatial co-occurrence to OCT4 (Figure 3.09.A, B).  Only PKM1 localization was 
correlated with both OCT4 and GAPDH localization in these cultures (Figure 3.09.B).  
PKM1 exhibited a ‘strong’ correlation and a ‘strong’ overlap with OCT4 localization, a 
‘moderate’ correlation and a ‘strong’ overlap to GAPDH localization (PCC range: strong 
= 0.49-0.84, MOC range: strong = 0.89-0.97) (Zinchuk, Wu, and Grossenbacher-Zinchuk 
2013).  PKM2 displayed a ‘weak’ correlation to both OCT4 and GAPDH with a ‘strong’ 
overlap to OCT4 and a ‘moderate’ overlap to GAPDH (PCC range: weak = -0.26-0.09, 
MOC range: moderate = 0.71-0.88, strong = 0.89-0.97).  Using airyscan processing, 
individual cells of mEpiLC colonies displayed consistent correlation and spatial overlap 
compared to the colony (Supplementary Figure 3.08. A, B).  Immunofluorescence 








Figure 3.09.  PKM1 and PKM2 are translocated to the nuclei of mEpiLCs and 
PKM1 is associated with OCT4 and GAPDH localization.    
A) Immunofluorescence of mEpiLCs stained for OCT4 (green), GAPDH (green), and 
PKM2 (orange) for a confocal, colocalization analysis.  Images taken using 40x 
magnification and scale bars represent 20 𝜇𝑚.  Histogram comparing PKM2 to OCT4 
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s 
Correlation Coefficient (PCC).  Error bars represent SEM, n=3.  (B) Immunofluorescence 
of mEpiLCs stained for OCT4 (green), GAPDH (green) and PKM1 (orange) for a 
confocal, colocalization analysis.  Images taken using 40x magnification and scale bars 
represent 20 𝜇𝑚.  Histogram comparing PKM1 to OCT4 and GAPDH spatial localization 
by Manders’s Overlap Coefficient (MOC) and Pearson’s Correlation Coefficient (PCC).  
Error bars represent SEM, n=3, *p<0.05.  Statistics represent a two tailed Mann-Whitney 
test of mean±SEM MOC and PCC scores run in at least n=3 biological replicates and at 









Supplementary Figure 3.07.  mEpiLC PKM1, PKM2, OCT4 and GAPDH 
colocalization settings.   
Immunofluorescence microscopy of mEpiLCs demonstrating single fluorescence images 
for PKM1, PKM2, OCT4, and GAPDH along with their respective thresholds.  Images 
taken using 40x magnification and scale bars represent 20 𝜇𝑚.  Confocal laser channels 






















Supplementary Figure 3.08.  PKM1/2 colocalization within individual cells of 
mEpiLC colonies.   
Immunofluorescence microscopy of mEpiLC colonies, colocalization analysis compared 
MOC and PCC of the total colony to that of a single cell.  (A) PKM2 staining versus 
OCT4 and GAPDH in mEpiLCs comparing orthogonal projections of whole colonies to 
individual cells by airyscan processing.  (B) PKM1 staining versus OCT4 and GAPDH in 
mEpiLCs comparing orthogonal projections of whole colonies to individual cells by 
airyscan processing.  Images taken using 40x magnification with scale bars represent 20 
𝜇𝑚 and 63x magnification with scale bars representing 5 𝜇𝑚.  Square boxes indicate 
areas of interest from the 40x for 63x magnification.  White outlines around cells 

















3.4.6.  Subnuclear Localization of PKM1 and PKM2 with Oct4 in mEpiSCs.  
As observed for the naïve mESCs and the formative mEpiLCs, a high degree of PKM1 
and PKM2 spatial overlap to both OCT4 and GAPDH in mEpiSCs was observed (Figure 
3.10.A, B).  However, unlike the mESCs and mEpiLCs, there were only low levels 
representing no meaningful correlation of PKM1 or PKM2 with OCT4 or GAPDH in 
these cultures (Figure 3.10.A, B).  PKM1 and PKM2 immunofluorescence each showed a 
‘strong’ overlap to both OCT4 and GAPDH immunolocalizations (MOC range: 0.89-
0.97) (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  PKM1 and PKM2 displayed a 
‘weak’ correlation to OCT4 and a ‘moderate’ correlation to GAPDH (PCC range: weak = 
-0.26-0.09, moderate = 0.1-.48).  Using airyscan processing, individual cells of mEpiLC 
colonies displayed consistent correlation and spatial overlap compared to the colony 
(Supplementary Figure 3.10.A, B).  Immunofluorescence controls and colocalization 








Figure 3.10.  PKM1 and PKM2 are translocated to the nuclei of mEpiSCs and 
neither isoform is associated with OCT4 or GAPDH localization.   
(A) Immunofluorescence of mEpiSCs stained for OCT4 (green), GAPDH (green), and 
PKM2 (orange) for a confocal, colocalization analysis.  Images taken using 40x 
magnification and scale bars represent 20 𝜇𝑚.  Histogram comparing PKM2 to OCT4 
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s 
Correlation Coefficient (PCC).  Error bars represent SEM, n=3.  (B) Immunofluorescence 
of mEpiSCs stained for OCT4 (green), GAPDH (green) and PKM1 (orange) for a 
confocal, colocalization analysis.  Images taken using 40x magnification and scale bars 
represent 20 𝜇𝑚.  Histogram comparing PKM1 to OCT4 and GAPDH spatial localization 
by Manders’s Overlap Coefficient (MOC) and Pearson’s Correlation Coefficient (PCC).  
Error bars represent SEM, n=3.  Statistics represent a two tailed Mann-Whitney test of 









Supplementary Figure 3.09.  mEpiSC PKM1, PKM2, OCT4, and GAPDH 
colocalization settings.   
Immunofluorescence microscopy of mEpiSCs demonstrating single fluorescence images 
for PKM1, PKM2, OCT4, and GAPDH along with their respective thresholds.  Images 
taken using 40x magnification and scale bars represent 20 𝜇𝑚.  White outlines represent 
area of analysis to exclude areas of MEF staining.  Confocal laser channels labelled as 






















Supplementary Figure 3.10.  PKM1/2 colocalization within individual cells of 
mEpiSC colonies. 
Immunofluorescence microscopy of mEpiSC colonies, colocalization analysis compared 
MOC and PCC of the total colony to that of a single cell.  (A) PKM2 staining versus 
OCT4 and GAPDH in mEpiSCs comparing orthogonal projections of whole colonies to 
individual cells by airyscan processing.  (B) PKM1 staining versus OCT4 and GAPDH in 
mEpiSCs comparing orthogonal projections of whole colonies to individual cells by 
airyscan processing.  Images taken using 40x magnification with scale bars represent 20 
𝜇𝑚 and 63x magnification with scale bars representing 5 𝜇𝑚.  Square boxes indicate 
areas of interest from the 40x for 63x magnification.  White outlines around cells 


























3.4.7.  PKM1 and PKM2 are differentially localized to OCT4 and GAPDH between 
naïve, formative, and primed pluripotent states. 
To obtain a deeper understanding of the cellular co-occurrence of nuclear PKM1 and 
PKM2 during the transition from mESCs, mEpiLCs, and mEpiSCs cultures, I contrasted 
the outcomes between overall co-occurrence (MOC) with Hoechst and OCT4 (positive 
reference) and Hoechst and GAPDH (negative reference).  Relative to the positive 
reference, there was no significant (p>0.05) changes to MOC of PKM1 or PKM2 
localization to OCT4 localization in mESCs, mEpiLCs, or mEpiSCs, indicating that 
PKM1 and PKM2 do indeed occupy nuclear associated regions in these pluripotent cells 
(Figure 3.12.B).  Relative to the positive reference, there was a no significant (p>0.5) 
changes to the MOC of PKM1 or PKM2 localization to GAPDH localization in mESCs 
and mEpiSCs, indicating that PKM1 and PKM2 do indeed occupy cytoplasmic regions in 
these cells as well (Figure 3.12.B).  However, relative to the positive reference, there was 
a significant (p<0.05) decrease in MOC of PKM1 and PKM2 localization to GAPDH 
localization in the mEpiLCs, indicating a decreased cytoplasmic presence in these cells 
(Figure 3.12.B). 
 
To further interrogate the subnuclear association of nuclear PKM1 and PKM2 during 
transitioning mESCs, mEpiLCs, and mEpiSCs cultures, I compared the outcomes 
between overall correlation (PCC) with Hoechst and OCT4 (positive reference) and 
Hoechst and GAPDH (negative reference).  Each mPSC state examined showed 
differential PKM1/2 subnuclear expression correlation to OCT4 and GAPDH compared 
to the positive reference.  Relative to the positive reference indicating nuclear OCT4 







localization to OCT4 or GAPDH in mESCs (Figure. 3.11.B).  In contrast, mEpiLCs and 
mEpiSC displayed significantly (p<0.05) less PCC of PKM2 localization to OCT4 
relative to the positive reference, however, these values did not reach a meaningful linear 
correlation level (Figure 3.11.B).  Relative to the positive reference indicating nuclear 
association, there was no significant (p>0.05) PCC difference in PKM1 and a significant 
(p<0.05) decrease in correlation of PKM2 localization to OCT4 and GAPDH localization 
relative to the positive reference in mEpiLCs, suggesting nuclear association of PKM1 
and reduced nuclear association of PKM2 with OCT4 (Figure 3.11.B).  Relative to the 
positive reference indicating nuclear association, there was a significant (p<0.05) 
decrease in PCC of PKM1 and PKM2 localization to OCT4 and GAPDH localization 
relative to the positive reference in mEpiSCs (Figure 3.11.B).  However, in the case of 
mEpiLCs and mEpiSCs, values with PCC = 0 reflect no meaningful linear correlation and 
a meaningful association of PKM1 or PKM2 localization to these fluorophores of interest 
cannot be conclusively inferred.   
 
Using the standard ranges set by Zinchuk et. al. to describe these values with qualifying 
terms, there is an observed ‘strong correlation’ and ‘strong overlap’ in the Hoechst/OCT4 
positive reference (PCC = 0.49±0.06, MOC = 0.95± 0.00) and a ‘very weak correlation’ 
and ‘strong overlap’ in the GAPDH/Hoechst negative reference (PCC = -0.07±0.08, 
MOC =0.89±0.01) (Figure 3.11.A) (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  
These standards promote the superiority of the PCC over the MOC, however, there was a 
significant difference between the positive and negative references and our sample data 








In summary, PKM1 and PKM2 occupy the same spatial localization as OCT4 nuclear 
regions and differentially correlate to subnuclear localizations relative to OCT4 and 
GAPDH localization in mESCs, mEpiLCs, and mEpiSCs.  I demonstrate that both the 
PCC and MOC metrics are valuable in comparison to known positive nuclear references, 
in this case Hoechst staining.  Reference stains and colocalization thresholds are available 



















Figure 3.11.  PKM1/2 are moderately associated with OCT4 localization in mESC, 
PKM1 is strongly associated with OCT4 localization in mEpiLCs, and PKM1/2 
overlap in nuclear regions of mESCs, mEpiLCs, and mEpiSCs.   
(A) Immunofluorescence of mESCs immuno-stained for OCT4 (green), GAPDH (green), 
and Hoechst (blue) for a confocal, colocalization analysis.  Images taken using 40x 
magnification and scale bars represent 20 𝜇𝑚.  Histogram comparing Hoechst to OCT4 
and GAPDH spatial localization by Manders’s Overlap Coefficient (MOC) and Pearson’s 
Correlation Coefficient (PCC).  Error bars represent SEM, n=3.  (B)  Total results of 
colocalization study comparing positive and negative references to mESCs, mEpiLCs, 
and mEpiSC MOC and PCC values.  Standard range qualifiers set by Zinchuk et al. 
(2013) compare overlap and correlation differences.  Error bars represent SEM, n=3.  
Statistics of PCC and MOC treatments relative to the positive reference represent a two-
way ANOVA with Sidak’s multiple comparisons test of mean±SEM PCC and MOC 









Supplementary Figure 3.11.  mESC positive and negative colocalization controls.   
Immunofluorescence microscopy of mESCs demonstrating single and double stains for 
Hoechst, OCT4 and GAPDH along with their respective thresholds.  Images taken using 
40x magnification and scale bars represent 20 𝜇𝑚.  Confocal laser channels labelled as 















Nuclear localization of PKM1 and PKM2 in naïve mESCs by cell fractionation 
To  validate the results of the orthogonal projection immunofluorescence analysis, a 
nuclear and cytoplasmic fractionation of naïve mESCs using the REAP protocol was 
conducted (Nabbi and Riabowol 2015).  Naïve mESCs were selected as they were the 
only mPSC that exhibited both a nuclear co-occurrence and correlation of PKM1 and 
PKM2 with OCT4 immunofluorescence from our colocalization study.  The REAP 
protocol was validated by comparing the nuclear and cytoplasmic fractions with the 
nuclear marker LAMIN A and the cytoplasmic marker ∝-TUBULIN.  A significant 
(p<0.05) increase in ∝-TUBULIN in the cytoplasmic fraction compared to the nuclear 
fraction validating successful fractionation was observed (Supplementary Figure 3.12. A, 
B, C).  The results effectively demonstrated the nuclear localization of PKM1 from naïve 
mESC protein lysates (Supplementary Figure 3.12. C).  This was evident as the ratio of 
nuclear-to-cytoplasmic fraction PKM1 trended towards elevated levels of nuclear PKM1 
in the mESC, however, this did not reach statistical significance (Supplementary Figure 






















Supplementary Figure 3.12.  PKM1 is translocated to the nuclei of mESCs.   
(A) Histogram comparing protein abundance of nuclear and cytoplasmic fractioned 
lysates of pPKM2, ∝-TUBULIN, and LAMIN A relative to total protein Ponceau staining 
in mESCs. Error bars represent SEM, n=3, *p<0.05.  (B) Histogram comparing protein 
abundance of nuclear and cytoplasmic fractioned lysates of PKM2, ∝-TUBULIN, and 
LAMIN A relative to total protein Ponceau staining in mESCs. Error bars represent SEM, 
n=3, *p<0.05.  (C) Histogram comparing protein abundance of nuclear and cytoplasmic 
fractioned lysates of PKM1, ∝-TUBULIN, and LAMIN A relative to total protein 





















3.5.0.  Discussion: 
Despite traditionally being considered a passive trait of cell-fate determination, mounting 
evidence now supports metabolism as having a direct role in self-renewal, cell fate and 
differentiation (Dahan et al. 2019).  Our study investigated differences in pyruvate kinase 
muscle isoforms 1 and 2 (PKM1/2) in naïve, formative, and primed pluripotent stem cells 
and found differential expression and nuclear localization of these metabolic isoforms 
during pluripotent state transitioning.  Densitometry of total protein lysates indicated that 
over the course of pluripotent progression there is an increase protein abundance of 
PKM1, PKM2, and phosphorylated PKM2 in the formative state.  Despite this increase in 
protein abundance, the ratio of PKM1 to PKM2, a common ratio used to examine aerobic 
glycolytic preferential cancer cells, was not different between each pluripotent state, 
indicating that a stable PKM1/2 ratio is likely required for maintaining pluripotency, 
which one differentiation occurs is not observed (Qin et al. 2017).  There was an observed 
nuclear immunofluorescence for both PKM1/2 isoforms in naïve mouse embryonic stem 
cells (mESCs), formative mouse epiblast-like stem cells (mEpiLCs), and primed mouse 
epiblast stem cells (mEpiSCs). To verify this observation, I conducted an improved 
confocal colocalization approach to compare differences in nuclear and cytoplasmic 
localization by contrasting orthogonal projections with well-established reference 
markers.  Using this technique, I determined that in each pluripotent state, PKM1 and 
PKM2 both reside in nuclear regions and that PKM1 and PKM2 are moderately 
associated with OCT4 localization patterns in mESCs.  PKM1 is strongly associated with 
OCT4 localization patterns in mEpiLCs and both isoforms have a weak association to 
OCT4 immunolocalization in mEpiSCs showing a progressive decline in association to 








The measurement of colocalization is a complicated and hotly debated area of biology 
(Adler and Parmryd 2010; Aaron, Taylor, and Chew 2019).  The term colocalization is 
largely used to measure two main components with different applications, namely 
correlation or co-occurrence of two fluorophores to each other based on pixel distribution 
(Aaron, Taylor, and Chew 2018).  Co-occurrence in immunofluorescence is the 
presentation of fluorescent pixels existing in the same spatial distribution, and it is an 
indicator of overlap between markers (Manders, Verbeek, and Aten 1993).  Correlation is 
a measurement of the relationship between the pixel intensities and may indicate a 
biochemical interaction (Manders, Verbeek, and Aten 1993).  Both the Manders’s overlap 
coefficient (MOC) and Pearson’s correlation coefficient (PCC) are valid measures of 
colocalization, but they inform different biological questions (Aaron, Taylor, and Chew 
2019).  Immunofluorescence microscopy is commonly thought of as a qualitative 
technique and the literature into colocalization often uses descriptors such as moderate or 
strong association within PCC ranges.  Zinchuk et al. (Zinchuk, Wu, and Grossenbacher-
Zinchuk 2013) developed a method of colocalization range descriptors to bring greater 
consistency to the field and offer more validity to the quantitative nature of 
colocalization.  I implemented a quantitative designate to the colocalization of PKM1 and 
PKM2 within the mPSCs of this study.  This study supports claims that the MOC is a 
valuable metric of colocalization.  By comparing MOC and PCC values to a positive and 
negative biological reference, I demonstrate that this methodology sets a stronger baseline 
than using only improved descriptors.  OCT4 and GAPDH were used as nuclear and 
cytoplasmic reference proteins control markers to compare to another known nuclear 







allowed us to directly compare MOC and PCC values to.  Comparing known positive and 
negative references to the qualifying range standards set by Zinchuk et al. this studies 
data supports comparing colocalization by correlation being superior to spatial overlap 
(Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  However, while MOC still provided 
valuable knowledge, the PCC data showed an improved distinction between internal 
reference controls.  These findings demonstrate that it is critical to run positive and 
negative references relative to dual fluorophore colocalization and that in the case of 
mouse embryonic stem cells, the spatial overlap data may not be sufficient to reach 
quality colocalization assessment compared to correlation data when considering the 
qualifying standards set by Zinchuk et al.  I observed that the MOC metric in mPSCs did 
not delineate nuclear and cytoplasmic distinctions by colocalization and that the PCC 
metric was a highly effective and viable tool for such distinction and analysis.  To 
increase the power of our colocalization study, a simple analysis single images was not 
employed, instead, I investigated orthogonal projections of stacks examining the data of 
individual slices to characterize the localization patterns of a true three-dimensional 
structure.  I also accounted for the inherent flaws of the MOC calculation by examining 
only the individual colonies and individual cells in the orthogonal and airyscanned images 
respectively to prevent autofluorescence or background pixel offset to influence the 
algorithm.   
 
Naïve mESCs, in the metabolically bivalent state, proved to be a unique and attractive 
cell type for colocalization analysis.  By examining the correlation of PKM1 and PKM2 
immunolocalizations to OCT4 and GAPDH immunolocalizations, not only was an 







subnuclear pixel intensity were related was as well.  Additonally, both isoforms occupy 
the same spatial regions in comparison to the controls, and both PKM1 and PKM2 were 
clearly associated with the localization patterns of both OCT4 and GAPDH.  Together, 
these results promote the concept that PKM1 and PKM2 both translocate to the nuclei of 
mESCs.  A recent study using mass spectroscopy of human lung carcinoma cells 
determined that PKM1 and PKM2 interact with each other (Prakasam et al. 2017) 
suggesting a possible PKM1/2 interaction in the nuclei of mouse ESCs.  Supporting this 
claim, I completed a REAP fractionation for nuclear and cytoplasmic protein abundance 
in mESCs and demonstrate the presence of both PKM1 and PKM2 in nuclear fractions 
(Nabbi and Riabowol 2015).  This methodology was able to cleanly discriminate 
cytoplasmic fractions from nuclear proteins as controlled by LAMIN A, however, nuclear 
fractions were not fully separated from cytoplasmic proteins, likely due to the high ratio 
of nuclear-to-cytoplasm in PSCs. 
 
In the initial PKM protein abundance characterization of total cell lysate, I found that 
there was an increase of PKM1 and PKM2 levels in mEpiLCs.  Despite this increase in 
protein abundance, the ratio of PKM1 to PKM2 protein abundance did not change 
between any of the pluripotent cell types examined.  As PKM2 switches to increased 
PKM1 expression during differentiation and development, with the reverse occurring 
during tumor formation, the role of the PKM1 to PKM2 ratio has become a focus of 
interest (Morita et al. 2018).  It may be more pertinent to examine the nuclear-to-
cytoplasmic ratio of PKM1/2 including the dimer to tetramer conformations of PKM2 in 
various pluripotent states.  Surprisingly, the formative state mEpiLCs had significantly 







the positive reference. This demonstrates very low amounts of either isoform occupying 
the traditional cytoplasmic region occupied by GAPDH for both isoforms.  When 
examining mEpiLCs for correlation of PKM1 and PKM2 colocalization to OCT4 and 
GAPDH, I determined that PKM1 was associated with both OCT4 and GAPDH 
compared to the controls.  Coupling this finding with the results of the colocalization 
overlap findings, the formative state mEpiLCs were unique in primarily localizing PKM1 
in the nucleus, suggesting that PKM1 may be key in the transition of bivalent metabolism 
to preferential aerobic glycolysis.  Previous studies have shown that the transcription 
factor promyelocytic leukemia protein (PML), a known PKM2 mediator that maintains 
the homotetrameric conformation and suppresses the Warburg Effect, interacts with 
OCT4 and NANOG and is necessary for maintaining naïve pluripotency (Hadjimichael et 
al. 2017; Jiancong Liang et al. 2008; Shimada, Shinagawa, and Ishii 2008).  Knocking 
down or deleting PML resulted in flat, slower growing mESC colonies with reduced 
OCT4, SOX2, cMYC and NR0B1 and diminished naïve-associated BMP, LIF/STAT3 
and PI3K signaling whereas Activin A and FGF signalling increased (Hadjimichael et al. 
2017).  Overexpression of PML resists mESC transitioning towards primed pluripotency 
and is required for efficient iPSC generation (Hadjimichael et al. 2017).  Future studies 
should examine the influence of PML in the generation of formative state mEpiLCs.  As 
mEpiLCs are the only cells currently described that can efficiently give rise to primordial 
germ-like cells, PML and PKM1/2 may be important targets for controlling cell fate to 
efficiently produce mEpiLCs (Hayashi et al. 2011).   
 
I determined that of all the mPSCs studied, the primed mEpiSCs had the greatest spatial 







colocalization to OCT4 and GAPDH yet significantly lower PKM1 and PKM2 
correlation (PCC) to OCT4 and GAPDH.  This was unexpected as other aerobic 
glycolytic cells, such as, glioma stem cells display an interaction between PKM2 and 
OCT4 (Morfouace et al. 2014).  The reduced association as assessed by the Pearson 
correlation coefficient (PCC) of PKM2 and OCT4 may reflect differential chromatin 
targets in the primed pluripotent state and may be associated with lineage priming and 
reduced differentiation potential (Morfouace et al. 2014).  Interestingly, there is also a 
decrease in PKM1 correlation to OCT4 as assessed by PCC, but only in the primed 
mEpiSCs.  Using the refined colocalization analysis, I demonstrated  that PKM1 and 
PKM2 co-occur (MOC) in the nuclei of mPSCs across the pluripotent continuum and that 
PKM1 and PKM2 are differentially correlated (PCC) with OCT4 and GAPDH in each 
examined pluripotent state.  This data suggests that ChIP-sequencing of PKM1 and 
PKM2 targets should be examined in mPSC varieties encompassing the pluripotent 
continuum.  Further, the correlation of PKM2 colocalization to OCT4 decreases from 
naïvety through the formative state and into primed pluripotency.  As such, I conclude 
that nuclear PKM1 and PKM2 are implicated as contributors to the maintenance and 
progression of embryonic stem cell pluripotency.   
 
Recent literature has reported instances of nuclear and mitochondrial translocation of 
PKM2 (Qi et al. 2019; Ji Liang et al. 2017).  The nuclear translocation of PKM2 is 
implicated in the regulation of the master glycolysis regulator HIF-1 (Wang et al. 2014).  
Jumonji C Domain-containing dioxygenase 5 (JMJD5)-PKM2 interaction hinders PKM2 







into the nucleus to regulate HIF-1-mediated gene transcription (Wang et al. 2014).    
JMJD5 regulates the cell cycle and maintains pluripotency in human embryonic stem 
cells (Zhu, Hu, and Baker 2014), however, its role in the nuclear translocation of PKM2 
and regulating metabolism in pluripotent stem cells has not been explored.  
Overexpression of PKM2 maintains the undifferentiated state by fine tuning redox control 
in naïve mESCs grown as embryoid bodies (Konno et al. 2015).  Future studies treating 
naïve stem cells with pharmacological agents such as shikonin or DASA-58, which 
promote the tetrameric conformation of PKM2, may resist formative state transitioning by 
maintaining the naïve state (J. Chen et al. 2011; Giannoni et al. 2015).  Adjusting PKM2 
levels has been completed in mESCs and a complete knockout should be feasible as 
PKM2-null mice are viable though they experience some metabolic distress and have a 
reliance on PKM1 (Jacks et al. 2016).  However, these mice show induction of late onset 
formation of spontaneous hepatocellular carcinomas (Jacks et al. 2016).  PKM2 is 
certainly a potential target for cancer treatments and likely a key player in cellular 
reprogramming and differentiation (Jacks et al. 2016; Qin et al. 2017).  Despite several 
non-canonical roles being characterized, it is likely that other roles exist and have yet to 
be discovered (Weiwei Yang et al. 2011). 
 
While PKM2 has been extensively studied in cancers and stem cells (Morita et al. 2018; 
Jacks et al. 2016; Konno et al. 2015; Wei et al. 2018; C. C. L. Wong et al. 2014; 
Taniguchi et al. 2015; N. Wong, De Melo, and Tang 2013), the PKM1 isoform has not 
been investigated to the same extent.  There is a growing body of evidence to suggest that 







subtypes.  Until recently, PKM1 was thought to be only expressed with spatial 
heterogeneity in non-proliferative cells of tumors, however, recent publications have 
found this is not always the case (Israelsen et al. 2013; Morita et al. 2018).  PKM1 is 
essential for the proliferation and tumor-promoting capabilities of small cell lung cancer 
(SCLCs) and other net endocrine tumors (Morita et al. 2018).  Oxygen consumption in 
PKM1 overexpressed cancer cells does not change although there are more mitochondria 
with a greater rate of mitochondria dysfunction, while there are more reactive oxygen 
species generated in the PKM2 overexpressed cells compared to the PKM1 overexpressed 
cells (Morita et al. 2018).  These characteristics of PKM1 overexpressed cells are 
accompanied with increased autophagic flux and increased tumor growth with increased 
autophagy and mitophagy (Morita et al. 2018).  PKM1 could play a non-canonical role in 
promoting autophagic and mitophagic roles during pluripotent stem cell state 
transitioning.  When either PKM1 or PKM2 was overexpressed in mESCs, it was found 
that the pluripotency markers Nanog, Eras, and Rex1 were upregulated and an embryoid 
body formation assay showed that overexpression did not influence differentiation (W. 
Zhou et al. 2012).  Taken together, these results indicate that PKM1 contributes to 
proliferation, stemness, and pluripotency.  Based on this investigation’s protein 
abundance analysis, PKM2 or both isoforms may promote the generation of mEpiLCs 
and the formative pluripotent state (Qin et al. 2017).  The results suggest that preserving 
an equal ratio of PKM1 to PKM2 may be necessary to maintain mouse pluripotency.  
Such a trend is not found following lineage specialization into various somatic cells (Qin 
et al. 2017).  I also report a unique localization of PKM1 that suggests a novel, non-
canonical role just as nuclear, dimeric pPKM2 has been implicated in several non-







Recently, the role of PKM1 in highly proliferative cells has been highlighted (Morita et 
al. 2018).  These results along with our current data questions PKM2’s role as the 
traditional prototypic isozyme of development as it is now clear that PKM1 is expressed 
and likely has non-canonical roles (Morita et al. 2018).  Nuclear PKM1 has recently been 
reported in other highly proliferative cell types such as human liver cancer cells (HepG2 
and SMMC-7721) (Wei et al. 2017).  Following treatment with drug Oroxylin A (OA), an 
O-methylated flavonoid derived from the Oroxylum indicum tree, PKM1 is translocated 
to the nucleus with hepatocyte nuclear factor 4 α (HNF4α), and increases the PKM1 to 
PKM2 ratio resulting in hepatoma differentiation (Wei et al. 2017).  PKM1 overexpressed 
in embryoid bodies generated from mESCs resulted in increased endoderm transcript 
abundance of FOXA2, AFP, and HINF1B, implicating PKM1 in endoderm differentiation 
(Konno et al. 2015).  Given the colocalization findings, nuclear localization of PKM1 is 
certainly implicated in formative state generation, and the addition of a drug such as OA 
may modulate the occurrence of this transient pluripotent state. 
 
To fully validate to the colocalization study, I examined nuclear and cytoplasmic 
fractionation protein abundance in the mESCs.  Due to the inherent difficulty of nuclear 
and cytoplasmic extraction and the exceptionally high nuclear-to-cytoplasmic ratio of 
mESCs, the most successful method of extraction was the REAP ( Rapid, Efficient and 
Practical) method of extraction (Y. Zhou et al. 2016; Nabbi and Riabowol 2015).  While 
nuclear extraction of PSCs is generally considered a challenging technique, clean 
extractions have been published (Bechard and Dalton 2009).  Using this technique, 
protein densitometry demonstrates PKM1 and PKM2 do have increased nuclear lysate 







in the nuclear fraction compared to the cytoplasmic fraction of mESCs, further supporting 
that PKM1 is being translocated to the nuclei of naïve mESCs.   
 
In summary, the data supports differential nuclear and subnuclear localization of both 
PKM1 and PKM2 in mouse pluripotent stem cells and suggest a novel regulatory role for 
nuclear PKM1.  These results establish differential nuclear, subnuclear, and cytoplasmic 
association of PKM1 and PKM2 in mESC cells as they transition from naïve 
pluripotency, through formative state (primed-like mEpiLCs) towards primed mEpiSCs 
(Figure 3.12.).  Protein colocalization studies applied to PSCs should give greater weight 
to their correlation data and not their spatial overlap findings especially if the standards 
set by Zinchuk et al. are implemented (Zinchuk, Wu, and Grossenbacher-Zinchuk 2013).  
The presence of nuclear PKM1/2 and the dynamic redistribution of PKM1 and PKM2 
during pluripotency continuum suggests potential non-canonical roles for both isoforms 











Figure 3.12.  PKM1/2 are differentially localized to subcellular regions with 
potential interaction with OCT4 and GAPDH in naïve, formative, and primed 
mouse embryonic stem cells.   
Pyruvate kinase muscle isoforms are localized to nuclear regions in mESCs, mEpiLCs, 
and mEpiSCs.  There is indication of potential biomolecular interaction of PKM with 
OCT4 or GAPDH denoted by circled proteins overlapping in the schematic.  As mESCs 
become more developmentally lineage primed for differentiation (mEpiSCs), the 
correlation of PKM1/2 with OCT4 and GAPDH decreases.  This could mean decreased 
potential for biomolecular interaction of the isoforms with OCT4 and a potential 
rearrangement of subcellular localization patterns in the cytosol such as mitochondrial 
colocalization as demonstrated in previous studies (Ji Liang et al. 2017).  This illustration 
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4.0.2.  Summary: 
 
Here we describe methodologies to characterize, delineate, and quantify pluripotent cells 
between naïve, formative, and primed pluripotent state mouse embryonic stem cell 
(mESCs) populations using flow cytometric analysis.  This methodology can validate 
pluripotent states, sort individual cells of interest and determine the efficiency of 
transitioning naïve mESCs to a primed-like state as mouse epiblast-like cells (mEpiLCs) 
and on to fully primed mouse epiblast stem cells (mEpiSCs).  Quantification of the cell 
surface markers: SSEA1(CD15) and CD24, introduces an effective method of 
distinguishing individual cells from a population by their respective positioning in the 
pluripotent spectrum.  Additionally, this protocol can be used to demarcate and sort cells 
via fluorescently activated cell sorting for downstream applications.  Flow cytometric 



















4.1.0.  Introduction: 
 
Flow cytometry is a method of single cell analysis utilizing a microfluidic system where 
individual cells are directed, single file, through a laser, or series of lasers.  Cell size and 
granularity can be assessed using flow cytometry through the analysis of laser light 
scatter.  The measurement of side-scatter shows the level of granularity, or, the amount of 
light that reflects off the individual cell and intracellular interface, whereas the forward-
scatter parameter is a measure of the light that passes around the cell in question.  Taken 
together, an understanding of the size and intracellular complexity of the cells in a 
population can be quantified and organized into subpopulations (Leif 1986).  Cells can be 
sorted through the process of fluorescently activated cell sorting (FACS) following the 
process of gating out specific traits of a population for downstream applications.   
 
Several methods of mouse epiblast cell-like cell (mEpiLCs) generation have been devised 
(Morgani, Nichols, and Hadjantonakis 2017).  This protocol have utilizes ground state 
mouse embryonic stem cell (mESCs) transitioned into mEpiLCs over 48, 72, and 92 
hours in transitioning media containing Activin A and Fibroblast growth factor 5 (Fgf5), 
replacing mESC media containing leukemia inhibitory factor (LIF) and a small molecule 
cocktail of inhibitors for Glycogen synthase kinase 3 beta (GSK3b) and Mitogen-
activated protein kinase, kinase (MEK) (Hayashi et al. 2011).  This flow cytometric 
analysis methodology includes quantification of the cell surface markers: Stage-Specific 
Embryonic Antigen-1 (SSEA1/CD15) and Cluster of differentiation 24 (CD24).  SSEA1 
is a naïve pluripotency associated cell surface protein marker that is expressed in mESCs 
(Solter and Knowles 1978).  Alternatively, CD24 is an expressed primarily in primed 







I propose that SSEA1 and CD24 can be used to discriminate between either end of the 
pluripotent spectrum in human and mouse pluripotent stem cells (PSCs), and can also be 
used to distinguish formative pluripotent state mouse epiblast-like cells (mEpiLCs) as 
well (Shakiba et al. 2015).  Additional methods of flow cytometric normalization, 
practises, and troubleshooting are beyond the scope of this chapter, however, for these 
additional details, we refer the reader to following excellent resources (Hahne et al. 2010; 
Herzenberg et al. 2006).   
 
4.2.0.  Materials: 
 
1. Washing Solution: Sterile Dulbecco’s Phosphate Buffered Saline (no magnesium, 
no calcium) (DPBS(-/-))(DPBS(-/-))(GibcoTM 14190144). 
2. Flow Cytometry Staining Buffer – 10 % Fetal bovine serum (Embryonic stem-cell 
FBS, qualified, US origin (Gibco 16141061)) in DPBS(-/-) filter sterilized. 
3. Trypan Blue Solution (ThermoFisher Scientific 15250061). 
4. Fixing Agent: 4 % paraformaldehyde (Sigma Aldrich, St Louis MO) diluted in 
DPBS(-/-). 
5. Cell passaging agent (StemPro Accutaseâ). 
6. Antibody dilutions: 
• Live/Dead: Live/Dead viability dye such as Zombie Aqua™ Fixable Viability 
Kit (BioLegend 423101), diluted 1:1000/1 million cells. 
• SSEA1: Brilliant Violet 421™ anti-mouse/human CD15 (SSEA-1) Antibody 







• CD24: APC/Cyanine7 anti-mouse CD24 Antibody (BioLegend 101821) 
diluted at 0.25 mg/1 million cells. 
7. 20-40 µM sterile cell strainers (Falcon™ Cell Strainers 08-771-1). 
8. Flow tubes and corresponding caps, specific to your flow cytometer of choice. 
 
4.3.0.  Methods: 
 
In the following protocol, I describe how to characterize and distinguish between 
pluripotent stem cell populations representing naïve, formative, and primed pluripotent 
states using flow cytometry.  Methods for using both live and fixed cell preparations are 
detailed.  Live cell staining may be used for downstream sorting of purified populations, 
and additional experimentation such as omics data analysis or differentiation assays, 
whereas fixed cell staining can be sorted for downstream applications limited to non-
viable cells, such as protein and transcript abundance studies.  This methodology is useful 
in determining the transition efficiency of generating primed-like mEpiLCs from mESCs 
in comparison to primed mEpiSCs by a comparison of SSEA1 and CD24 cell surface 
expression levels.  These markers can be compared for both human and mouse PSCs 
(Shakiba et al. 2015). 
 
During the experimental planning step, aim to grow your pluripotent stem cells into their 
third, fourth, and fifth (PX+3/4/5 minimum) passage following cryopreservation thaw. 
This will allow for 3 biological replicates.  To analyze geometric mean, mode, or median 
data, each biological replicate should be analyzed in the same flow cytometric 







biological replicate can be run on their own session only if the full set of controls are used 
for each run.  Additionally, grow cells to a quantity that allows for 3 technical replicates 
of each biological replicate of each cell type to be analyzed.  Regardless of gating 
scheme, ensure colonies are morphologically healthy with little to no signs of 
differentiation and with similarly spaced-out cell densities.  
 
Individual treatment groups require having an unstained control cell population, a single 
stain control of each protein marker, a full minus one (FMO) tube containing all protein 
markers except for one, and lastly a full stain sample containing each protein marker, 
each of these needs to be completed for each cell type examined.  Additionally, a 
live/dead control is necessary to avoid autofluorescence readings produced by examining 
dead and ruptured cells.  This can be accomplished by using a 50/50 % mixture of live 
and dead cells stained using a viability dye (e.g., Zombie Aqua) that penetrates dead cells 
only.  Laser intensity compensation should be completed on the unstained and single 
stained specimens instead of traditionally compensation beads (see Note 1).  Always 
consult a spectral overlap calculator prior to ordering and running a multi-stained flow 
cytometry experiment to ensure individual readings can be differentiated from each other.  
The Spectral Viewer by BD Biosciences (San Jose, CA) is especially useful if you are 
using a BD Biosciences flow cytometer.  Prior to a running a complete experiment, it is 
advised that an antibody titration series be completed for each new cell type and stain, 
this can be accomplished by testing the recommended controls.  See Table 4.1 for 












Live/Dead SSEA1 CD24 
1. Unstained    
2. 50% Live/50%Dead Zombie Aqua   
3. Single stain Zombie Aqua   
4. Single stain  BV421  
5. Single stain   APC 
6. Full minus one  BV421 APC 
7. Full minus one Zombie Aqua  APC 
8. Full minus one Zombie Aqua BV421  
9. Full – n1 Zombie Aqua BV421 APC 
10. Full – n2 Zombie Aqua BV421 APC 
11. Full – n3 Zombie Aqua BV421 APC 
 
4.3.1.  Live pluripotent stem cell preparation. 
Twenty-four hours prior to the day of harvest, remove cells for live/dead cell 
compensation.  This can be accomplished by leaving a conical tube of cells out of the 
incubator in DPBS(-/-) overnight.  Combine 200,000 dead cells with 200,000 live cells. 
Aim for approximately 400,000 cells overall for the live/dead treatment.  Live cells 
benefit from the addition of 10 mM rho kinase inhibitor (Y-27632; STEMCELL 
Technologies). This should be added gently to fresh, pre-warmed (37 °C) media on cells 







suspension for 5 minutes incubated at 37 °C using StemPro Accutase, cover the entire 
growth surface area to be effective, agitation is not necessary (see Note 3). Transfer the 
lifted cells to pre-warmed (37 °C) media and centrifuged (244 rcf) for 3 minutes or until 
pelleted (see Note 4).  Aspirate supernatant and perform a viability cell count using 
trypan blue with a hemocytometer or similar cell counting method (Strober 1997).  Each 
treatment should have a minimum of 400,000 cells.  Divide cells into sterile, labelled, and 
capped flow tubes, reconstituted in 100 µL/treatment with flow cytometry staining buffer 
(FCSB).  Stain live/dead viability treatments by incubating for 30 minutes in a light-tight 
box at room temperature (see Note 5). For treatments without live/dead staining skip this 
step and proceed to adding the appropriate fluorophore.  Wash treatments with 2 mL of 
FCSB, centrifuge (244 rcf) for 3 minutes.  Aspirate the supernatant and reconstitute with 
100 µL of FCSB.  Add appropriate fluorophore conjugated antibodies taking note of 
product concentration/cell count, gently vortex and incubate for 30 minutes in a light-
tight box at room temperature.  All samples, except for the unstained controls, are now 
light sensitive and should always be handled in dim lighting conditions.  Wash treatments 
with 2 mL of FCSB, centrifuge (244 rcf) for 3 minutes.  Reconstitute with 200 µL of 
FCSB and gently vortex.  Pipette the cell suspension over an upside-down 20 µm cell 
strainer.  Wash with 100 uL of FCSB.  Flip cell strainer and pipette from the inside to get 
residual cells held by surface tension.  Proceed immediately to running cells through a 










4.3.2.  Fixed pluripotent stem cell preparation. 
Twenty-Four hours prior to the day of harvest, remove cells for live/dead cell 
compensation.  This can be accomplished by leaving a conical tube of cells out of the 
incubator in DPBS(-/-) overnight (see Note 1.).  Aim for approximately 400,000 cells.  
Lift cells from their plate; enzymatic lifting works well.  Colonies need to be separated 
into single cells, cover the growth surface with lifting agent for 5 minutes in an incubator 
(see Note 5).  Centrifuge (244 rcf) the single cell suspension for 3 minutes.  Aspirate 
supernatant and perform a viability cell count using trypan blue with a hemocytometer or 
similar cell counting method(Strober 1997).  Each treatment should have a minimum of 
400,000 cells. Divide cells into sterile, labelled, and capped flow tubes, reconstituted in 
100 µL/treatment with flow cytometry staining buffer (FCSB).  Reconstitute in DPBS(-/-) 
(100 mL x tubes required), divide into flow tubes.  Stain live/dead viability treatments by 
incubating for 30 minutes in a light-tight box at room temperature (see Note 5). For 
treatments without live/dead staining skip this step and proceed to fixation.  Wash 
treatments with 2 mL of FCSB and centrifuge (244 rcf) for 3 minutes.  Aspirate the 
supernatant and reconstitute with 100 mL of FCSB.  Wash treatments with 2 mL of FCSB 
and centrifuge (244 rcf) for 3 minutes.  Aspirate the supernatant and add appropriate 500 
mL of fixative agent (freshly made and chilled 4 % paraformaldehyde in DPBS(-/-) is 
recommended for cell surface marker analysis), incubate for 10 minutes in a fume hood 
on ice (see Notes 1 and 6).  Wash with 2 mL of DPBS(-/-) and centrifuge (244 rcf) for 3 
minutes.  Aspirate supernatant and reconstitute with 100 µL of PBS(-/-) per treatment.  
Add appropriate fluorophore conjugated antibodies taking note of product 
concentration/cell count, gently vortex and incubate for 1 hour in a light-tight box at on 







handled in dim lighting conditions.  Wash once with 2 mL of DPBS(-/-) and centrifuge 
(244 rcf) for 3 minutes.  Aspirate supernatant and reconstitute with 200 µL of DPBS(-/-) 
and gently vortex.  Pipette the cell suspension over an upside-down 20 µm cell strainer 
and wash with 100 µL of DPBS(-/-).  Flip the cell strainer and pipette from the inside to 
get residual cells held by surface tension.  Leave tubes in the fridge in a light-tight box 
until you are ready to run on a flow cytometer.  Run on a flow cytometer within 24 hours 
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Figure 4.1.  Flow cytometric characterization of SSEA1 and CD24 and gating 
strategy of mEpiSCs. 
a) Side-scatter-area versus forward-scatter-area flow plot detailing granularity of light 
refracting off subcellular structures and cell size by light passing over the same individual 
cell events.  This population display can show subpopulations within the data.  In 
mEpiSCs, examine P1, the lower population if grown on MEFs.  Forward-scatter area 
versus forward-scatter-height further delineates the shape of cells passing through the 
cytometer as population P2.  b)  Gating of viability-stained samples.  Cells expressing the 
viability stain are not living, the live population on interest is compared to either the 
Live/Dead single stain or Live/Dead FMO specimens.  c) SSEA1 versus CD24 channel 
expression with crosshair gating of the SSEA1 FMO specimen with the x-axis threshold 
set just above the main population of cells.  d) SSEA1 versus CD24 channel expression 
with crosshair gating of the CD24 FMO specimen with the y-axis threshold set just to the 
right of the main population of cells.  The x-axis threshold of c) is maintained.     
e) SSEA1 versus CD24 channel expression with crosshair gating of the fully stained 
specimen with both the x-axis and y-axis thresholds maintained.  Adjunct histograms can 


















4.3.3.  Flow Cytometric Analysis. 
Flow cytometric analysis will depend largely on the cytometer the user has selected.  For 
the development of this methodology, a BD FACSCanto™ Cell Analyzer flow cytometer 
was used, however, all the steps outlined will be consistent for any current flow 
cytometer.  Regardless of the cytometer used, these steps should be followed to ensure 
consistent and qualified results.  Consult with the manufacturer for setting individual laser 
parameters and ensure proper cleaning and maintenance has been completed prior to any 
use.  Daily quality control checks need to be completed using qualified beads to optimize 
results. 
 
Compensation was completed using BD FACSDiva™ Software.  Gating was completed 
using BD FlowJo™ Software.  While other post-flow cytometric analysis software is 
available, FlowJo™ currently provides the most comprehensive and advanced methods of 
flow cytometric analysis.  The following gating strategy can be applied in most situations, 
however, if FlowJo is not your software of choice, start at Step 3.  Each cell population 
refinement can be brought into the subsequent step for a final gated flow plot (see Note 
7).  
 
Import or drag individual .fsc files into FlowJo.  Drag unstained, single stained treatments 
of each cell type into the compensation tab.  Post-flow cytometric compensation can now 
be improved using FlowJo’s Compensation Wizard.  Compensated samples will be 
indicated with a colored 3x3 grid marker.  Begin examining the unstained sample, setting 
the x- and y- axes to forward-scatter-area and side-scatter-area respectively, gate out the 







Note 8).  Now, compare the Live/Dead stain only specimen to either the Live/Dead FMO 
or the unstained specimen.  Examine these using forward-scatter-area versus the 
appropriate Live/Dead corresponding channel.  A simple box gate scheme should suffice 
for both a live and dead gate (Figure 4.1. b).  This step and the following steps can be 
portrayed using biexponential axes.  Open both the SSEA1 FMO and CD24 FMO 
specimens.  Set the x- and y- axes to the corresponding CD24 and SSEA1 laser channel 
respectively.  Choose the crosshair gating option and set the crosshair above and to the 
right of each population (Figure 4.1.c, d).  These options can be performed in either order.  
Finally, apply the complete gating scheme to the fully stained specimen.  If possible, add 
adjunct histogram to show the event density (Figure 4.1.e) (see Note 9).   
 
4.3.4.  Statistical Representations 
If each biological replicate was run during the same session, FlowJo can accurately 
calculate the geometric mean, mode, and median for an analysis relatively synonymous to 
that of densitometry in immunoblotting studies.  These options can be found under 








Figure 4.2.  Flow cytometric expression of SSEA1 and CD24 during naïve to primed 
transitioning in mESCs, mEpiLCs, and mEpiSCs. 
mESCs, mEpiLCs (72 hours of transitioning), and mEpiSCs examined for SSEA1 and 
CD24 run on a flow cytometry within a single session can be compared within a single 
flow plot to demonstrate the shifting of transitioning formative state mEpiLCs towards a 
primed-like pluripotent fate.  Overlay of flow cytometric plots is best represented with 
adjunct histograms as pseudo-coloring of the individual events in an overlay is not 














































Typical percentages of each population you may encounter can be found in Table 4.2. 
 
Table 4.2.  Quadrant event frequencies of SSEA1/CD24 cell surface marker 
















29.8±1.9 3.2±1.4 6.1±2.9 61.0±3.2 
Formative
, 48- hour 
mEpiLCs 





38.6±5.2 14.9±10.9 5.9±2.5 40.3±14.1 
Primed 
mEpiSCs 













4.4.0.  Notes: 
1. Growing mEpiSCs is optimal on a layer of MEF feeders.  mEpiSCs are much 
smaller than MEFs and examining side-scatter and forward-scatter attributes can 
be used as a form of size exclusion.  This method of gating is limited, and it is 
preferential to run samples both fixed and feeder-free when possible.  Otherwise 
include a pluripotent marker not expressed on MEFs, especially in the case of a 
FACS study. 
 
2. In the case of metabolism related scientific studies, consider avoiding feeding 
cells prior to or during the flow cytometry or immunofluorescent imaging process 
to maintain consistency and avoid spiking of metabolites and corresponding 
enzymatic processes/pathways. 
 
3. Live/Dead cell compensation requires that you have a mix of live and dead cells.  
Some protocols use heated water (typically 65 °C) however mESCs can withstand 
65 °C for 30 minutes, maintaining >98 % viability.  Traditional compensation 
beads will not work with Live/Dead stains.   
 
4. Spectral overlap of fluorophores can confound flow cytometry results depending 
on the stain and the flow cytometer used.  Several spectral overlap calculators are 
available, and it is highly recommended that all stains be reviewed and applied 








5. It is often recommended that compensation beads are used with single stains for 
flow cytometry. However, pluripotent stem cell marker expression will 
fluorescence brighter in PSCs than current commercially available compensation 
beads.  
 
6. Fluorochromes such as phycoerythrin (PE) or allophycocyanin (APC) are large 
protein molecules and will be affected the same way as other proteins by the 
fixation so try to avoid alcohols. However, small fluorochromes such as 
AlexaFluor488 or FITC are generally unaffected by whichever fixative is used. 
 
7. Doing this instead of importing the .wsp file containing the experiment will result 
in the x- and y- axes being flipped.  This is a longstanding issue with FlowJo but 
may be corrected in the future. 
 
8. This population can be refined by setting the x- and y- axes to forward-scatter-
area and forward-scatter-height respectively, further gate out the main population 
of cells. A tightly, set polygonal gate works well (Fig. 4.2.a)). 
 
9. This can be especially useful if combining and comparing several cell types or 
treatments and the pseudo-color display option can’t be selected.   See Figure 4.2. 










4.5.0.  Discussion: 
This protocol is specifically designed to sort naïve, formative, and primed pluripotent 
stem cell states.  Studies examining newly derived or altered mPSCs could find such 
methods useful in validating pluripotent state, calculating transitioning efficiency of 
generating various pluripotent states, or following genetic manipulation (Kinoshita et al. 
2020; Hayashi et al. 2011; Shakiba et al. 2015; Vidal, Stadtfeld, and Apostolou 2015).  As 
pluripotency is described as a continuum, this method is invaluable for studying 
differences between cell types found in the developing epiblast.  Originally, these 
methods have focused on sorting differences between naïve mESCs and primed mEpiSCs 
(Shakiba et al. 2015).   
 
Here we uniquely describe how this procedure can be extended to also sort cells 
designated as the formative stage of pluripotency (Shakiba et al. 2015).  As formative 
state cells are the only known pluripotent cell type capable of primordial germ cell 
differentiation, this method is applicable and necessary for the investigation of 
mechanisms controlling the differentiation of naïve, mESCs transitioning to a formative 
pluripotent state and onward to specialized germ cell-like cells following bone 
morphogenetic protein (BMP) treatment (Hayashi et al. 2011).  During the development 
of this methodology, a non-transient formative state was described in mouse and human 
embryonic stem cells (Kinoshita et al. 2020).  With the addition of Fgf/nodal signalling, 
Dr. Austin Smith’s group, which originally hypothesized the formative pluripotent state, 
utilized tankyrase inhibitor to inhibit Wnt signalling in cells explanted from the inner cell 
mass of embryonic day 5.5 mouse embryos (Kinoshita et al. 2020).  Previously, the 







new methodology, cells can be passaged for >20 passages maintaining characteristics of 
the formative state.  The protocols outlined in this methodology paper could be applied to 
this landmark study in generating stable formative pluripotent lines (Hayashi et al. 2011).  
Given proper bone morphogenetic protein stimuli, formative state cells can efficiently 
differentiate into primordial germ-like cells unlike any other pluripotent stem cell stage.  
Using this flow cytometric method, one can quantify the transitioning efficiency of 
formative state cells from mESCs compared to explanted formative state cells to 
determine differences in chemically transitioned and native states in vitro.   
 
Traditionally, reprogramming somatic human cells and explanting embryonic stem cells 
from human embryos results in pluripotent stem cells representing the primed pluripotent 
state.  Recently, naïve and formative state human pluripotent stem cells have been derived 
from both embryonic and adult origins (Ware et al. 2014; Giulitti et al. 2019; Kinoshita et 
al. 2020).  The described methodology is applicable in the study of naïve pluripotent 
reversion from the primed pluripotent state and from somatic fates via reprogramming.  
From the human naïve pluripotent state, it is possible to transition to formative state and 
capture the transitioning efficiency as well as compare transitioned cells (i.e., naïve-like 
cells) to the traditional primed state as previous studies have compared naïve and primed 
mouse pluripotent states (Shakiba et al. 2015).  The addition of CD40, a cell surface 
pluripotency marker associated with the primed pluripotent state, could additionally be 
utilized (Shakiba et al. 2015).  Through previous attempts in the mouse system, we 








Currently, naïve, formative, and primed pluripotency discrimination can be completed 
through transcript abundance studies, epigenetic landscape differences, differentiation 
assays, and chimeric contributions (Kinoshita et al. 2020; Morgani, Nichols, and 
Hadjantonakis 2017).  This novel method has the added benefit of potential downstream 
applications through the option of fluorescently activated cell sorting (FACS) of distinct, 
purified cell populations.  Following FACS, sorted fixed cells can be examined for 
protein or transcript abundance studies and perhaps single cell analysis or proteomics and 
live cells can be re-plated into more homogenous populations for expansion and 
differentiation assays.  With the advent of stable formative pluripotent states, the 
described methodology with the addition of FACS could allow for the study of 
subpopulations for improved studies into the development of germ cell differentiation.  
Future improvements to this protocol are likely to be optimized using stable and pure 
formative state PSC lines.  A comparative study examining the transition of mESCs to 
formative mEpiLCs compared to actual explanted formative state cells and primed 
mEpiSCs examining the transition throughout the pluripotent spectrum within a smaller 













4.6.0.  Acknowledgements: 
Flow cytometry was completed in at the London Regional Flow Cytometry Facility at 
Robarts Research Institute of Western University.  mESC and mEpiSC pluripotent stem 
cell lines were graciously gifted from Dr. Janet Rossant. This research was funded by a 
Canadian Institutes of Health Research operating grant to A.J.W. and D.H.B. and Natural 
Sciences and Engineering Research Council of Canada grant to D.H.B. The funding 
sources played no role in design, data collection, analysis, decision to publish, or 


























4.7.0.  References: 
Giulitti, Stefano, Marco Pellegrini, Irene Zorzan, Paolo Martini, Onelia Gagliano, 
Margherita Mutarelli, Michael Johannes Ziller, et al. 2019. “Direct Generation of 
Human Naive Induced Pluripotent Stem Cells from Somatic Cells in Microfluidics.” 
Nature Cell Biology 21 (2): 275–86. https://doi.org/10.1038/s41556-018-0254-5. 
Hahne, Florian, Alireza Hadj Khodabakhshi, Ali Bashashati, Chao-Jen Wong, Randy D 
Gascoyne, Andrew P Weng, Vicky Seyfert-Margolis, et al. 2010. “Per-Channel 
Basis Normalization Methods for Flow Cytometry Data.” Cytometry Part A 77A (2): 
121–31. https://doi.org/https://doi.org/10.1002/cyto.a.20823. 
Hayashi, Katsuhiko, Hiroshi Ohta, Kazuki Kurimoto, Shinya Aramaki, and Mitinori 
Saitou. 2011. “Reconstitution of the Mouse Germ Cell Specification Pathway in 
Culture by Pluripotent Stem Cells.” Cell 146 (4): 519–32. 
https://doi.org/10.1016/j.cell.2011.06.052. 
Herzenberg, Leonore A, James Tung, Wayne A Moore, Leonard A Herzenberg, and 
David R Parks. 2006. “Interpreting Flow Cytometry Data: A Guide for the 
Perplexed.” Nature Immunology 7 (7): 681–85. https://doi.org/10.1038/ni0706-681. 
Kinoshita, Masaki, Michael Barber, William Mansfield, Yingzhi Cui, Daniel Spindlow, 
Giuliano Giuseppe Stirparo, Sabine Dietmann, Jennifer Nichols, and Austin Smith. 
2020. “Capture of Mouse and Human Stem Cells with Features of Formative 
Pluripotency.” Cell Stem Cell. 
https://doi.org/https://doi.org/10.1016/j.stem.2020.11.005. 
Leif, Robert C. 1986. “Practical Flow Cytometry.” Cytometry 7 (1): 111–12. 
https://doi.org/https://doi.org/10.1002/cyto.990070119. 
Morgani, Sophie, Jennifer Nichols, and Anna Katerina Hadjantonakis. 2017. “The Many 
Faces of Pluripotency: In Vitro Adaptations of a Continuum of in Vivo States.” BMC 
Developmental Biology 17 (1): 10–12. https://doi.org/10.1186/s12861-017-0150-4. 
Shakiba, Nika, Carl A. White, Yonatan Y. Lipsitz, Ayako Yachie-Kinoshita, Peter D. 
Tonge, Samer M.I. Hussein, Mira C. Puri, et al. 2015. “CD24 Tracks Divergent 
Pluripotent States in Mouse and Human Cells.” Nature Communications 6: 7329. 
https://doi.org/10.1038/ncomms8329. 
Solter, D, and B B Knowles. 1978. “Monoclonal Antibody Defining a Stage-Specific 
Mouse Embryonic Antigen (SSEA-1).” Proceedings of the National Academy of 
Sciences 75 (11): 5565 LP – 5569. https://doi.org/10.1073/pnas.75.11.5565. 
Strober, Warren. 1997. “Trypan Blue Exclusion Test of Cell Viability.” Current 
Protocols in Immunology 21 (1): A.3B.1-A.3B.2. 
https://doi.org/https://doi.org/10.1002/0471142735.ima03bs21. 
Vidal, Simon E., Matthias Stadtfeld, and Eftychia Apostolou. 2015. “F-Class Cells: New 
Routes and Destinations for Induced Pluripotency.” Cell Stem Cell 16 (1): 9–10. 
https://doi.org/10.1016/j.stem.2014.12.007. 
Ware, C. B., A. M. Nelson, B. Mecham, J. Hesson, W. Zhou, E. C. Jonlin, A. J. Jimenez-
Caliani, et al. 2014. “Derivation of Naive Human Embryonic Stem Cells.” 










Chapter 5  
A version of this Chapter is being submitted for publication. 
 
5.0.0.  Title: Modulation of PKM1/2 levels by steric-blocking morpholinos alters the 
metabolic and pluripotent state of murine pluripotent stem cells.  
 
5.0.1.  Author contributions: 
CRediT Author Statement: 
Joshua G. Dierolf: Conceptualization, Methodology, Validation, Formal Analysis, 
Investigation, Writing – Original Draft, Writing – Review & Editing, Visualization  
Hailey Hunter: Methodology, Writing – Review & Editing 
Dean H. Betts: Resources, Writing – Review & Editing, Funding Acquisition, 
Supervision 













5.1.0.  Abstract:  
Metabolism is implicated in playing both an active and passive role in embryonic 
development, cell pluripotency, and cell-fate, however, little is known regarding the role 
of metabolic state in the recently described formative pluripotent state.  This 
developmental pluripotent continuum is accompanied by a metabolic switch from a 
bivalent metabolism (both glycolysis and oxidative phosphorylation) in naïve cells, to 
predominantly glycolysis in primed cells.  Metabolic preferences promote the 
maintenance and generation of various pluripotent states.  I have investigated the role of 
pyruvate kinase muscle isoforms (PKM1/2) in naïve, formative, and primed mouse 
embryonic stem cells through modulation of PKM1/2 mRNA transcripts using steric-
blocking morpholinos that downregulate PKM2 and upregulate PKM1.  I have examined 
these effects in naïve, formative, and primed cell states by quantifying the effects of 
PKM1/2 modulation on pluripotent and metabolic transcripts and by measuring shifts in 
the populations of cells expressing naïve and primed markers by flow cytometry.  I found 
that modulating PKM1 and PKM2 levels alters the transition from the naïve state into a 
formative and primed-like pluripotent states.  Therefore, I conclude that PKM1/2 actively 
contributes to mechanisms that oversee early stem pluripotency and their progression 
towards a primed pluripotent state.  
 
5.2.0.  Introduction: 
Pluripotent stem cells (PSCs) are characterized by their unlimited self-renewal and 
potential to specialize into cell types of the adult organism.  Approximately 3.5 days 







blastocyst and encircled by the trophectoderm called the inner cell mass (ICM) of the pre-
implantation embryo (Evans and Kaufman 1981; Martin 1981).  This niche of 10-20 cells 
represents the earliest pluripotent stem cell (PSC) population of the developing embryo 
and these cells are the origin of the primary germ layers that result in the formation of the 
fetus.  These cells also represent the origins of mouse embryonic stem cells (ESCs) that 
are important research models for unraveling early developmental cell fate control 
mechanisms and are also key resources for the development of cell-based therapeutics.  
PSCs of the developing mouse can be explanted from the embryo until E8.0, however, 
several key differences underlying changes in their pluripotency arise between the E3.5 
and E8.0 (Morgani, Nichols, and Hadjantonakis 2017).  Some of these differences include 
developmentally programmed changes in gene expression, epigenetic landscape, 
metabolic preferences, and ability to contribute to all germ cell layers and chimeric 
development (Nichols and Smith 2009; Zhou et al. 2012).  Explanted mouse ESCs 
(mESCs) between E3.5 and E4.5 and mouse epiblast stem cells (mEpiSCs) from between 
E7.25 and E8.0 both express core pluripotency genes including sex determining region Y 
– box 2 (Sox2), octamer-binding transcription factor 4 (Oct4), and Nanog (lower in 
mouse epiblast stem cells; mEpiSCs), however, mESCs express pluripotency associated 
genes such as reduced expression 1 (Rex1), platelet endothelial cell adhesion molecule 1 
(Pecam-1), and orphan nuclear receptor Esrrb at greater levels than mEpiSCs (Wray et al. 
2011).  Conversely, mEpiSCs express pluripotency genes such as Zinc finger protein 2 
(Zic2), T(Brachyury), and Cerberus (Cer1) more so than mESCs (Morgani, Nichols, and 
Hadjantonakis 2017).  Metabolically, mESCs are bivalent in their preference for 
metabolic pathways utilizing both glycolysis and oxidative phosphorylation (OXPHOS).  







preferences of most cancer cells, where regardless of oxygen availability glycolysis takes 
on precedence despite OXPHOS being capable of generating more adenosine 
triphosphate (ATP) (Zhou et al. 2012).  Primed cells, adult stem cells, and typical cancer 
cells with high rates of proliferation opt for glycolysis in this manner to generate 
metabolic precursors for other anabolic processes (Vander Heiden, Cantley, and 
Thompson 2009; Mathieu and Ruohola-Baker 2017).  Recent studies have indicated there 
is an intermediate state of pluripotency existing between the naïve and primed ends of the 
pluripotent spectrum referred to as ‘formative pluripotency’, representative of the E5.5-
E6.0 post-implantation epiblast (Smith 2017).  Therefore, E3.5-E4.5, E5.5-6.0, and 
E7.25-E8.0 represent distinct states of the pluripotent continuum, and are referred to as 
naïve, formative, and primed pluripotent states respectively, and represent the ICM cells 
of the pre- and post-implantation epiblast (Nichols and Smith 2009; Morgani, Nichols, 
and Hadjantonakis 2017; Osorno et al. 2012; Kinoshita et al. 2020). 
 
This newly defined formative pluripotent state is consistent within the phased progression 
model suggesting that all differentiating naïve cells must phase through the formative, 
then primed state before exiting pluripotency.  The exception to this rule is germ cell 
lineages, however, it is this exception that supports the phased progression model as 
formative state cells have the potential to become primordial germ cells.  The formative 
pluripotent state and the phased progression model rely on the concept of germ line 
competence.  When mESCs and are incorporated into chimeras and allowed to develop, 
germ cells arise, however, when mESCs are cultured in vitro they do not produce 
primordial germ cell-like cells (mPGCLCs) (Hayashi et al. 2011).  In contrast, ICM cells 







mPGCLCs through addition of bone morphogenic protein 4 (Bmp4) (Ohinata et al. 2009).  
Developmentally, germ line competency occurs during the interval between naïve and 
primed pluripotent states and the phased progression model hypothesis adds that somatic 
cell differentiation competency is also gained at this time.  The switch from metabolic 
bivalency to aerobic glycolysis also begins during this transition (Kalkan et al. 2017).  
Ground state mESCs that are chemically transitioned towards a primed pluripotent state 
through the replacement of LIF/2i with activin and fibroblast growth factor (Fgf) 
supplementation (FA), hereafter referred to as mouse epiblast-like cells (mEpiLCs), do 
not fully commit to primed pluripotency and exhibit an intermediate potency with the 
potential to differentiate into mPGCLCs (Guo et al. 2009; Hayashi et al. 2011).  
Formative state mEpiLCs show increased expression of genes including de novo DNA 
methyltransferase 3a/b (Dnmt3a/b), fibroblast growth factor 5 (Fgf5), Sal-like protein 2 
(Sall2), Sox3, and POU domain class 3 transcription factor 1 (Oct6; Pou3f1), following a 
decrease in Nanog expression (Smith 2017; Buecker et al. 2014).   
 
There is a growing body of evidence showing that not only are the metabolic preferences 
of naïve and primed pluripotent states are distinct, but metabolic preferences also act to 
promote developmental processes, maintain pluripotency state, and enable cell fate 
decisions (Dahan et al. 2019; Tsogtbaatar et al. 2020; P. Wei et al. 2018).  The concept of 
metabolic remodelling and reprogramming has been demonstrated in a variety of stem 
cells including T cell fate control, direct reprogramming of glial cells to neurons, 
neuronal metabolic preferences during differentiation, and improving stemness through 
mitochondrial function by nicotinamide adenine dinucleotide (NAD) repletion (Buck et 







metabolic preferences, glycolysis and OXPHOS play a primary role in pluripotent state 
differences (Zhou et al. 2012).  On either end of the pluripotent continuum, naïve and 
primed states observe unique preferential metabolic phenotypes.  Naïve cells are 
metabolically bivalent, in vitro colonies use both glycolytic and oxidative 
phosphorylation processes, whereas primed cell colonies are preferentially glycolytic 
representing a trend referred to as the ‘Warburg Effect’ (WE).  These in vitro metabolic 
preferences may exist as a by-product of their in vivo correlate’s metabolism due to 
restricted physiological oxygen access of the pre- and post- implantation cell niches.  The 
recently described and stabilized intermediate pluripotent state, the formative state, has 
yet to be metabolically profiled, however, as this interval is representative of the recently 
post-implantation blastocyst, it may indicate a bias for aerobic glycolysis (Kinoshita et al. 
2020; Smith 2017). 
 
A key metabolic enzyme that not only links glycolysis and OXPHOS but is also a 
hallmark factor in the WE is pyruvate kinase muscle isoforms 1/2 (Pkm1/2 (transcript), 
PKM1/2 (protein)).  Pkm1/2 is an allosterically regulated and alternatively spliced gene 
that produces the pyruvate kinase enzyme responsible for the catalysis of a phosphoryl 
group from phosphoenolpyruvate in glycolysis to form pyruvate, and the phosphoryl 
group is transferred to adenosine diphosphate to form ATP (Jurica et al. 1998; Valentini 
et al. 2000).  PKM2 is implicated in cancer and the WE and recently PKM1 has been 
shown to have a contributing role to small cell lung cancer (W. Yang and Lu 2015; 
Growth 2018; L. Wei et al. 2017).  PKM2 impinges on OXPHOS when nuclear 







Co-A over a mitochondrial OXPHOS fate – a hallmark of the WE (Wang et al. 2014; 
Weiwei Yang and Lu 2013). 
 
As PKM1/2 are implicated in aerobic glycolysis and proliferation, it is critical to 
investigate their contributions to naïve and primed cell pluripotency.  Previous attempts to 
study the role of PKM1/2 in naïve and primed pluripotent states did not consider the 
intermediate, formative phases of the pluripotent continuum (Qin et al. 2017; Konno, 
Ishii, et al. 2015; Prigione et al. 2014).  This study utilized steric-blocking morpholinos to 
modulate PKM1 and PKM2 isoforms in naïve and primed mouse pluripotent stem cells 
and during the chemical transitioning to formative, primed-like stem cells from the naïve 
state.  The outcomes include effects to Pkm1 and Pkm2 transcript abundance in naïve, 
formative, primed-like, and primed pluripotent stem cells, and the impact of modulating 
Pkm1/2 on metabolic and pluripotent state.  I also determined the impact of altering 
Pkm1/2 during transitioning mESCs-to-formative and formative-to-primed-like 
pluripotency.  This study demonstrates that downregulation of PKM2 alone through 
splice modifications results in altered metabolic transcript abundance and promotes naïve-
to-primed transitioning in formative mEpiLCs and downregulation of PKM2 and 
upregulation of PKM1 results in a new population of naïve and primed marker expressing 
cells in primed-like mEpiLCs.  This study promotes metabolism as a driver of 
pluripotency and development, demonstrates how to delineate intermediate states from 
ground and primed pluripotency and provides evidence of PKM1 having a role in the 







5.3.0.  Methods:  
5.3.1.  Stem cell culture conditions: 
Mouse embryonic stem cells (mESCs, R1 strain – 129X1 x 129S1 (gifted from Dr. Janet 
Rossant, The Hospital for Sick Children, Toronto, Ontario, Canada), formative and 
primed-like mouse epiblast-like cells (mEpiLCs, chemically converted R1 mESCs over 
48 and 96 hours) and primed mouse epiblast stem cells (mEpiSCs, strain – 129S2 ((gifted 
from Dr. Janet Rossant, The Hospital for Sick Children, Toronto, Ontario, Canada); were 
cultured in the following base media; a 1:1 mixture of KnockOut DMEM/F12 (Thermo 
Fisher Scientific 12660012) and Neurobasal Media (Thermo Fisher Scientific 21103049) 
with 0.1% 2-Mercaptoethanol (Gibco 21985-029), 0.25% GlutaMAX (Thermo Fisher 
Scientific 35050061), 1.0% N2 Supplement (100x) (Thermo Fisher Scientific 17502048), 
and 2.0% B27 Supplement (50x) (Thermo Fisher Scientific 17504044) (Supp. Figure 1a).  
mESCs and mEpiLCs were cultured on 0.1% porcine gelatin (Sigma-Aldrich G2500) and 
mEpiSCs and MEFs were cultured on 10 µg/mL/cm2 fibronectin (Roche 11051407001).  
Base media for the culture of mESCs were supplemented with 1000 units/mL ESGRO 
Recombinant mouse LIF protein (EMD Millipore ESG1107), and 2i small molecule 
inhibitors: 1 M PD0325901 (Reagents Direct 39-C68) and 3M CHIR99021 (Reagents 
Direct 27-H76).  Base media for the culture of mEpiLCs and mEpiSCs were 
supplemented with 20ng/mL Activin A from mouse (Sigma-Aldrich SRP6057) and 12 
ng/mL Fgf-2 from mouse (Sigma-Aldrich SRP3038).  mESCs were passaged using 
StemProTM AccutaseTM (Thermo Fisher Scientific A1110501) and centrifuged at 300 x g 
for 5 minutes.  Primed mouse epiblast stem cells were cultured in the base medium and 







fibroblasts (MEFs).  One hour prior to passaging, growth medium was replaced.  
Passaging was completed using Gentle Cell Dissociation Buffer (GCDB) (Gibco 13151-
014) for 5 minutes at room temperature.  Lifted cells were then centrifuged at 244 x g for 
3 minutes and plated at a seeding density of 1:12 onto MEFs.  RNA and protein 
abundance studies were completed by excluding MEFs for feeder-free conditions and 
passaging mEpiSCs once with StemProTM AccutaseTM (Thermo Fisher Scientific 
A1110501) followed by a GCDB passage, this resulted in a clean and healthy population 
of feeder-free mEpiSCs ready for transcript and protein abundance studies.  Cells were 
utilized within three to five passages following cryopreservation when possible and 
studies were carried out in biological triplicate. 
5.3.2.  siRNA Transfection: 
mESCs were grown to approximately 70-80% confluency and washed with fresh, pre-
warmed (37 °C) LIF/2i supplemented media.  Transfection was completed using the lipid-
based carrier Lipofectamine3000 (ThermoFisher L3000001) and optimal siRNA and 
carrier concentrations were assessed using a FITC fluorescein conjugated siRNA control 
quantitatively via flow cytometry qualitatively by fluorescent imaging.  
Lipofectamine3000 was diluted in 50 µL of Opti-MEM (FisherScientific 31985070) prior 
to mixing with siRNA and incubated together at room temperature for 15 minutes.  Cells 
were washed with Opti-MEM once and the Lipofectamine3000 and siRNA solution in 
Opti-MEM were incubated on the cells for 5 hours.  Cells were then aspirated and given 
fresh media.  Pkm1/2 siRNA design constructs were made with the aid of ThermoFisher’s 








5.3.3.  Morpholino Delivery: 
Morpholinos were transfected into mESCs, formative mEpiLCs and mEpiSCs through the 
scrape delivery method (Partridge et al. 1996). In brief, once cells achieved 
approximately 70-80% confluency, fresh pluripotent specific media supplemented with 5, 
10, or 20 M morpholino (as a series for optimization and 20 M for experimental 
studies) (fluorescein-tagged control, PKM MO 1 or PKM MO 2 morpholino) that had 
been 2 m filter sterilized was ejected onto a PBS(+/+) washed growth surface (either 
gelatin or fibronectin).  The MO supplemented media was swirled for 10 seconds both 
clockwise and counterclockwise before being allowed to incubate at room temperature for 
1 minute.  Rubber policeman cell scrapers (Sarstedt 83.3951) were used vertically across 
the plate, then perpendicularly.  Cells co-endocytosed the morpholinos through now open 
transient pores for 10 minutes without permitting the cells to reattach to their substratum.  
Transfected cells were replated onto larger growth spaces and allowed to incubate for 24 
hours before downstream applications including fluorescent imaging, immunoblotting, 
transcript abundance and flow cytometry studies.  Transfected cells were compared by 
phase contrast to determine if morphology was influenced.  Imaging of fluorescently 
transfected cells and phase contrast microscopy was completed using a Leica DMI 
6000B.  Morpholino design, targeting sites and post-transfection changes to PKM1/2 
protein can be found in Table 5.1.  Experimental timelines for morpholino transfection 











Figure 5.01.  mESC, mEpiLC, and mEpiSC culture and timing schematic. 
 
Ground state, naïve mESCs, formative/primed-like transitioning to mEpiLCs, and primed 
mEpiSCs experimental planning schematic.  a) Experimental plating set-up and media 
transitioning from mESCs into formative and primed-like mEpiLCs through media 
supplementation and timing.  b) Morpholino scrape delivery and incubation timelines 












Table 5.1.  Morpholino Design. 
 






























5.3.4.  Transcript Abundance: 
RNA isolation was completed using a RNeasy RNA isolation kit (Qiagen 74104) and 
Trizol (Ambion 15596018) hybrid protocol followed by DNAse treatment (Invitrogen 
AM1906).  cDNA synthesis was completed using iScript (BioRad 170-8891) on 500 ng 
of RNA.  Quantitative PCR was completed using SensiFAST™ SYBR® No-ROX Kit 
(FroggaBio BIO-98020).  Optimal annealing temperatures for each primer were tested in 
temperature gradients followed by a dilution series to determine primer efficiencies.  
Relative transcript abundance was calculated using the Pfaffl method of quantification, 
normalized to mESCs not treated with a morpholino and relative to 𝛼-Tubulin transcript 
abundance(Pfaffl 2001).  Forward and reverse primer designs and annealing temperatures 
are available in Table 5.2.  TaqMan PCR was completed using TaqMan™ Advanced 
Master Mix (Thermo Fisher Scientific 4444557). Relative transcript abundance was 
calculated using the ∆∆Ct method of quantification, normalized to mESCs not treated 
with a morpholino and relative to Hprt transcript abundance (Livak and Schmittgen 
2001).  The fold change in transcript abundance levels for both qPCR and TaqMan 




































57.0-63.0 F- AACCAGATGGTGAAATGTGACCCT 
R- CACAGTGGGAGGCTGGTAGTTAAT 
Pecam Naïve  90.0 63.0 
F- CAAGGCCAAACAGAAACCCG 
R- GCCTTCCGTTCTCTTGGTGA 
Rex1 Naïve 96.6 63.0 
F- AGAAGAAAGCAGGATCGCCT 
R- TATGACTCACTTCCAGGGGG 
Esrrb Naïve 103.7 63.0 
F- CAGGCAAGGATGACAGACG 
R- GAGACAGCACGAAGGACTGC 
Lef1 Formative 108.1 57.0 
F- AGAAGAAGAAGAGGAAGAGAGAGAAGC 
R- AGATGTAGGCAGCTGTCATTCTGG 
Dnmt3 Formative 99.0 63.0 
F- GGCAAGGACGACGTTTTGTG 
R- GTTGGACACGTCCGTGTAGTGAG 
Pou1fc Formative 99.0 60.0 
F- TTTCTCAAGTGTCCCAAGCC 
R- ACCACCTCCTTCTCCAGTTG 
Zic2 Primed 90.0 63.0 
F- GGTGACCCACGTCTCTGTG  
R- CGGATGTGGTTGACCAGTTT 
Cer1 Primed 99.8 60.0 
F- ACCTATGTGTGGATGGCTGC 
R- AGATCCGGCTTGTCTTCTGC 
T(Bra) Primed 104.1 60.0 
F- CGGTGGCGAGAGAAGTGAAG 
R- CTTCCCTGCGCTCTCTGTG 
Hk2 Glycolysis 91.8 63.0 
F- CCTGCTACAGGTCCGAGCCATCTT 
R- GAGGATGAAGCTTGTACAGTGTCC 
Gpi Glycolysis 102.3 63.0 
F- AACCGGCCGACCAACTCAAT TGTG 
R- TGCCGTCCAGCTCTGGCTCAATTT 
Pgam1 Glycolysis 94.0 63.0 
F- TACGCAGACCTTACTGAAGACCAG 
R- AGCTCCATGATGGCCTCTTCTGAG 





63.0 F- AATGTGCTGGGCCACTTGCAGCAG 
R- TGACCGGACTGAAGGCCACTACCT 
 
Aldoa Glycolysis 101.2 63.0 
F- ATGAGGAGATTGCCATGGCAACGG 
R- TTTAGAGCAGAGGCCTGCAGGGCT 














Fh1 OXPHOS 98.4 63.0 
F- CGGTTTCGCAGAAAAGGTGG 
R- ACAGCAACGTGATTCCCCAT 
Sdha OXPHOS 90.5 63.0 
F- AGAGATACGCACCTGTTGCC 
R- ACTGGGATGGGCTCCTTAGT 
Suclg1 OXPHOS 108.7 63.0 
F- GGTGAAATTGGTGGTCACGC 
R- AAGGACACTACAGGCTTGGC 
Cs OXPHOS 104.0 63.0 
F- TGCCGGTTTGTCTACCCTTC 
R- GGCAGGATGAGTTCTTGGCT 










































5.3.5.  Protein Abundance: 
Cells were washed with chilled (PBS(+/+)) (Gibco 14040-133) and lysed with PierceTM 
RIPA Buffer (Thermo Fisher Scientific 89900) supplemented with 1X Phosphatase 
Inhibitor Cocktail Set 2 (Calbiochem 5246251) and 1X Protease Inhibitor Cocktail Set 1 
(Calbiochem 539131).  Protein quantification was completed using a PierceTM BCA 
Protein Assay kit (Thermo Fisher Scientific 23225). Loading mixes were prepared at 20 
µg in MilliQ H2O, LDS (NuPAGE™ LDS Sample Buffer (4X) Invitrogen NP0007) and 
Reducing Agent (NuPAGE™ Sample Reducing Agent (10X) Invitrogen NP0004) at 
70°C for 10 minutes before loading in NuPAGETM 4-12% Bis-Tris Gels (Invitrogen 
NuPAGE NP0336). 1x MOPS (BOLT Invitrogen B000102) and 500 µL of antioxidant 
containing dithiothreitol (Thermo Fisher Scientific NP0009) was added and 
electrophoresis was completed at 200V for 50 minutes. Proteins were transferred to a 
PVDF membrane at 100V over 2 hours.  The protein transferred PVDF membrane (EMD 
Immobilon IPVH00010) was blocked in 5% bovine serum albumin (BSA) (ALB001) for 
pPKM2 and 5% skimmed milk (Carnation) for PKM1 and PKM2 in 1x Tris-Buffered 
Saline with 0.1% Tween 20 for 1 hour at room temperature with end-to-end agitation.  
Primary antibodies were incubated overnight at 4 °C with end-to-end rotation. HRP-
conjugated secondary antibodies were incubated for 1 hour at room temperature with end-
to-end rotation.  Membranes were imaged with Luminata Classico Western HRP 
Substrate (EMD WBLUC0500) and stripped using Restore Western Blot Stripping Buffer 
(Thermo Fisher Scientific 21059).  Bands of interest were compared to 𝛽-ACTIN.  







































































5.3.6.  Flow Cytometry: 
mPSCs were lifted with StemProTM AccutaseTM (Thermo Fisher Scientific A1110501) 
incubated at 37 °C for 5 minutes.  Centrifugation steps were completed at 244 x g for 3 
minutes.  Dead cell compensation and gating was completed using a 50% mixture of live 
and dead mESCs stained with Zombie Aqua™ Fixable Viability Kit (BioLegend 423101) 
and incubated in the light-tight container at room temperature for 30 minutes.  Cells were 
washed with 2 mL of flow cytometry staining buffer (FCSB) containing: 90% PBS (-/-), 
10% FBS (qualified, ESC grade), and fixed with 4% paraformaldyde (PFA) in PBS (-/-).  
Fixed cells were washed with PBS(-/-), centrifuged and divided into unstained, single, 
full-minus-one and full stained combinations of each cell type.  Fixed cells were stained 
with conjugated antibodies for 1 hour in a light-tight box at room temperature prior to 
washing, centrifugation and resuspension in PBS(-/-) and ejected through a 40 µm cell 
strainer (Fisherbrand™ Sterile Cell Strainers 22-363-547) with a final wash of 100 µL of 
PBS (-/-). Flow cytometry was completed on a FACSCanto flow cytometer.  Antibodies 




























































5.3.7.  Statistical Analyses: 
Statistics were completed using a one- and two-way ANOVAs where applicable.  
Characterization by flow cytometry of SSEA1/CD24 in mPSCs was completed using a 
one-way ANOVA with Tukey’s multiple comparisons test.  Flow cytometric analysis of 
transfection efficiency compared random control morpholino groups using a one-way 
ANOVA with Tukey’s multiple comparisons test.  Immunoblotting for protein abundance 
in the influence of PKM1/2 morpholinos utilized a one-way ANOVA with a Dunnett’s 
multiple comparisons test.  Determining the influence of PKM1/2 morpholinos on 
transitioning formative and primed-like mEpiLCs as quantified by flow cytometry of 
SSEA1/CD24 in mPSCs was completed using a one-way ANOVA with Dunnett’s 
multiple comparisons test.  Transcript abundance studies examining the influence of 
PKM1/2 morpholinos on mPSCs was accomplished using a two-way ANOVA with 
Dunnett’s multiple comparisons test. 
 
5.4.0.  Results: 
5.4.1.  Formative and primed-like mEpiLCs can be distinguished from primed 
mEpiSCs through SSEA1 and CD24 cell surface expression. 
mEpiLCs can be distinguished from naïve mESCs and primed mEpiSCs based on Stage -
Specific Embryonic Antigen-1 (SSEA1) and Cluster of differentiation 24 (CD24) 
expression (Figure 5.02.a-e).  Representative flow cytometry plots demonstrate cell 
population quantification (%) of pluripotent cells with high and low expression of SSEA1 







values of pluripotent cell types expressing high levels of SSEA1 and low levels of CD24 
(F(3,8)=8.993, p=0.0061) (Figure 5.02.a).  Tukey’s multiple comparisons post hoc test 
determined that the percentage of mEpiSCs expressing high levels of SSEA1 and low 
levels of CD24 was significantly greater than mESCs, mEpiLCs (formative), or mEpiLCs 
(primed-like) (p=0.0253, p=0200, p=0.0058 respectively) (Figure 5.02.a).  Moreover, 
there was a significant difference between group mean values of pluripotent cell types 
expressing high levels of SSEA1 and CD24 (F(3,8)=5.777, p=0.0212) (Figure 5.01.a).  
Tukey’s multiple comparisons post hoc test determined that the percentage of mEpiSCs 
expressing high levels of SSEA1 and CD24 was significantly greater than mESCs or 
mEpiLCs (formative) (p=0.0458, p=0.0319 respectively) (Figure 5.02.a).  There was also 
a significant difference between group mean values of pluripotent cell types expressing 
low levels of SSEA1 and high levels of CD24 (F(3,8)=142.9, p<0.0001) (Figure 5.02.a).  
Tukey’s multiple comparisons test determined that the percentage of mEpiSCs expressing 
low levels of SSEA1 and high levels of CD24 was significantly greater than mESCs, 
mEpiLCs (formative), or mEpiLCs (primed-like) (p=<0.0001 in all instances) (Figure 
5.02.a).  Lastly, there was a significant difference between group mean values of 
pluripotent cell types expressing low levels of SSEA1 and CD24 (F(3,8)=15.54, 
p<0.0011) (Figure 5.02.a).  Tukey’s multiple comparisons test determined that the 
percentage of mEpiSCs expressing low levels of SSEA1 and CD24 was significantly 
greater than mESCs, mEpiLCs (formative), or mEpiLCs (primed-like) (p=0.0021, 














Figure 5.02.  mESC, mEpiLC (Formative), mEpiLC (Primed-like), and mEpiSC 
SSEA1 and CD24 cell surface marker characterization. 
Delineation of naïve mESCs, formative and primed-like mEpiLCs, and mEpiSCs by a) 
flow cytometric analysis of SSEA1 and CD24 cell surface marker expression.  
Biexponential scale flow plots represent portrayals of SSEA1-compensated Brilliant 
Violet 421 on a 450 nm laser versus CD24-compensated APC on a 670 nm laser of b) 
mESCs, c) formative mEpiLC, d) primed-like mEpiLC, and e) mEpiSC.  Data shown as 
mean±SEM of treatments compared in biological triplicate as a one-way ANOVA with a 
Tukey’s multiple comparisons relative to the control of each corresponding cell type; * 



























5.4.2.  Efficient transfection of siRNAs and morpholino oligonucleotide delivery into 
mESCs. 
Transfection efficiency was determined using a FITC Fluorescein tagged control siRNA 
at 10, 30, 50 pmol concentrations delivered into mESCs using the lipid-based carrier 
Lipofectamine3000 at 1.5 and 3.0 µL volumes, further diluted in 50 µL of Opti-MEM.  
Optimal siRNA concentration and carrier volume were determined to be 30 pmol in 3µL 
respectively using flow cytometry relative to no siRNA and carrier controls (Figure 
5.03.).  mESCs transfected with the optimized parameters of Pkm1/2 siRNA constructs 
(Table 5.5.) were assessed at 24-, 48-, and 72-hours post-transfection by a transcript 
abundance study (Figure 5.04.a-c).  Initial results show an upregulation of Pkm1/2 
transcript abundance following siRNA transcript, with a slow leveling off towards 72 
hours post-transfection.  Importantly, a scrambled siRNA control influenced Pkm1/2 
transcript (Figure 5.04.a,b) and protein abundance (Figure 5.05.) drawing skepticism as to 
the true specificity of the siRNA constructs.  Originally, this project sought to determine 
the role of PKM1/2 in mESCs exiting the naïve state during a chemically driven 
conversion to mEpiLCs.  Our first knockdown strategy was centered around using small 
interfering ribonucleic acids (siRNAs) specific to either PKM isoform, and PKM total 
(both isoforms 1 and 2).  Our initial troubles came from difficulties efficiently 
transfecting and validating siRNAs in mESCs, and after several approaches I was able to 
transfect a control siRNA tagged with a fluoresceine conjugate A as determined by flow 
cytometry (Figure 5.03.).  I used flow cytometry to assess an optimal concentration of 
siRNA and lipid-based carrier, determining optimal transfection parameters of 30.0 pmol 


















































































































































Figure 5.03.  mESCs can be efficiently transfected using Lipofectamine3000. 
Cells were transfected using Lipofectamine3000 and FITC Fluorescein Conjugate-A.  
gating comparison between the greatest transfection efficiency of a) no siRNA and no 
transfection agent, and b) 30 pmol of siRNA and 3µL of Lipofectaine3000.  c) 
Transfection efficiencies comparing combinations of transfection agent and siRNA 































Following validation of the transfection process, I assessed our PKM1/2 siRNA designs.  
These siRNAs were designed with the help of ThermoFisher bioinformatics team and 3 
different sets of siRNAs targeting each isoform were made (Table 5.5.).  These siRNA 
constructs were transfected into mESCs, and RNA was extracted after 24, 48, and 72 
hours of incubation at 10.0, 30.0, and 50.0 pmol concentrations (Figure 5.04.).  
Examining the transcript abundance of these constructs following transfection 
demonstrated that increases and decreases in Pkm1/2 that were not compatible with our 
current question regarding downregulating Pkm1/2.  Optimal siRNA constructs were 
tested in mESCs for PKM1/2 protein abundance (Figure 5.05.).  Unfortunately, there was 
a significant influence of the scramble control siRNA on protein abundance and a lack of 





























Table 5.5.  siRNA construct designs 
 
Construct Sense Anti-Sense 
Pkm1-A CAGCAGCUUUGAUAGUUCUTT AGAACUAUCAAAGCUGCUGCT 
Pkm1-B GGAGGCCUCUUAUAAGUGUTT ACACUUAUAAGAGGCCUCCAC 
Pkm1-C UGAUAGCUCGGGAGGCUGATT UCAGCCUCCCGAGCUAUCAGG 
Pkm2-A CCAUUAUCGUGCUCACCAATT UUGGUGAGCACGAUAAUGGCC 
Pkm2-B AUCUACCACUUGCAGCUAUTT AUAGCUGCAAGUGGUAGAUGG 
Pkm2-C GCUAUUCGAGGAACUCCGCTT GCGGAGUUCCUCGAAUAGCTG 
Pkm-Total -Targets exon 4  
 
















Figure 5.04.  PKM1/2 siRNA transfected mESCs altered Pkm1/2 transcript 
abundance. 
Cell culture conditions included N2B27 media supplemented with LIF and 2i in 20% 
oxygen conditions over 3 days. Cells were transfected using custom designed Silencer 
Select siRNAs, Lipofectamine3000 and Opti-MEM. mRNA abundance relative to Tbp 
and calculated using △△Ct algorithm., A) Pkm1, B) Pkm2 C) Pkm Total transcript 
abundance studies for 24-, 48-, and 72-hour time points. Treatments were measured using 










Figure 5.05.  Most optimal siRNA constructs for PKM1 and PKM2 influence protein 
abundance in mESCs. 
Naïve mESCs treated with a scramble control siRNA, PKM1, and PKM2 designed 
custom silencer siRNAs transfected with Lipofectamine 3000 show a downregulation of 
PKM2 protein abundance.  PKM1 and PKM2 siRNAs alone downregulated PKM1 
protein abundance.  Protein densitometry was compared relative to -ACTIN and samples 








Random control Morpholinos tagged with a fluorescein label were scrape delivered into 
mESCs as a concentration series of 5, 10, or 20 M (Figure 5.03.a-c).  At 10 M, tagged 
control morpholinos were detectable by fluorescent microscopy (Figure 5.06.a).  Scrape 
delivered cells were measured via flow cytometry for transfection efficiency as assessed 
by FITC+ events relative to the total live cell population and mean fluorescence intensity 
as measured by geometric mean of fluorescent events (Figure 5.06.b, c).  There was a 
significant concentration-dependent difference between FITC+ cell events using random 
control morpholino treatments as determined by a one-way ANOVA (F (2,6)=45.77, 
p=0.0002) (Figure 5.06.b).  The concentration series for FITC+ events demonstrated: 5 
M (mean=73.9%, SEM=2.1), 10 M (mean=94.7%, SEM=2.3), and 20 M (mean=98.0, 























Figure 5.06.  mESCs can be efficiently and effectively transfected with morpholinos 
by scrape delivery at 20 M. 
 
Scrape delivered morpholinos tagged with a fluorescein label were visible in a) mESCs as 
demonstrated by fluorescent phase contrast microscopy at concentration of 10 M. Scale 
bars represent 75 m.  Transfection of morpholinos was optimized by comparing 5, 10, 
and b) 20M fluorescein-tagged control morpholinos as determined through c) FITC+ 
frequency relative to total population and d) geometric mean by flow cytometric analysis 
of FITC wavelength laser channel.  Data shown as mean±SEM of treatments compared in 




























5.4.4.  Steric-blocking Morpholinos affects PKM1 and PKM2 protein levels. 
Forty-eight hours-post 20 M morpholino scrape delivery produced significant changes 
to PKM1 and PKM2 protein levels in mESCs (Figure 5.07.a, Figure 5.01.b).  The 
transfection of a random control morpholino did not affect PKM1 or PKM2 protein 
abundance compared to mESCs scraped without a morpholino (Figure 5.04.a-f). There 
was a significant difference between group mean values of PKM1 protein abundance 
following Morpholino treatments as determined by a one-way ANOVA (F(3,8)=52.21, 
p<0001) (Figure 5.07.b).  There was a significant difference between group mean values 
of PKM2 protein abundance following morpholino treatments as determined by a one-
way ANOVA (F (3,8)=4.619, p=0.0371) (Figure 5.07.c).  A Dunnett’s multiple 
comparison test determined that the addition of the PKM1 designed Morpholino, now 
referred to as ‘PKM MO 1’ significantly decreased PKM2 protein abundance (p=0.0212) 
(Figure 5.07.b, c). The PKM2 designed morpholino, now referred to as ‘PKM MO 2’ 
significantly decreased PKM2 protein abundance (p=0.0480) and significantly increased 
PKM1 protein abundance (P<0.0001) (Figure 5.07.b, c).  There was a significant increase 
in the ratio of PKM1:PKM2 protein abundance with the addition of the PKM MO 2 
(p<0.0001) (Figure 5.07.e).  There was a significant increase in the ratio of PKM1:PKM2 
protein abundance with the addition of the PKM MO 1 and the PKM MO 2 (p=0.0082 
and p<0.0001) (Figure 5.07.e).  There was a significant increase in the ratio of 
pPKM2:PKM2 protein abundance with the addition of the PKM MO 1 and the PKM MO 














Figure 5.07.  Splice-modifying morpholinos modulate PKM1 and PKM2 protein 
abundance in mESCs. 
 
a) Representative PKM1/2 immunoblotting of morpholino transfected mESCs 
demonstrates b) upregulation of PKM1 and c) downregulation of PKM2 by transfecting 
the PKM MO2, whereas PKM MO1 significantly downregulates PKM2.  The PKM MO 
2 additionally e) upregulates protein abundance of PKM1/PKM2 ratio.  There was d) no 
significant change in pPKM2 with the inclusion of a PKM morpholino.  Data shown as 
mean±SEM of treatments compared in biological triplicate as a one-way ANOVA with a 




























5.4.5.  Pkm1/2 transcript abundance is altered in mESCs, formative mEpiLCs, 
primed-like mEpiLCs, and mEpiSCs following PKM1/2 spliceosome modification. 
A two-way ANOVA was conducted to examine the influence of treating each pluripotent 
state with the PKM MO 1 or PKM MO 2 morpholinos at 20 M on Pkm1/2 transcript 
abundance levels (Figure 5.08.a-c).  There was a statistically significant interaction, 
meaning the effects of different pluripotent cell types depends on each morpholino 
treatment, for Pkm1 (Figure 5.08.a) and Pkm2 (Figure 5.08.b) transcript abundance, but 
not the Pkm1/Pkm2 (Figure 5.08.c) transcript abundance ratio, (F(6,24)=11.92, p<0.001), 
(F(6,24)=2.695, p=0.0382), and (F(6,24)=1.904, p=0.1214) respectively between 
pluripotent cell type and morpholino treatment.  Simple main effect analysis 
demonstrated that within pluripotent cell types, the addition of PKM MO 1 or PKM MO 2 
morpholinos significantly influenced Pkm1 transcript abundance (F(3,24)=6.253, 
p=0.0027, and F(2,24)=25.86, p<0.001 respectively).  Simple main effect analysis also 
demonstrated that pluripotent cell type and the addition of PKM MO 1 or PKM MO 2 
morpholinos significantly influenced Pkm1/Pkm2 transcript abundance ratio 
(F(3,24)=14.26, p<0.0001, and F(2,24)=21.79, p<0.0001 respectively).  Based on 
Dunnett’s multiple comparisons tests relative to the control treatment of each pluripotent 
cell type, adding a PKM MO 2 morpholino significantly enhanced Pkm1 transcript 
abundance in mESCs (p<0.0001), mEpiLC (formative) (p=0.0006), and mEpiSCs 
(p=0.0080), and Pkm1/Pkm2 transcript abundance ratio in mESCs (p=0.0023) and 
mEpiLCs (formative) (p=0.0025).  Based on Dunnett’s multiple comparisons tests 







MO 2 morpholino significantly reduced Pkm1 and Pkm2 transcript abundance in mEpiLC 














Figure 5.08.  PKM morpholinos influence Pkm1/2 transcript abundance in naïve 
mESCs, formative mEpiLCs, primed-like mEpiLC, and primed mEpiSCs. 
Delivery of the PKM MO 2 significantly influences a) Pkm1 transcript abundance in 
mESCs, formative mEpiLCs, primed-like mEpiLCs, and mEpiSCs relative to control 
cells of each pluripotent state.  b) Pkm2 transcript abundance was significantly 
downregulated in mEpiLCs with PKM2 morpholino delivery.  mESCs and formative 
mEpiLCs c) Pkm1 to Pkm2 transcript abundance ratio was upregulated following PKM2 
morpholino transfection.  Data shown as mean±SEM of treatments compared in 
biological triplicate as a two-way ANOVA with a Dunnett’s multiple comparisons 
relative to the control of each corresponding cell type; * p<0.05, n=3 biological replicates 
run in technical triplicate.  Data represents Log2 of fold change relative to Hprt and 
























5.4.6.  Decreased PKM2 and increased PKM2 protein abundance by morpholino 
modulation decreases glycolytic genes Eno1 and Hk2 transcript abundance in 
primed mEpiSCs. 
A two-way ANOVA was conducted that examined the influence of treatment with PKM 
MO 1 or PKM MO 2 morpholinos (20 M) on glycolytic and oxidative phosphorylation 
(OXPHOS) metabolic transcript abundance following transfection in mESCs, 
transitioning mEpiLCs to the formative and primed-like pluripotent states and mEpiSCs 
over 48 hours.  There was no significant interaction for the glycolysis genes Hexokinase 2 
(Hk2), Lactate dehydrogenase A (Ldha), Phosphofructokinase 1 (Pfk1), and Alpha-
enolase (Eno1) transcript abundance (Figure 5.09.a), however, there was a statistically 
significant difference in transcript abundance between pluripotent cell types 
(F3,24)=38.12,p<0.0001), (F(3,24)=13.80, p<0.0001), (F(3,24)=5.361, p=0.0057), and 
(F(3,24)=4.815, p<0.0092) respectively.  Based on Dunnett’s multiple comparisons tests 
relative to the control treatment of each pluripotent cell type, treatment with the PKM 
MO 2 morpholino significantly reduced Eno1 and Hk2 transcript abundance in mEpiSCs 
(p=0.0268 and p=0.0128 respectively).  There was no significant interaction for the 
OXPHOS genes Isocitrate dehydrogenase 2 (Idh2), malate dehydrogenase 2 (Mdh2), and 
Succinate-CoA ligase (Suclg1) transcript abundance (Figure 5.06.b), however, there was 
a statistically significant difference in transcript abundance was observed between 
pluripotent cell types (F(3,24)=10.35, p=0.0001),(F(3,24)=6.679, p=0.0019), and 

















Figure 5.09.  PKM morpholinos influence key glycolytic transcript abundance 
markers in naïve mESCs, formative mEpiLCs, primed-like mEpiLC, and primed 
mEpiSCs. 
Quantification of transcript abundance following scrape delivery of 20 M PKM MO 1 
and PKM MO 2 morpholinos into mPSCs over 48 hours.  Transcript markers include a) 
glycolysis genes Hk2, Gpi, Pfkl, Aldoa, Pgam1, Eno1, and Ldha, and b) oxidative 
phosphorylation genes Cs, Idh2, Suclg2, Sdh-a, Fh, and Mdh2.  Transcript abundance was 
compared using the Pfaffl method and data is shown as mean±SEM of treatments 
compared in biological triplicate as a two-way ANOVA with a Dunnett’s multiple 
comparisons relative to the control of each corresponding cell type; * p<0.05, n=3 
biological replicates run in technical triplicate.  Data represents Log2 of fold change 























5.4.7.  PKM1/2 modulation does not alter naïve, formative, or primed pluripotency 
associated transcripts in mESCs, formative mEpiLCs, primed-like mEpiLCs, and 
mEpiSCs. 
A two-way ANOVA was conducted that examined the influence of treating with the 
PKM MO 1 or PKM MO 2 morpholinos on transcript abundance of naïve, formative, and 
primed pluripotent associated transcripts.  There was no significant interaction for the 
naïve pluripotency genes Rex1, Pecam, or Esrrb transcript abundance (Figure 5.09.a), 
however, there was observed a statistically significant difference in transcript abundance 
between pluripotent cell types (F(3,24)=54.98, p<0.0001), (F(3,24)=15.93, p<0.0001), 
and (F(3,24)=25.06, p<0.0001) respectively. There was no significant interaction for the 
formative pluripotency genes Lef1 (Lymphoid Enhancer Binding Factor 1), Dnmt3b, or 
Pou1fc transcript abundance (Figure 5.09.b), however, there was a statistically significant 
differences in transcript abundance between pluripotent cell types (F(3,24)=7.380, 
p=0.0011), (F(3,24)=60.28, p<0.0001), and (F(3,24)=85.18, p<0.0001) respectively. 
There was no significant interaction for the primed pluripotency genes Zic2, Cer1, or 
T(Brachyury) transcript abundance (Figure 5.09.c), however, there was an observed 
statistically significant difference in transcript abundance between pluripotent cell types 
(F(3,24)=4.071, p=0.0180), (F(3,24)=27.79, p<0.0001), and (F(3,24)=70.40, p<0.0001) 














Figure 5.010.  PKM morpholinos do not influence key naïve, formative, and primed 
pluripotency transcript abundance markers in naïve mESCs, formative mEpiLCs, 
primed-like mEpiLC, and primed mEpiSCs. 
Quantification of transcript abundance following scrape delivery of 20 M PKM MO 1 
and PKM MO 2 morpholinos into mPSCs over 48 hours.  Transcript markers include a) 
naïve pluripotency associated genes Pecam, Esrrb, and Rex1, b) formative pluripotency 
associated genes Dnmt3b, Pou1fc, and Lef1, and c) primed pluripotency associated genes 
Zic2, Cer1, and T(Brachury).  Transcript abundance was compared using the Pfaffl 
method and data is shown as mean±SEM of treatments compared in biological triplicate 
as a two-way ANOVA with a Dunnett’s multiple comparisons relative to the control of 
each corresponding cell type; * p<0.05, n=3 biological replicates run in technical 

























5.4.8.  PKM1/2 modification alters SSEA1 and CD24 ratios in transitioning mESCs 
into formative state and formative mEpiLCs into primed-like state mEpiLCs. 
There was an observed a significant difference between group mean values of morpholino 
treatments expressing low levels of SSEA and high levels of CD24 in formative mEpiLCs 
as determined by a one-way ANOVA (F (2,6)=8.167, p=0.0194) (Figure 5.11.a).  A 
Dunnett’s multiple comparison test detected that the percentage of mEpiLCs (formative) 
transfected with the PKM MO 1 morpholino (Figure 5.11.c) was significantly enhanced 
compared to control mEpiLCs (p=0.0128).  There was an observed significant difference 
between group mean values of morpholino treatments expressing high levels of SSEA 
and CD24 in primed-like mEpiLCs as determined by a one-way ANOVA (F(2,6)=8.486, 
p=0.0178) (Figure 5.11.a).  A Dunnett’s multiple comparison test determined that the 
percentage of mEpiLCs (primed-like) transfected with the PKM MO 1 (Figure 5.12c.) 
and PKM MO 2 morpholinos (Figure 5.12.d) was significantly greater than control 




























Figure 5.11.  Influence of downregulating PKM on SSEA1 and CD24 expression in 
transitioning formative mEpiLCs. 
 
Scrape delivery of 20 M PKM MO 1 and PKM MO 2 morpholinos into mESCs 
transitioned over 48 hours into formative mEpiLCs compared by a) SSEA1 and CD24 
cell surface markers by flow cytometry.  Transitioning into formative b) mEpiLCs with 
the addition of c) PKM MO 1 morpholinos and significantly increased the population of 
SSEA1H and CD24H cells and both PKM MO 1 and d) PKM MO 2 delivery resulted in 
decreased SSEA1L and CD24L cell populations.  Biexponential scale flow plots represent 
portrayals of SSEA1-compensated Brilliant Violet 421 on a 450 nm laser versus CD24-
compensated APC on a 670 nm laser.  Data shown as mean±SEM of treatments compared 
in biological triplicate as a one-way ANOVA with a Dunnett’s multiple comparisons 




























Figure 5.12.  Influence of downregulating PKM on SSEA1 and CD24 expression in 
transitioning primed-like mEpiLCs. 
Scrape delivery of 20 M PKM MO 1 and PKM MO 2 morpholinos into formative 
mEpiLCs transitioned over 48 hours into primed-like, mEpiLCs compared by a) SSEA1 
and CD24 cell surface markers by flow cytometry.  Transitioning into primed-like b) 
mEpiLCs with the addition of c) PKM MO 1 morpholinos and d) PKM MO 2 morpholino 
delivery significantly increased the population of SSEA1H and CD24H cells and 
decreased SSEA1L and CD24L cell populations.  Biexponential scale flow plots represent 
portrayals of SSEA1-compensated Brilliant Violet 421 on a 450 nm laser versus CD24-
compensated APC on a 670 nm laser.  Data shown as mean±SEM of treatments compared 
in biological triplicate as a one-way ANOVA with a Dunnett’s multiple comparisons 























5.5.0.  Discussion:  
There is a growing body of evidence promoting metabolism as having an active role in 
cell pluripotency, differentiation, and development (Tsogtbaatar et al. 2020; Dahan et al. 
2018; J. Zhang et al. 2018).  Within the cells of the early embryo and the pluripotent 
spectrum, pyruvate kinase muscle isoforms 1 and 2 are suggested to play a variety of 
roles (Konno, Koseki, et al. 2015; Konno, Ishii, et al. 2015; Jacks et al. 2016).  Isoform 
specific lentiviral overexpression of either Pkm1 or Pkm2 in mESCs significantly 
increased the pluripotency associated genes Nanog, Eras, and Rex1 transcript abundance, 
but did not influence specialization when subjected with differentiation media (Qin et al. 
2017).  This same study found that when Pkm1/2 were downregulated via shRNA, the 
same pluripotency transcripts were significantly downregulated.  Additionally, Pkm1/2 
are implicated in the reprogramming of somatic cells to naïve mESCs as downregulating 
total Pkm1/2 via shRNA significantly hindered induced pluripotent stem cell (iPSC) 
generation as quantified by measuring alkaline phosphatase staining (Qin et al. 2017).  
Alternatively, overexpression of Pkm2, but not Pkm1 significantly increased alkaline 
phosphatase staining during reprogramming, suggesting that Pkm2 is the PKM isoform 
that facilitates iPSC generation.  The metabolic switch from OXPHOS to glycolysis is 
linked to activation of hypoxia inducible factor 1 (HIF-1), where PKM2 interacts with 
the HIF1 subunit promoting transactivation domain function as well as p300 recruitment 
to the HIF1’s response element during somatic cell reprogramming (Luo et al. 2011).  
This interaction promotes the WE and thus the switch from OXPHOS to aerobic 
glycolysis (Palsson-McDermott et al. 2015).  The reprogramming of human OXPHOS 







exhibit an aerobic glycolytic metabolic preference, a metabolic transition not far from the 
naïve-to-primed bivalency to glycolytic transition of mESCs-to-mEpiSCs (Zhou et al. 
2012).  In the presence of differentiation media, naïve mESCs with a Pkm2 allele knock-
in resist differentiation compared to the Pkm1 knock-in as measured by a microarray 
analysis (Konno, Ishii, et al. 2015).  Additionally, the Pkm2 allele knock-in enhances 
methionine metabolism during differentiation suggesting a pro-oxidative role (Konno, 
Ishii, et al. 2015).  In Chapter 3, I demonstrate that PKM1 and PKM2 protein abundance 
significantly increases in formative mEpiLCs, therefore, knocking down Pkm2 during this 
transition could destabilize the pro-oxidative controls necessary for the developmental 
transition through the formative state during differentiation.        
 
Despite employing an isoform targeted approach of the exclusive splice sites between 
PKM1 and PKM2, the results of the protein abundance study demonstrate that one of 
constructs downregulated PKM2 with an upregulation to PKM1.  This is not a typical 
expectation when using morpholinos but is potentially related to the morpholino in 
question binding across splice regulatory proteins.  In this case, the alternative splicing 
mechanism of PKM1/2 could be impacted by altering splice suppressor and enhancer 
proteins binding to pre-mRNAs.  This would cause a feedback mechanism leading to 
unintended splicing edits.  This alteration has been demonstrated previously in a study 
examining PKM2 and myotonic dystrophy (Gao and Cooper 2013).   
 
Between either end of the pluripotent spectrum exists a recently described and poorly 
understood executive, formative stage, of which, metabolic trends and PKM expression 







through spliceosome modification, influences metabolic and pluripotent cell surface 
marker expression.  Contrary to the hypothesized direction that transitioning formative 
and primed-like mEpiLCs would take, knocking down PKM1/2 promoted primed 
pluripotency associated cell surface marker expression and promoted an enhanced 
population of cells expressing high levels of the naïve cell surface marker SSEA1 and the 
primed cell surface marker CD24.  Notably, there was no significant differences in 
pluripotency associated transcripts following the addition of morpholinos from their non-
transfected control states.  While previous research has found Pkm2 to play an important 
role in naïve pluripotency maintenance and reprogramming from somatic cells to either 
naïve or primed states, these results demonstrate that Pkm1/2 splice modifications do alter 
the pluripotent phenotype in transitioning formative and primed-like pluripotent states 
towards a primed state.  It has been demonstrated that naïve mESCs express high levels 
SSEA1 and primed mEpiSCs express high levels of CD24, potentially the downregulation 
of PKM2 and upregulation of PKM1 promotes formative state cell expression, however, 
at this time little is known regarding formative state metabolic preferences (Shakiba et al. 
2015).  Profiling true, stable formative state cells would confirm this potential cell surface 
marker trend and the role of PKM1/2 during transitioning.  This investigation sheds light 
on the metabolic preference of formative state cells through our transcript abundance 
study.  I demonstrate a downregulation of OXPHOS transcripts such as Idh2 and an 
increase in glycolytic transcripts such as Ldha, these trends suggest the initiation of the 
WE and reflect the in vivo correlate following post-implantation of the blastocyst.  Of 
note, the transcript abundance study found key differences between the formative 
mEpiLCs and primed mEpiSCs, including an increase in OXPHOS transcripts in Mdh2 







players in the WE, suggesting that the formative state has not fully adhered to aerobic 
glycolysis (Kitazawa et al. 2020).  As metabolically bivalent cells, naïve mESCs 
transitioning to the formative state rewire their transcriptional and epigenetic landscape, 
gaining the competency to differentiate into other cell types (Smith 2017; Kinoshita and 
Smith 2018).  Previous studies demonstrate that reactive oxygen species (ROS)-mediated 
interactions with mitochondria and nuclear functions are clearly implicated in stem cell 
fate and potency (Bigarella, Liang, and Ghaffari 2014).  As PKM1 plays a critical role in 
the metabolic shunting of pyruvate towards an OXPHOS fate as acetyl-CoA in the 
mitochondria, the ROS generated by increased PKM1 may further impinge upon the 
developmental progression of the pluripotent continuum and lineage competency.  This 
upregulation could promote metabolic reprogramming by inducing a shift to OXPHOS or 
an OXPHOS-burst to increase ROS and stabilize hypoxia inducible factor 1 (HIF-1), 
such an event could be verified by examining extracellular acidification rate and oxygen 
consumption rate.  The master metabolic regulator HIF-1 is activated during instances 
of hypoxia, decreased ROS and the glycolytic shift towards primed pluripotency. PKM2 
can interact with HIF1 to further promote the WE (Prigione et al. 2014).  Through 
PKM2 reduction and PKM1 upregulation, these findings suggest that PKM2 reduction 
promoted the primed CD24 high cell surface marker population when generating 
formative state mEpiLCs and may conversely indicate a role for PKM1 in promoting 
naïve pluripotency.  Upregulation of PKM1 appears to have stunted the influence of 
PKM2 reduction, potentially as a compensatory mechanism.  This study demonstrates 
that formative and primed-like pluripotent states can be effectively distinguished from the 







markers SSEA1 and CD24.  This finding can be utilized to determine transitioning and 
differentiation efficiencies within the pluripotent continuum and exit during cell lineage 
specification.  Previously, only naïve and primed states have been examined using these 
markers and here I demonstrate that unique expression dynamics could additionally be 
utilized for fluorescently activated cell sorting for downstream studies and population 
purifications (Shakiba et al. 2015).  This method should be used in the study of primordial 
germ cell-like cell generation along with somatic lineage competency during pluripotent 
development. 
 
The results of the transcript abundance demonstrate that the glycolysis genes Pgam1 and 
Gpi significantly decreased in primed mEpiSCs following PKM2 downregulation.  This is 
not surprising as Pkm2, Pgam1, and Gpi are heavily implicated in WE and biosynthesis; 
downregulating a key protein such as PKM2 appears to have downstream effects on other 
WE associated genes and may disrupt aerobic glycolysis in cells that have achieved true 
primed pluripotency (Hitosugi et al. 2012; de Padua et al. 2017).  Importantly, the genes 
Hk2 and Eno1 significantly increased in primed mEpiSCs, and Hk2 also significantly 
increased in primed-like mEpiLCs following PKM2 downregulation and PKM1 
upregulation.  This follows the currently described preferences for primed pluripotency, 
and exit of the naïve state, by promoting a glycolytic preference over OXPHOS, and 
elevated WE transcription of these two critical genes (Capello et al. 2016).  The transcript 
abundance results also demonstrate that the OXPHOS genes Mdh2, Fh1, and Suclg1 all 
significantly increased when PKM2 was downregulated and PKM1 was upregulated in 
primed-like mEpiLCs.  This further promotes the primed pluripotent state as Mdh2 is 







(NAD), thus supporting the glycolytic shift (Hanse et al. 2017).  Fumarate hydratase 
(Fh1) works to process the accumulated fumarate, which in turn works to activate 
hypoxia response (Isaacs et al. 2005; Frezza et al. 2011).  The increased PKM1 may 
contribute towards compensating towards fumarate accumulation, however, increased 
Fh1 relative to the control primed-like cells and even the naïve mESCs is unexpected and 
may play a new role in generating the unique naïve SSEA1 high coupled with primed 
CD24 high population.  Suclg1 works to generate ADP and succinyl-CoA in the 
tricarboxylic acid cycle and can work to promote substrate level phosphorylation even in 
the absence of oxygen, and thus can work within the shift towards aerobic glycolysis 
model in primed-like mEpiLCs (Chinopoulos and Seyfried 2018).  Metabolic profiling on 
the protein level through immunoblots and non-denaturing gels paired with live cell acute 
measure of extracellular acidification rate and oxygen consumption rate will help to 
elucidate metabolic trends in the formative state and PSCs treated with PKM 
morpholinos.  As both the downregulated PKM2 and the combination of downregulation 
of PKM2 and upregulation of PKM1 yielded similar levels (mean of 36.4% and 38.7% 
respectively) of unique population of SSEA1 high and CD24 high primed-like mEpiLCs, 
the effects of PKM1 upregulation are either not strong enough to compensate or do not 
have a role in the transition out of the formative state to primed state pluripotency.  This 
trend could additionally be in response to, or in addition to the significant increase in the 
ratio of PKM1/PKM2 with the PKM MO 2 treatment.  In summary, the metabolic 
transcript abundance results demonstrate modulating PKM1 and PKM2 expression 
appears to impact the primed-like mEpiSCs and primed mEpiSCs (Figure 5.13). This may 
promote the unique population of naïve and primed cell surface marker expressing cells 







displacing the WE (Figure 5.12.).  My strategy of targeting PKM1/2 splice events resulted 
in an elevated ratio of phosphorylated-PKM2 (pPKM2), the conformation associated with 
the WE, to total-PKM2, lysates showing the cumulative expression of both homo-
tetrameric and dimeric (pPKM2) conformations.  This result implicates pPKM2 as 
playing a role in generating this novel expression pattern of SSEA1 high and CD24 high 
expressing cells following the transition from the formative state to a primed-like 
pluripotency.  Previously, in Chapter 3, I demonstrated maintenance of the ratio of 
PKM1/PKM2 protein abundance throughout the pluripotent continuum in murine cells, 
by modulating the ratio of pPKM2/PKM2 with morpholinos, a further promotion of the 




















Figure 5.13.  Summary of Chapter 5 research findings. 
 
The influence of PKM1/2 morpholinos on protein and transcript abundance, and cell 
surface marker expression in mESCs, mEpiLCs (formative and primed-like), and 
mEpiSCs.  mPSCs representing the states of the pluripotent continuum treated with PKM 
morpholinos result in altered metabolic transcripts related to the WE in primed-like 
mEpiLCs and primed mEpiSCs.  There was no difference found in pluripotency 
associated transcripts across the spectrum with the addition of PKM morpholinos, 
however, the cell surface markers for the pluripotency proteins SSEA1 and CD24 were 
altered in mESCs transitioning to the formative state and from formative mEpiLCs 












Here, I demonstrate that downregulating PKM2 alone promotes primed pluripotent stem 
cell populations (CD24 High) when generating formative state mEpiLCs.  Importantly, 
downregulating PKM2 with PKM1 upregulation does result in a significant increase in 
CD24 High expressing cells.  In this instance, the pro-OXPHOS nature of Pkm1 may 
promote the bivalent nature of mESCs to counter the pro-transitioning influence of 
downregulating PKM2.  Through germline deletion of PKM2 in mice, it was found that 
PKM1 becomes the predominant isoform in all cells of the developing PKM2-null mouse 
compensating for the loss of PKM2, the traditional predominant form during development 
(Jacks et al. 2016).  These results suggest that downregulating PKM2 appears to yield a 
population expressing both naïve and primed cell surface markers.  Interestingly, another 
intermediate pluripotent cell state referred to as ‘f-class’ cells have been shown to contain 
a similar population of SSEA1+/CD24+ cells (Vidal, Stadtfeld, and Apostolou 2015; 
Urbanska et al. 2017).  These f-class cells are generated in rare populations following 
extended transgene expression of reprogramming factors Oct4, Klf4. Sox2 and c-Myc 
(Vidal, Stadtfeld, and Apostolou 2015).  When the formative pluripotent state was 
hypothesized, the notion that formative cells could occupy the transcriptional profile of 
both naïve and primed states was suggested, potentially disrupting the fine-tuning pro-
oxidative controls associated with the Pkm2 isoform during a transition that promotes the 
formative state in vitro (Smith 2017). The lack of PKM1 specificity introduced us to an 
unexpected beneficial strategy that being that our Pkm1/2 morpholinos can induce both 
downregulation of PKM2 alone and downregulation of PKM2 while simultaneously 
upregulating PKM1.  This occurrence has been demonstrated previously using 
morpholinos on the alternative spliced gene Proteolipid protein 1 (Plp1/DM20), where 







specificity in the targeted morpholino approach could be due to a duplication mutation as 
the exclusive exons share a very similar sequence, downstream mutations could further 
change the exonic structure.  A PKM1 specific morpholino is necessary to delineate the 
role of the M1 isoform in maintaining individual pluripotent states and pluripotent 
transitioning.  A CRISPR or TALEN strategy is possible for an alternatively spliced 
isoform such as PKM1/2, however, PKM1/2 specificity has been shown using shRNAs, 
germline loss of function and lentiviral allele-knock in (Qin et al. 2017; Konno, Ishii, et 
al. 2015; Jacks et al. 2016).  When taken together, this study promotes PKM1 and PKM2 
having a role in the WE as upregulation in formative and primed-like mEpiLCs and 
mEpiSCs promotes WE genes and primed pluripotency associated CD24 expression.  
This is surprising as PKM2 is associated with the WE, and PKM1 has only recently been 
implicated in specific cancers, this finding promotes both isoforms as having a potential 
role in development and the pluripotent continuum (L. Wei et al. 2017; Morita et al. 
2018).  These findings promote Pkm1 and Pkm2 having distinct roles in metabolism and 
pluripotency along with contributing to the growing body of evidence that metabolism is 
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Chapter 6  
6.0.0.  General Discussion. 
Pluripotent stem cells (PSCs) are hallmarked by two key traits: i) they can divide in the 
undifferentiated state indefinitely and ii) they have the potential to specialize into any cell 
type of the adult organism including the germ cells.  These traits are referred to as self-
renewal, trilineage differentiation, and germ cell specialization.  Pluripotency is described 
as a developmental continuum reflecting in vivo embryological origins as individual 
states (Nichols and Smith 2009; Morgani, Nichols, and Hadjantonakis 2017).  The cells of 
the developing inner cell mass (ICM) of the pre-implantation embryo can be explanted 
and grown in vitro, with cells of this developmental stage are referred to as having naïve 
pluripotency (Evans and Kaufman 1981; Martin 1981).  Recently an executive, 
intermediate pluripotent state has been described, also known as formative pluripotency 
(Smith 2017).  Immediately following implantation cells enter the formative interval and 
towards the end of pluripotency, cells exhibit primed pluripotency.  These three phases 
represent sequential developmental intervals of the phased progression model of 
pluripotency, whereby a developing cell of the embryo needs to progress throughout each 
phase before specializing through the progress of differentiation (Smith 2017).  Naïve, 
formative, and primed pluripotency represent distinct intervals of pluripotent 
development and have only recently been stably produced into cell lines instead of 
transiently existing states (Kinoshita et al. 2020).  Aside from their developmental 
timeline, one distinguishing feature of these pluripotent states is their metabolic 
preference (Zhou et al. 2012).  Naïve PSCs utilize both glycolysis and oxidative 







preferential in most cancer cells commonly referred to as the ‘Warburg Effect’ (Zhou et 
al. 2012).  The formative pluripotent state has yet to have its metabolic preferences 
delineated and requires further investigation.  Based on our transcript abundance study in 
Chapter 5, the formative pluripotent state appears to show the onboarding of an increase 
in aerobic glycolytic transcripts and a decrease in oxidative phosphorylation transcripts. 
 
My project investigated the rate limiting and last step of glycolysis, metabolic enzymes 
pyruvate kinase muscle isoforms 1 and 2 (PKM1/2).  PKM2 has been found to regulate 
endothelial-to-mesenchymal transition in cancer cells and is known to enhance the 
reprogramming of adult cells into pluripotent cells (Hamabe et al. 2014; Qin et al. 2017). 
When a PKM1 allele is knocked into naïve mouse ESCs (mESCs) grown in 
differentiation media, the result is increased endoderm transcripts, whereas with a PKM2 
allele knock-in there is a resistance to differentiation (Konno et al. 2015).  Currently, we 
have a limited understanding of PKM1/2’s role in embryonic development, formative 
pluripotency, and transitioning between pluripotent states.   
 
While there has been extensive research into characterizing naïve and primed pluripotent 
states, current understanding of how ESCs transition between states and formative state 
pluripotency is not well known (Zhou et al. 2012).  In particular, what is known regarding 
how ESCs exit from naïve state through differentiation stimulus is poorly understood 
(Kalkan and Smith 2014).  Several models have been published regarding the transition of 
naïve cells to a primed-like pluripotent state in vitro, and artificially transitioned cells 
retain the transcriptional circuitry and traits of their in vivo correlates to serve as an 







investigation’s main question by verifying if modulating PKM1 or PKM2 will influence 
the maintenance of the naïve or primed states, and to alter the generation of the formative 
or primed-like pluripotency when transitioning from a naïve pluripotent state.   
 
One aspect of my investigation regarding metabolic preferences and cell culture 
conditions that appeared to show an influence in pluripotency was altering oxygen 
tension.  Oxygen tension was promising as primed pluripotency is associated with aerobic 
glycolysis, potentially, this trend is intrinsically programmed due to the developmental 
origins of in vivo post-implantation epiblast (Shyh-Chang and Ng 2017).  This trend holds 
true during the reprogramming process of somatic cells to primed PSCs (Mathieu and 
Ruohola-Baker 2017).  Oxygen tension works to influence metabolic enzymes important 
in pluripotent conversion such as HIF-1 (Zhou et al. 2012).  It is well documented that 
human PSCs prefer low oxygen cell culture conditions, this works to promote primed 
pluripotency (Lees et al. 2019).  Naïve mESCs, transitioning formative mEpiLCs, and 
primed mEpiSCs can be cultured at normoxic (~21% oxygen tension) and low oxygen 
(hypoxic ~2-5% and 5% oxygen tension in this study).  Morphologically, mEpiSCs grew 

















Figure 6.1.  Phase contrast imaging of naïve mESCs, chemically transitioned of 
formative, and primed-like mEpiLCs. 
Naïve mESCs can be chemically transitioned from glistening, domed colonies 
characteristic of the naïve pluripotent state, into flattened colonies like the primed 
pluripotent cells of the post-implantation epiblast.  This conversion can be accomplished 
through the swapping of required growth factors from LIF/2i conditions to FA media.  
Cells were cultured in both 21% oxygen representative of normoxic conditions and 5% 
oxygen conditions, referred to as hypoxic.  Phased contract microscopy was completed on 














To study the influence of oxygen tension on each pluripotent state we additionally 
examined protein lysates for metabolic and pluripotency and early lineage markers 
(Figure 6.2.).  Naïve mESCs, mEpiLCs transitioning over 5 days (each day harvested), 
primed mEpiSCs, and as a somatic cell control, mouse embryonic fibroblasts (MEFs) 
were grown in both 21% oxygen to simulate normoxic conditions and 5% oxygen to 




















Figure 6.2.  Immunoblotting and Ponceau staining of mESCs, transitioning 
mEpiLCs, mEpiSCs, and MEFs in normoxic and hypoxic cell culture conditions. 
Naïve mESCs, transitioning mEpiLCs, mEpiSCs, and MEFs immunoblotted for 
pluripotency and metabolic protein markers.  Cells were grown in 21% oxygen 
(atmospheric/normoxic) and 5% oxygen (hypoxic) conditions.  Each lane represents an 








Examining the protein abundance of 21% and 5% oxygen tensions revealed differential 
metabolic and pluripotent expression patterns throughout the pluripotent continuum 
(Figure 6.3.A-G).  My findings suggest that primed mEpiSCs show a beneficial influence 
of culture in 5% oxygen over 21% as demonstrated with a statistically significant increase 
in T(BRACHYURY) protein abundance for low oxygen conditions (Figure 6.3.C).  A 
significant decrease in NANOG confers an exit of the naïve state in transitioning 
mEpiLCs (Figure 6.3.D) (Kinoshita and Smith 2018).  While a decrease in NANOG is 
expected, a drop in OCT4 is not, potentially the finding of a significant decrease in OCT4 
protein abundance between 21% and 5% conditions in 4 to 5 days of transitioning 
mEpiLCs may suggest that the formative pluripotent state has an elevate degree of 
preference for OXPHOS (Figure 6.3.E).  Early in the transitioning process (days 1 and 2) 
indicate that hypoxic conditions promote the primed pluripotency associated protein 
SOX17 (Figure 6.3.F) (Kinoshita and Smith 2018).  It is hypothesized that the early post-
implantation epiblast cell of the murine embryo should reflect the decreased oxygen 
availability (Mathieu and Ruohola-Baker 2017).  This may explain why the greatest 
metabolic protein abundance changes in PKM1, pPKM2, and PKM2 reflect the early 
formative transitioning mEpiLCs and the metabolically bivalent mESCs.  There was a 
significant increase in PKM1 for hypoxic conditions relative to normoxic conditions in 
naïve mESCs and 1 day of transitioning mEpiLCs (Figure 6.3.A) and a significant 
increase in pPKM2/PKM2 in mESCs and mEpiLCs transitioning on days 1-3 (Figure 


















Figure 6.3.  Metabolic and pluripotent state associated protein abundance in naïve 
mESCs, transitioning mEpiLCs, primed mEpiSCs, and somatic MEFs. 
Naïve mESCs, transitioning mEpiLCs (over 5 days of chemical transitioning), primed 
mEpiSCs, and somatic MEFs were compared relative to a loading control consisting of a 
combination of each lysate.  Metabolic and pluripotency associated markers were 
compared by densitometry and normalized to the loading control.  Data consists of mean 























6.1.0.  Summary of Findings: 
My research contributes to evidence that metabolism has an active and passive role in 
development and pluripotency.   I have found differences in PKM1/2 expression and 
subcellular localization between naïve, formative, and primed mouse embryonic stem 
cells.  Metabolism has been thought of as a by-product of cell fate, but this idea has been 
challenged as metabolism has now been found to be as a necessary driver of development 
(Zhang et al. 2018; Dahan et al. 2019; Tsogtbaatar et al. 2020).  By better understanding 
the role of metabolism during the transition between naïve and primed PSCs, in vitro 
research can more closely recapitulate the in vivo mammalian development of pre-
gastrulation embryos.   
 
In Chapter 2, I detail a novel, comprehensive methodology in colocalization.  This 
methodology is beneficial in the study of nuclear and cytoplasmic protein localization of 
pluripotent stem cells (PSCs).  Due to the increased nuclear to cytoplasmic size ratio of 
PSCs, my method utilizes the addition of 3D imaging, background negation, and an 
additional nuclear reference relative to the nuclear pluripotency marker of comparison to 
the protein of interest for validation. This methodology was used to demonstrate nuclear 
and cytoplasmic colocalization of PKM1/2 in naïve mESCs, formative mEpiLCs, and 
primed mEpiSCs relative to OCT4 and GAPDH localization, validated with Hoechst 
nuclear staining.  These findings show that it is critical to run positive and negative 
references relative to dual fluorophore colocalization and that in the case of mouse 
embryonic stem cells (mESCs), the spatial overlap data may not be sufficient to reach 
quality colocalization assessment compared to correlation data when considering the 







the MOC metrics in PSCs were insufficient to delineate nuclear and cytoplasmic 
distinctions by colocalization and that the PCC metric was a highly effective and viable 
tool for such distinction and analysis.  To increase the power of traditional colocalization 
studies, I did not simply analyze single images, but I also employed orthogonal 
projections of stacks examining the data of individual slices to characterize the 
localization patterns of a true three-dimensional structure.  Additionally, I accounted for 
the inherent flaws of the MOC calculation by examining only the individual colonies and 
individual cells in the orthogonal and airyscanned images respectively to prevent 
autofluorescence or background pixel offset.  Using this methodology, my research 
demonstrates that PKM1 and PKM2 have a moderate correlation and a strong spatial 
overlap to the nuclear localized OCT4 and the cytoplasmic localized GAPDH in naïve 
mESCs.  In formative state mEpiLCs, there is a significant decrease in spatial overlap of 
PKM1 and PKM2 localization relative to GAPDH.  Additionally, there was a strong 
correlation of PKM1 to OCT4 and a moderate correlation of PKM1 to GAPDH, whereas 
PKM2 had a weak correlation to both OCT4 and GAPDH in mEpiLCs.  Finally, primed 
mEpiSCs had a strong overlap of PKM1 and PKM2 to the localization of OCT4 and 
GAPDH, but only a weak correlation of PKM1 and PKM2 relative to OCT4 and a 
moderate correlation to GAPDH.  These results provide evidence of differential 
subcellular localization patterns of PKM1/2, which are traditionally localized to the 
cytoplasm.  Nuclear translocation of each isoform may indicate non-canonical roles for 
this metabolic gene similar to documented roles within cells exhibiting the Warburg 








In Chapter 5, I utilized a novel method of naïve, formative, primed-like, and primed 
pluripotent state delineation by flow cytometry, quantifying the pluripotent state 
associated cell surface markers SSEA1 and CD24.  This methodology allowed for the 
distinguishing of unique SSEA1/CD24 expression for each state and allowed for the 
transitioning efficiency to be determined following the addition of pre-mRNA splice 
morpholinos designed to target PKM1 and PKM2.  This study demonstrated that altering 
PKM1/2 expression by morpholinos modulated SSEA1/CD24 expression in transitioning 
pluripotent states within the pluripotent continuum and works to promote the notion that 
metabolism is a driver of development.  As such, blocking pre-mRNA splicing of PKM1 
and PKM2 during a naïve-to-primed transition of mESCs to mEpiLCs modulates the exit 
from naivety and initiation of primed pluripotency.  Specifically, downregulation of 
PKM2 promotes the frequency of cell events expressing the primed pluripotency cell 
surface marker CD24 in naïve mESCs transitioning to the formative pluripotent state.   
Additionally, downregulation of PKM2 alone or coupled with upregulation of PKM1 
increases the frequency of cells expressing high levels of both the naïve cell surface 
marker SSEA1 and the primed marker CD24 when transitioning from the formative state 
to a primed-like pluripotency.  Modulation of PKM1/2 with either targeted approach 
increased the ratio of pPKM2 (homodimeric conformation attributed to the Warburg 
Effect) to total PKM2 (homo-tetrameric and dimeric conformations), giving rise to the 
likely possibility that pPKM2 plays a role in generating this novel expression pattern.  
This enhanced ratio has been postulated to indicate a shift towards biosynthesis over 
energetic processes (W. Yang and Lu 2015; Zahra et al. 2020).  In Chapter 3, I 
demonstrate the stable ratio of PKM1/PKM2 is demonstrated throughout the pluripotent 







Effect and enhance the metabolic shift from bivalency to aerobic glycolysis.  
Colocalization data by confocal microscopy, and flow cytometric results and analysis 
using the comprehensive techniques are detailed in Chapters 2 and 4, and are respectively 
summarized in Figure 6.4.   
 
 
Collectively, I demonstrate differential nuclear localization of PKM1 and PKM2 in 
mPSCs across the pluripotent continuum.  My initial observations of the presence of 
nuclear PKM1 appeared to be the first of its kind, and only recently has been shown in 
hepatoma cells (Wei et al. 2017).  Coupled with nuclear fractionation data, my 
comprehensive methodology to colocalization, detailed in Chapter 2, works to clearly 
demonstrate nuclear PKM1/2 in mPSCs across the spectrum, detailed in Chapter 3.  
These findings indicate a potential non-canonical role outside of metabolic processing for 
PKM1/2 within the developmental process.  My study proceeded to delineate the 
influence of modulating PKM1/2 through spliceosome modifying morpholinos to alter 
PKM1/2 expression in each pluripotent and during a transition throughout the continuum.  
In chapter 5, I found that altering PKM1/2 expression had little impact on metabolic 
transcripts associated with glycolysis and OXPHOS or pluripotency transcripts, however, 
there was an impact on key pluripotency cell surface marker expression during 
transitioning.  Modulation of PKM1 and PKM2 in cells chemically transitioning from 
naïve mESCs into formative mEpiLCs and subsequently into primed-like mEpiLCs 
indicate that PKM1/2 are drivers of the development of the pluripotent continuum.  
Decreasing PKM2 protein abundance during the in the transition to the formative state 







downregulating PKM2 or downregulating PKM2 while upregulating PKM1 formative 
state mEpiLCs developing into primed-like mEpiLCs exhibit a novel subset of cells 
expressing both the naïve pluripotency cell surface marker SSEA1 and CD24.  Using the 
methodology of I describe in Chapter 4, I delineated between these mPSCs with a model 
of PKM1/2 modulation, and demonstrate a means of discrimination for the formative 
state.  Together, these results demonstrate a novel differential nuclear expression pattern 
of PKM1/2 across the pluripotent continuum and by modulating expression of PKM1/2 
key pluripotency cell surface markers are influenced indicating a role in pluripotent state 

























During the developmental transition of naïve-to-primed pluripotent states in mouse 
embryonic stem cells, there is a switch in metabolic preference from bivalent oxidative 
phosphorylation and glycolysis in the naïve state, to aerobic glycolysis in primed stem 
cells.  Using my improved colocalization technique, I examined orthogonal projections 
with references to known nuclear and cytoplasmic markers, I determined that PKM1 and 
PKM2 proteins are differentially expressed in nuclear and cytoplasmic regions of PSCs 
throughout the pluripotent continuum, importantly, overlap of proteins indicates potential 
biomolecular interaction of the protein of interest PKM1/2 and either OCT4 or GAPDH, 
the nuclear and cytoplasmic reference respectively.  To elucidate the potential role that 
PKM1/2 has within the development of the pluripotent continuum, I utilized a 
morpholino strategy targeting PKM1/2 splice modifications during chemical transitioning 
between naïve-to-formative and formative-to-primed-like pluripotent states.   
Alteration of PKM1/2 (downregulation of PKM2 or downregulation of PKM2 coupled 
with upregulation of PKM1) through the addition of splice modifying morpholinos 
resulted in an increased frequency of cells expressing high levels of the cell surface 
marker SSEA1 and CD24 during a formative-to-primed-like pluripotent state transition.  
Taken together, these results promote non-canonical roles for PKM1 and PKM2 in 
mPSCs across the pluripotent continuum. 
 







6.2.0.  Research Limitations: 
This thesis was limited by PKM MO targeting specificity, limited metabolic profiling of 
live cells and protein abundance analyses of metabolic and pluripotent sates.  After 
several designs, attempts, and redesigns, my PKM1 and PKM2 knockdown strategy failed 
to be specific exclusively for one or the other isoform.  However, I made the most of this 
lack of specificity to further promote the individual role of decreasing PKM2 alone and 
upregulating PKM1 concomitantly with a reduction in PKM2.  To truly show the role of 
PKM1/2 during this period of development, an inducible overexpression model of each 
isoform should be employed.  Originally, I attempted to employ a strategy of small 
interfering RNAs (siRNA), however, this method did was not truly convincing.  The 
details of my siRNA study attempts are described in Chapter 5 (Figures 5.11.-13.).  The 
main issue with the siRNA investigation was a lack of PKM1 or PKM2 specificity by 
protein abundance (Chapter 5., Figure 5.13.) and an apparent upregulation of Pkm1 and 
Pkm2 transcript abundance (Chapter 5., Figure 5.12.).  Additionally, the scrambled 
control siRNA resulted in an influence of the siRNA transcript and protein abundance.  
These conflicting results may be a result of the heterogenous transcriptional landscape in 
naïve cells and epigenetic rewiring during development and transitioning.  Naïve and 
primed cells can be distinguished in terms of their DNA methylation including changes to 
promotor-interactions and chromatin state maps (Chovanec et al. 2021; Messmer et al. 
2019).  Future studies could include an inducible overexpression model that would allow 
for the study of increasing either isoform during developmental transitioning from 
transient states such as the formative and primed-like states.  With the recent advent of a 
stably cultured formative pluripotent stem cell line, an inducible overexpression model is 







acute live cell extracellular acidification rate and oxygen consumption rate, measure of 
glycolysis and oxidative phosphorylation in each pluripotent state treated with PKM1/2 
modulation would demonstrate the metabolic reprogramming effect of PKM1/2.  Running 
this acute study in live cells and the newly derived stable formative state cells would 
remove the limitation of knowing metabolic preferences within these cells and their 
modulated states following morpholino incorporation.  Finally, using my comprehensive 
colocalization methodology described in Chapter 2, I demonstrate nuclear PKM1 in 
Chapter 3, however, this strategy was limited in proving nuclear translocation without the 
addition of ChIP-sequencing coupled with single cell RNA-sequencing.  The addition of 
these powerful molecular techniques would greatly benefit this study to transcriptional 
regulation of PKM1 during pluripotency transitioning.   
 
6.3.0.  Future Experiments: 
A final and definitive method of characterizing the metabolic profiles of naïve, formative, 
and primed cells will include examining extracellular acidification (ECAR) and oxygen 
consumption rates (OCR) which correspond to glycolysis and OXPHOS respectively.  
The Betts laboratory owns and operates a Seahorse XFe Extracellular Flux Analyzer, 
which is used to measure ECAR and OCR in live cells.  This technology has been shown 
to be effective in comparing naïve and primed cells based on metabolic demands and can 
show the influence of altering PKM splicing in live cells (Zhou et al. 2012).  Agilent, the 
company who created the Seahorse has expressed interest in us to profile the formative 
pluripotent state.  This could be a valuable part in better understanding the role of 







following adjustments PKM1/2 expression in naïve, formative and primed PSCs will 
provide valuable insight into PKM1/2’s role in glycolytic shifting during developmental 
progression.  Future experiments should consider culturing mPSCs in low oxygen 
conditions (5% oxygen) as we demonstrate an upregulation of metabolic and pluripotency 
associated proteins (Figure 6.1.-3.). 
 
Future studies should also include a stable line of formative state murine pluripotent stem 
cells.  These cells can be generated with the inclusion of tankyrase inhibitor with FA 
media (Kinoshita et al. 2020).  True formative state stem cells extracted from murine ICM 
from E5.5-E6.0 would be ideal in a comparison of explanted naïve mESCs and primed 
mEpiSCs.  It would be especially interesting to see if the unique SSEA1 high/CD24 high 
population corresponds with an increased expression of CD61 as expected of primordial 
germ cell differentiation (Kinoshita et al. 2020).  This may allude to PKM1/2 being 
implicated in direct conversion of germ cell specialization. 
 
Precise targeted disruption of PKM1/2 demonstrated by isoform specificity should be 
further explored.  This study utilized a PKM2 downregulation and PKM2 downregulation 
with PKM1 upregulation strategy using the tools we had at our disposal.  Future studies 
should utilize either a knockdown or knockout approach and overexpression specific to 
each isoform.  Additionally, the combination of such tactics to produce a knockdown or 
knockout of one isoform and an overexpression of the other would further promote the 
roles of each isoform and perhaps further validate our morpholino results in primed-like 
mEpiSCs and cell expressing both CD24 and SSEA1.  The incorporation of inducible 







necessary or sufficient to maintain or hinder pluripotency and developmental 
transitioning. 
 
Finally, the colocalization study would greatly benefit from a mass spectroscopy study of 
nuclear PKM1/2 and co-immunoprecipitation study with OCT4.  Previous studies have 
used mass spectroscopy to study nuclear PKM2 interactions with JMJD5 (Wang et al. 
2014).  This study should begin with a non-denaturing gel of each pluripotent state 
examining dimeric and tetrameric PKM2 levels, this has been completed in other cell 
types and is possible to complete (Verma and Patel 2019).  The work of this thesis 
demonstrates differences in each conformation; however, this experiment would further 
solidify differences and allow for downstream analysis by mass spectroscopy.  These 
aspects work to promote nuclear translocation during development.  Future studies into 
the role of nuclear PKM1 during this time interval is necessary to promote non-canonical 
roles of this metabolic enzyme that traditionally is not known to translocate into nuclear 
compartments (Wei et al. 2017).   To delineate novel targets of PKM1 and PKM2 within 
the nucleus, ChIP-sequencing and single cell RNA sequencing could be employed to 
identify potential regulatory targets of metabolism and pluripotency. 
 
Additionally, evidence of the role of PKM1/2 during a naïve-to-primed transition could 
be provided by a pharmacological approach.  There are a variety of commercially 
available chemical PKM1/2 inhibitors and activators.  Inhibitors such as shikonin, a 
Chinese herb derivative, have been reported to knockdown greater than 50% of PKM2 
activity with no apparent influence on PKM1 (Chen et al. 2011).  While chemical 







leaving PKM1 partially or fully functioning.  Chemical inhibitors such as DASA-58 and 
TEPP-46 work as a PKM2 activator, specifically enabling the homotetramer 
conformation and destabilizing the homodimer by preventing phosphorylation 
(Anastasiou et al. 2012).  Alternatively, promyelocytic leukemia protein works in the 
opposite fashion by maintaining the nuclear localizing PKM2 homodimer and 
destabilizing the homotetramer thus promoting aerobic glycolysis and the Warburg Effect 
(Shimada, Shinagawa, and Ishii 2008). 
 
6.4.0.  Significance of Findings:   
This area of research promotes metabolism as having an active role in pluripotent 
development, rather than a passive role as a by-product of differentiation.  Knowing 
whether PKM1/2 has a role in early development has yet to be determined and this 
project has further clarified that role.  Efficient transitioning of naïve and primed 
pluripotent states has regenerative medicine implications as well in terms of disease 
modelling or the scaling up of cells.  Human ESCs (hESCs) isolated from blastocysts are 
traditionally representative of the primed state and while hESCs are pluripotent, induction 
towards a naïve state is for desirable for improved scalability and the enhanced ability to 
be feeder-free (Vallier 2005).  Reprogramming somatic cells or inducing primed cells to a 
more naïve-like state is becoming an increasing important area of research that will yield 
benefits regenerative medicine. 
 
From a therapeutic standpoint, this aim works to transition mESCs to formative mEpiLCs 







transitioning in FA media) in a more homogenous and stable population.  Currently, 
induced pluripotent stem cells (iPSCs) are favored over ESCs for disease modelling, 
despite both being equally capable (Halevy and Urbach 2014).  Despite reduced 
reprogramming efficiency and epigenetic memory, the preference for iPSCs is largely due 
to challenges associated with ESCs legalities and genome editing. However, several 
diseases are better portrayed using ESCs largely due to epigenetic memory and landscape.  
In a comparison of X-linked autosomal diseases, it was found that disorders such as 
Turner’s Syndrome, epigenetic silencing in Fragile X Syndrome and Huntington’s 
Disease are better modelled using ESCs than iPSCs (Halevy and Urbach 2014).    
 
In summary, my investigation of differential pyruvate kinase muscle isoform expression 
in naïve-to-primed mESC development promotes PKM1 and PKM2 having an important 
role in in vitro pluripotency throughout the pluripotent continuum and may suggest a 
developmental link as these cells have appear to demonstrate a metabolic preference bias 
like their in vivo counterparts of the pre- and post- implantation blastocyst.  Differential 
localization patterns of PKM1/2 through the pluripotent continuum demonstrate 
subcellular changes to nuclear and cytoplasmic localization and potential interaction of 
both isoforms to the pluripotency protein OCT4 may indicate a role in governing 
pluripotency.  The presence of nuclear PKM1 was a first of its kind observation and 
indicates a potential non-metabolic role.  Modulation of PKM1/2 does not drastic alter 
metabolic or pluripotency transcript abundance, however, when transitioning between the 
naïve and formative state, downregulation of PKM2 enhances CD24 expression, a key 
protein associated with primed pluripotency.  Additionally, when transitioning from a 







downregulation of PKM2 with upregulation of PKM1 increases the frequency of cells 
expression both SSEA1 and CD24, characteristics of both naïve and primed cells.  Using 
the methodology findings of Chapter 4, I demonstrate that the formative pluripotency 
state can be distinguished from both the naïve and primed states.  My refined 
colocalization and flow cytometric methodology further the field of molecular techniques 
and fill benefit downstream analysis and applications such as improved cell sorting.  The 
results of this thesis support my governing hypothesis that PKM1/2 is differentially 
localized during the development of PSCs in the pluripotent continuum and altering 
PKM1/2 expression appears to modulate developmental progression during transition 
from the naïve pluripotent state and formative state.  My thesis sheds light on the role of 
metabolism and pyruvate shuttling during early development and has the potential to 
enhance our knowledge of mechanisms controlling pluripotent cell conversion, ultimately 
benefiting disease modelling and cell replacement therapies.  The findings of my works 
promote PKM1/2 as having a non-canonical role outside of metabolic processing during 
developing stem cells of the pluripotency continuum and further promotes metabolism as 
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